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Introduction 

Introduction 
General int roduct ion 
In our society hearing impairment is a very common type of sensory disability. In 
general, half of the population at the age of 80 years1 is hearing impaired (> 35 
dB). As society rapidly progresses into a more communicative one, the importance 
of normal hearing cannot be overestimated. Therefore, hearing impairment can 
be a considerable professional and social burden. The aetiology of hearing loss is 
multifactorial and includes environmental, infectious, traumatic and genetic 
causes. Increasing medical knowledge and preventive and protective measures 
against infectious and environmental causes have diminished the number of cases 
that can be attributed to these agents. Proportionately, the fraction of genetic 
causes has therefore increased. 
Historical note 
The awareness that hearing loss can be inherited is not recent. Annotations dating 
from the i6'h and 17th century suggest the notion of genetic involvement in 
familial hearing loss2,3. In the second half of the I9 lh century the importance of 
genetics in hearing loss became more and more apparent. In 1853 Sir William 
Wilde (1815-1876) described hereditary hearing loss in several families based on 
data obtained during an Irish census4. Arthur Hartmann presented evidence for 
autosomal dominant and autosomal recessive inheritance of hearing loss after 
studying a large Berlin population around 18805. The famous otologist Adam 
Politzer endorsed Hartmann's view in the second edition of his manual of otology 
'Lehrbuch der Ohrenheilkunde'6 (1887), in which he distinguished direct or 
dominant inheritance from indirect or recessive inheritance. Since then, heredity 
as an aetiology of hearing loss became a generally accepted concept. Soon after, 
in 1900, the significance of Mendel's original work7 (1865) was re-appreciated and 
provided insight into various patterns of inheritance. 
Besides studies and reports on non-syndromic hearing loss at schools and in 
isolated populations, scientific attention was focused on inherited types of 
hearing loss as part of a syndrome. Syndromes in general are quite rare. However, 
due to the usually apparent clinical features, they are more recognisable as a 
separate clinical entity than isolated types of hereditary hearing loss. Therefore 
the amount of reported syndromes rapidly increased in the second half of the 19th 
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century. Among others, the first descriptions of mandibulofacial dysostosis8 
(1846), Usher syndrome9 (1858) and Pendred syndrome10 (1896) all date from this 
period. With the advent of audiometry in the 1930s, genetic hearing loss could 
not only be characterised by the mode of inheritance but also by audiometrie 
configuration. Together with generally used features such as age of onset and 
progression, the characteristic shape of the audiogram became of great 
importance to characterise and subdivide genetic hearing loss. This comprised 
low, mid and high frequency hearing impairment as well as flat-type hearing loss. 
In their comprehensive work Gorlin and Koningsmark used these methods to 
phenotypically describe syndromic and non-syndromic types of hearing loss11. 
Genetic analysis 
A new era started with the unravelling of the structure of DNA by Watson and 
Crick in 195312, which led to the development of molecular biology. By identifying 
many genes, this new science discovered a genetic basis for many different 
hereditary diseases. Until now the most widely applied technique to investigate 
genetic hearing loss is linkage analysis. This method is based on the principle that 
a mutated gene causes a specific disease. Provided that a sufficient number of 
affected persons, preferably >io, are available, a pattern of inheritance of the 
disease can be deduced from the pedigree. The segregation of the investigated 
phenotype is compared to the segregation of 300-400 polymorphic marker alleles. 
Based on this segregation pattern and on epidemiological features, a statistical 
calculation is performed to find out whether the disease and a specific marker 
allele co-segregate significantly and therefore show "linkage". This calculation 
leads to a LOD (logarithm of odds) score whose value should be at least 3 to 
indicate linkage. Once linkage is found, a locus, i.e. a region on the human 
genome which harbours the disease-causing gene, can be assigned by testing 
flanking markers and its recombinations. Sometimes this candidate region can be 
narrowed down by analysing additional (affected) family members. Furthermore 
genetic database searching for a suitable candidate gene and finally mutation 
analysis are necessary to be able to identify the disease-causing gene. Questions 
remain to be answered once the gene has been identified. The characterised gene 
product, its expression pattern in the human body and, more specifically, within 
the cochlea, as well as an explanation as to why this specific protein is necessary 
for normal hearing still need to be unravelled. 
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Epidemiology and nomenclature 
Congenital hearing impairment, i.e. bilateral hearing thresholds of 8odB HL or 
more, occurs in every 1:1000 newborns1 and has a genetic cause in about half of 
the cases. Approximately 75% of these genetically caused cases of hearing 
impairment have a non-syndromic origin. Of these, the mode of inheritance is 
autosomal recessive in about 75%, autosomal dominant in approximately 25% 
and X-linked in less than 5% of the cases11314. In general most of the non-
syndromic forms will present with a sensorineural type of impairment1111315. 
During the early nineties of the past century, the first inherited forms of hearing 
loss were linked. The loci for non-syndromic forms of deafness are called DFN 
(DeaFNess) and are numbered in chronological order of discovery. According to 
the pattern of inheritance a locus is designated DFNA (autosomal dominant), 
DFNB (autosomal recessive) or DFN (X-linked). No specific annotation has been 
assigned to mitochondrially-inherited forms of hearing loss. An up-to-date 
overview of the currently known syndromic and non-syndromic forms of genetic 
hearing loss and their associated genes is given in Tables 1-5. The added year of 
discovery gives an impression of the progress that has been made since the first 
description in 199216. An up-to-date overview is available on the world wide web 
on the "The Hereditary Hearing Loss Homepage"17. 
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Table 1 Loci and genes associated with autosomal dominant, non-syndromic hearing impairment 
/.Deus 
DFNAl 
DFNA2 
DFNA3 
DFNA4 
DFNA5 
DFNA6/14/38 
DFNA7 
DFNA8/12 
DFNA9 
DFNAlO 
DFNAll 
DFNA13 
DFNA15 
DFNA16 
DFNAl? 
DFNA18 
DFNA19 
DFNA20 
DFNA21 
DFNA22 
DFNA23 
DFNA24 
DFNA25 
DFNA26 
DFNA27 
DFNA28 
DFNA29 
DFNA30 
DFNA31 
DFNA32 
DFNA33 
DFNA34 
DFNA35 
DFNA36 
DFNA37 
DFNA39 
DFNA40 
DFNA41 
DFNA42 
DFNA43 
DFNA44 
DFNA45-46 
DFNA47 
DFNA48 
DFNA49-50 
DFNA51 
Localisation 
5q3l 
1P34 
13ql2 
19ql3 
7P15 
4P16.3 
lq21-23 
llq22-24 
14q 12-13 
6q22-23 
l lq l2.3-21 
6p21 
5q31 
2q24 
22q 
3q22 
10 
17q25 
6p21 
6ql3 
14q21-22 
4q 
12q21-24 
17q25 
4qi2 
8q22 
15q26 
l l p l 5 
lq44 
9ql3-21 
lp21 
4q21.3 
I 6 p l 2 
12q24-qter 
4q28 
2pl2 
3q28-29 
9q21-22 
12ql3-14 
9q21 
Year 
1992 1 6 
1 9 9 4 , 9 
1 9 9 4 " 
1 9 9 5 " 
1995 2 6 
1996 2 8 , I 9 9 9 2 9 , 2 0 0 1 3 0 
1996 3 2 
1996 3 3 , 1997 3 4 
1996 î 6 
1996 3 β 
1996 4 0 
1997 4 2 
1 9 9 8 " 
1999 4 5 
1999 4 6 
Ι 9 9 8 4 β 
1998 4 9 
2000 5 0 
2000 5 2 
2 0 0 1 5 3 
2 0 0 0 " 
1 9 9 9 " 
1999 5 6 
2 0 0 0 " 
1999 5 β 
1999 5 9 
Reserved 
1 9 9 9 " 
Reserved 
2 0 0 0 " 
Reserved 
2000 6 3 
Reserved 
2000 6 3 
2000 6 5 
2 0 0 1 6 6 
Reserved 
2002 6 7 
2 0 0 3 ω 
2003 6 9 
Reserved 
2003™ 
2 0 0 3 " 
Reserved 
Gene 
HDIAl 
GIB3 (CX31); KCNQ4 
GIB2 (CX26); GJB6 (CX30) 
DFNA5 
WFSl 
TECTA 
COCH 
EYA4 
MYO7A 
C0L11A2 
POU4f3 
MYH9 
ACTGl 
MYO6 
ACTGl 
TFCP2L3 
TMCl 
DSPP 
Year 
1 9 9 7 " 
1998 : 0 , 1999 2 1 
19982 3, i g g g 2 4 
19982 7 
2 0 0 1 3 1 , 2 0 0 1 3 0 
19983 S 
19983 7 
2 0 0 1 3 ' 
19974 ' 
19994 3 
19984 4 
20004 7 
2003S 1 
2 0 0 1 5 3 
2ΟΟ351 
2002 6 0 
2 0 0 2 ^ 
2 0 0 1 6 6 
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Table 2 Loci and genes associated with autosomal recessive, non 
/.ecus 
DFNBl 
DFNB2 
DFNB3 
DFNB4 
DFNB5 
DFNB6 
DFNB7 
DFNB8 
DFNB9 
DFNB10 
D F N B l l 
DFNB12 
DFNB13 
DFNB14 
DFNB15 
DFNB16 
DFNBl? 
DFNB18 
DFNB19 
DFNB20 
DFNB21 
DFNB22 
DFNB23 
DFNB24 
DFNB25 
DFNB26 
DFNB27 
DFNB28 
DFNB29 
DFNB30 
DFNB3I 
DFNB32 
DFNB33 
DFNB34/36/38/39 
DFNB35 
DFNB37 
Localisation 
1 3 q l 2 
l l q l 3 5 
1 7 Ρ 1 1 2 
7 q 3 1 
1 4 q l 2 
3Ρ14-21 
9 q l 3 - 2 1 
21q22 
2Ρ22-23 
21q22 3 
9 q l 3 - 2 l 
10q21-22 
7q34-36 
7 q 3 1 
3 q 2 1 - 2 5 , 1 9 p l 3 
15q21-22 
7 q 3 1 
l l p l 4 - 1 5 1 
l 8 p l l 
l l q 2 5 - q t e r 
l l q 
I 6 p l 2 2 
l O p l l 2-21 
l l q 2 3 
4P15 3-12 
4 q 3 1 
2q23-31 
2 2 q l 3 
21q22 
1 0 p l 2 1 
9q32-43 
l p l 3 3-22 1 
9q34 3 
14q24 1-24 3 
6 q l 3 
Year 
1 9 9 4 " 
1994« 
1 9 9 5 " 
1995™ 
1995 7 9 
1995"° 
l 9 9 5 a 2 
Ι 9 9 6 β 3 
Ι 9 9 6 β 5 
1 9 9 6 s 7 
1 9 9 7 e 8 
1 9 9 6 " 
1 9 9 8 " 
1998 9 2 
1997 9 3 
Ι θ θ ? * 1 
1998 9 6 
1 9 9 8 " 
1998 9 9 
1 9 9 9 1 0 0 
1 9 9 9 1 0 1 
2 0 0 2 1 0 1 
Unpublished data 
Unpublished data 
Unpublished data 
2 0 0 0 1 0 3 
20001 0'1 
2 0 0 0 1 0 5 
2 0 0 1 1 1 " 
2 0 0 2 1 0 7 
2002"' 8 
2003m 
lOOl110 
Reserved 
2003"1 
2 0 0 3 1 , 2 
syndromic heanng 
Cene 
GIB2 
MYO7A 
MYO15 
SLC26A4 
TMIE 
TMCl 
TMPRSS3 
OTOF 
TMPRSS3 
TMCl 
CDH23 
STRC 
USHlC 
TECTA 
OTOA 
CLDN14 
MYO3 
MYO6 
impairment 
Year 
1997 7 3 
199T\ 1 9 9 7 " 
1998 7 7 
1998 7 β 
2 0 0 2 8 1 
2 0 0 2 6 ί 
2001" 
1999s6 
2001 ί " , 
2002 6 4 
2 0 0 1 9 l , 
2 0 0 1 9 5 
2 0 0 2 9 β 
1 9 9 9 " " 
2 0 0 2 " " 
2 0 0 1 1 0 6 
2 0 0 2 1 0 7 
2 0 0 3 u i 
Table 3 Loci and genes 
Locus 
D F N l 
DFN2 
DFN3 
DFN4 
DFN5/7 
DFN6 
DFN8 
associated with X-linked, non-syndromic heanng 
Localisation 
Xq22 
Xq22 
X q 2 l 1 
X p 2 1 2 
Xp22 
Year 
I 9 9 5 l l ä 
iggS" 5 
19951 '6 
1994 ' " 
Wi thdrawn 
Reserved 
impairment 
Cene 
DDP 
POU3F4 
Year 
1996 1 " 
1995" 6 
1 9 g 6 l i e 
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Table 4 Chromosomal localisations a nd genes associated with SOME frequent forms of sy 
Syndrome 
Alport syndrome 
Branchio-Oto-Renal syndrome 
Jervell and Lange-Nielsen syndrome 
Norrie disease 
Pendred syndrome 
Stickler syndrome 
Treacher Collins syndrome 
Usher syndrome 
Waardenburg syndrome 
BORI 
BORII 
JNLSl 
JLNS2 
STLl 
STL2 
STL3 
TCOFl 
USHlA 
USHlB 
USHlC 
USHlD 
USHlE 
USHlF 
USH1G 
USH2A 
USH2B 
USH2C 
USH3 
WSI 
WSII 
WSII 
WSIII 
WSIV 
WSIV 
ioco/jsotron 
Xq22 
2q36-37 
8ql3.3 
i q 3 l 
l lplS-S 
21q22.1-22.2 
Xpi i.3 
7q21-34 
12ql3. I I-I3.2 
6p21.3 
lp21 
5q32-33.1 
I4q32 
l l q l 3 . 5 
l l p l S . l 
loq 
2lq 
10q21-22 
17q24-25 
lq41 
3Ρ23-24.2 
5ql4.3-21.3 
3q21-25 
2q35 
3P14.1-12.3 
2q35 
I3q22 
20ql3.2-13.3 
22ql3 
Cene 
COL4A5 
COL4A3; COI4A4 
EYAl 
QVLQTl 
KCNEl(lsK) 
Nomn 
SLC26A4 
COL2A1 
COL11A2 
COLllAl 
TCOFl 
MY07A 
USHlC 
CDH32 
PCDH15 
SANS 
USH2A 
USH3 
PAX3 
MITF 
SLUG 
PAX3 
EDNRB 
EDN3 
SOXlO 
ndromic hearing loss 
Year 
iggo" 9 
1994120 
1 9 9 7 i 2 . 
2O0O1" 
1997,î3 
1997115124 
1 9 9 2 i 2 5 . 2 6 
I997127 
1996"8 
199511' 
1996130 
igge1 '1 
19921" 
1995133 
1992134,2000135136 
igge'^^ooi90138 
1997'39 
2 0 0 l l 4 O H . 
2002142 
1990"13, igg8'M 
iggg145 
20001'6 
199S"7, 2001"" 
I992'49 
I994150 
2002'5, 
I9931" 
I995153 
1996,H 
iggs155 
Table 5 Mitochondrial mutations associated with syndromic and non-syndromic hearing impairment 
Syndrome Gene Year 
MELAS (Mitochondrial Encephalopathy, Lactic Acidosis & Stroke-like episodes) 
MERFF (Myoclonic Epilepsy and Ragged Red Fibers) 
MIDD (Maternally inherited Diabetes and Deafness) 
Progressive myoclonic Epilepsy, ataxia 81 hearing impairment 
KSS (Kearns Sayre Syndrome) 
tRNALeu 
tRNALys 
tRNALeu 
tRNALys 
several 
tRNAGIu 
tRNASer 
Several 
iggo156 
iggo1", iggs159 
1 9 9 2 .59 
igge160 
1992161 
1995162 
iggs163 
ig89164 
Non-Syndromic 
12S rRNA 19g3165,1997'", iggB167 
tRNASer igg4l6e, iggs1" '70, 1998"3 m "\ 
iggg173175 
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Some genetic aspects 
As is clear from the tables, many genes have been found to be involved in genetic 
hearing loss. The specific type of mutation, e.g. missense, nonsense, splice-site, 
frameshift, insertions or deletions, can have a different effect on the produced 
protein that is encoded by the gene. They may not only lead to (subtle) 
phenotypic differences within a certain type of hereditary hearing loss, but even 
to a different pattern of inheritance, e.g. dominant, recessive or (non-)syndromic. 
Besides this, the final effect of a mutated gene depends on its function, on the 
cellular pathways in which the produced (defective) protein is required, as well as 
on other genetic factors, as is shown by the discovery of a modifier locus103 
(DFNMl). 
So far the type of genes involved in syndromic- and non-syndromic genetic 
hearing loss can be roughly divided in four categories. The first category of genes 
is involved in maintaining ion homeostasis for the cochlear hair cells and mainly 
consists of genes that encode channel (components) and ion pumps (CJB2, CJB3, 
GJB6, KCNQl, KCNQ4, KCNQEl, SCLC26A5 and ATP6B1). Another category of genes 
encodes essential molecules in hair cell function that are mainly expressed near 
the stereocilia of the inner and outer hair cells (MYOiA, MYO3A, MYO6, MYO7A, 
MYHg, MYO15, DIAPHl, OTOF, CDH23 and STRC). A third group of genes encodes 
protein components of the extracellular matrix and the tectorial membrane 
[TECTA, COCH, COL2A1, COL4A3/4/5 and COLllAl/2). Last but not least, a group of 
transcription factors is involved in cochlear development (POU3F4, POU4F3, EYAl, 
EYA4, PAX2, MITF, SOX10 and EDNRB). Figure 1 shows a schematic representation 
of a transverse section of the cochlear duct with localised gene expression. 
Outlining the effect of a mutated gene requires a critical and thorough clinical 
description, including evaluation of long-term audiometrie follow-up, speech-
recognition scores and vestibular function. Studies of the gene and its expression 
pattern combined with comprehensive phenotypic characterisation are in fact in-
vivo studies on the effect of a given genetic defect. 
17 
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Figure 1 Localised gene expression in syndromic and non-syndromic hearing impairment (modified 
after Steel et al1 7 6 
Diagnostics 
Although many different DFNA and DFNB families are known these days, the 
actual prevalence is low. Simply testing all genes involved in hereditary hearing 
loss as a routine diagnostic procedure is expensive and consumes a lot of time. 
Therefore genetic diagnostic procedures are designed for those with a relatively 
high frequency in the general population. In Nijmegen for example, mutation 
analysis on GJB2 (DFNBl; connexin 26) and COCH (DFNAg; cochlin) genes, as well 
as for certain syndromes, such as Wolfram, Usher (type lb and IIa), BOR and 
Pendred syndrome, have become routine diagnostic procedures in general 
practice, providing parents and affected individuals with aetiological answers. The 
increasing genetic knowledge in general and specifically in this field of research 
provides us with insight into the molecular mechanisms underlying (ab)normal 
hearing and vestibular (dys)function. Altogether this knowledge will hopefully 
pave the way for future adequate treatment strategies. 
18 
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Outline and objectives of this thesis 
There has been a special interest in genetic hearing impairment at the 
Departments of Otorhinolaryngology and Human Genetics of the University 
Medical Centre Nijmegen since 1973- In line with this tradition, this thesis deals 
with some clinical and genetic aspects of syndromic and non-syndromic forms of 
genetic hearing loss. Most of the work presented in this thesis is the product of 
joint efforts of both departments. The research on BOR syndrome (Chapter 2) has 
been realised in collaboration with Prof. dr. W.J. Kimberling and Prof. S. Kumar 
working at the Center for Hereditary Communication Disorders, Boys Town, 
Omaha, USA. The first results of this successful collaboration date from 1987. 
Chapter 2 deals with the branchio-oto-renal (BOR) syndrome. In 1864 a case report 
was published on a young girl presenting with mild dysplasia of the external ear, 
a preauricular sinus, severe hearing loss and cervical fistulae177. A few years later, 
Sir James Paget practically described the complete syndrome in two generations 
of one family178. Before Fraser et al proved that renal anomalies are also part of 
this syndrome179, it was known as the earpits-deafness syndrome. Due to lack of 
systemic renal investigations, such anomalies were not always mentioned at that 
time. Chapter 2 includes a review on BOR syndrome (Chapter 2.1). Since the late 
seventies of the past century several studies on BOR syndrome have been 
performed180185 at the Nijmegen ENT department. A clinical case report (Chapter 
2.2) on the radiological findings and audiometrie follow-up of a father and son 
affected by BOR syndrome initiated a series of studies on this disorder. The 
radiological malformations and audiometrie data found in this family encouraged 
us to perform a comprehensive magnetic resonance imaging (MRI) study (Chapter 
2.3) as well as a thorough audiometrie follow-up study (Chapter 2.4) in a total of 
six BOR families. Gene linkage and mutation analysis studies were initiated 
previously in these families in Boys Town, Omaha186189. The obtained results were 
used to detect any trends and/or existing correlations between radiology, 
audiometry and mutation analysis results. 
Chapter 3 provides a comprehensive summary on DFNA9/COCH (Chapter 3.1) and 
reports on two Dutch DFNA9/COCH families. The discovery of the first family dates 
from 1998, when this family was the subject of a term paper on familial 
autosomal dominant sensorineural hearing loss190. Soon after, the underlying 
19 
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disease-causing P51S mutation in the COCH gene was detected and published. 
This publication also included audiometrie and vestibular data to outline clinical 
features (Chapter 3.3). Chapter 3.2 reports on a G88E/COCH mutation present in a 
Dutch family and compares the available audiometrie and vestibular (follow-up) 
data to those of the originally reported family from the United States of America 
carrying the same mutation. 
In Chapter 4 another Dutch family with autosomal dominant inherited 
sensorineural hearing loss is presented. Linkage analysis enabled us to localize 
the disease to the DFNA20/26 and delimit the critical region. Not only genetic 
data, but also the clinical features of both families were studied and compared to 
outline the phenotype as accurately as possible. 
DFNBi/C7ß2 is the subject of Chapter 5. GJB2 mutations, also known as connexin 
26 mutations, are the most prevalent causes of autosomal recessively inherited 
hearing loss as well a sporadic deafness. This high prevalence has led to the 
implementation of GJB2 mutation analysis as a diagnostic tool in many genetic 
laboratories all over the world. This also applies to the University Nijmegen 
Medical Centre. Chapter 5 gives a review on connexin 26 and hearing loss and 
provides the first results bearing on GJB2 mutation analyses in Nijmegen and in 
The Netherlands. 
Finally, the conclusions of this thesis are summarised and discussed in the light of 
the present knowledge in Chapter 6. 
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Introduction 
Apart from brief descriptions dating from the 19th and the beginning of the 20th 
century, Melnick et al.1 were the first to report on the clinical aspects of the 
branchio-oto-renal (BOR) syndrome. The autosomal dominant BOR syndrome 
(OMIM #113650), formerly known as the earpits-deafness syndrome, shows a wide 
spectrum of highly variable clinical manifestations, comprising combinations of 
branchial-arch, otic and renal anomalies2. The four most characteristic clinical 
symptoms are: (i), hearing loss; (ii), second-branchial arch cleft, sinus of fistulas; 
(iii), malformations of the auricle, the ear canal, the middle and/or inner ear 
including earpits, and (iv), renal anomalies, ranging from mild hypoplasia to 
complete agenesis35. Chronic infection of a second-branchial arch cleft, sinus of 
fistulas can make surgical excision necessary. The frequencies of the main features 
in the BOR syndrome based on a review of 184 cases from the literature are 
summarised in Table 16. Other associated but less common features include 
facial/palatal abnormalities, lacrimal duct stenosis and external auditory canal 
stenosis1457. This disorder shows almost complete penetrance, whereas its 
expression can be quite variable1'3. BOR syndrome has an estimated general 
prevalence of 1:40,000 and occurs in 2% of profoundly deaf children". 
Table l Frequency of the main features of the BOR syndrome in 184 patients based on a review of 184 cases 
from the literature (with courtesy of Stinckens et ai6) 
Malformed auricles 
Second branchial arch 
fistula/cyst 
Preauricular sinus 
Renal anomalies 
Stenosis of nasolacrimal duct 
Hearing impairment 
Reported presence/absence 
of features in 184 cases 
121 
155 
169 
115 
34 
153 
Reported presence 
of main features 
105/121 (86.8%) 
134/155 (86 5%) 
147/169 (87.0%) 
67/115 (58.3%) 
16/34 (47.0%) 
146/153 (95.4%) 
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Figure l Pictures of typical clinical features in different BOR patients 
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Preauricular appendage 
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Figure 2 Example of a pedigree of a BOR family (with courtesy of Stinckens et al ) 
Hearing loss and vestibular funct ion 
The type of hearing loss can be conductive, sensorineural or mixed and was 
formerly considered to be stable. A few reports mentioned progressive hearing 
loss. A recent long-term audiometrie follow-up study of a number of suitable 
patients disclosed that progressive fluctuant hearing loss may be a regular finding 
in the BOR syndrome (authors' unpublished data)6,8 Vestibular studies are rarely 
reported. In one study vestibular impairment was reported to be present in about 
half of the affected cases (n = 13)9. 
Renal anomalies 
Renal involvement in the BOR syndrome is also characterised by great variability, 
ranging from asymptomatic minor deformities to severe dysplastic kidneys or 
even kidney agenesis3'510,11. The expression of any type of renal anomaly is almost 
25%. Due to its variability, many renal problems remain clinically and 
anamnestically undetected, whereas other patients depend on dialysis and await 
kidney transplantation. Especially minor renal abnormalities do not show any 
progressive characteristics10. Recent results of studies in mouse models suggest a 
role of the EYAi gene in the development of the kidney (see below). 
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Middle-ear and inner-ear morphology 
Branchial-arch involvement of the BOR syndrome accounts for the serious 
involvement of the middle- and inner-ear structures. Various types of middle-ear 
anomalies have been documented, including (i) displacement, hypoplasia, or 
aplasia of middle-ear ossicles, (ii) fusion and fixation of two or more ossicles, (iii) 
stapes ankylosis and/or absence of oval window, and (iv) varying size and shape 
of the middle-ear cavity9. Radiological studies of the inner ear in genetic syn-
dromes are few and mainly limited to individual cases. Both the cochlear and the 
vestibular partitions can be involved in inner-ear abnormalities, ranging from an 
enlarged vestibular aqueduct, hypo-/dysplastic cochlea, bulbous internal acoustic 
canals, a deep posterior fossa and acutely-angled promontories to hypoplastic 
vestibule and/or semicircular canals5·91216. 
i^à vestibule. semicircular canal 
Figure 3 High resolution (CISS) heavily T2 weighted MR image of the temporal bone at the level of the 
internal meatus (l.m.l. Tvoical examole of the enlaraed endolvmohatic duct (e.e.d.) on both sides. 
pfefe 
Figure 4 Multiplanar reformatted Figure 5 Another typical sign is the hypoplastic cochlea as shown here by 
image (MPR) of the same patient an MPR image of an affected cochlea. Image in the axial plane at the level 
(Figure 3). Semisagittal plane of the internal meatus and apex of the cochlea. Semicoronal section 
through the endolymphatic duct through the turns of the cochlea shows only 1 complete turn and no middle 
(e.e.d.) on the left side showing and apical turns, 
the course of this duct in the 
longitudinal direction. 
More recently performed MR-imaging studies confirmed the frequent occurrence 
of such inner-ear abnormalities in 7 families affected by the BOR syndrome 
(authors' unpublished data)6,8. Apart from these anomalies, the presence of an 
enlarged endolymphatic duct and/or sac could also be demonstrated in some 
affected family members. Although long-term audiometrie fol low-up 
demonstrated the presence of progressive fluctuant hearing loss in some of the 
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affected BOR patients, 
a clear correlation 
between the MR! 
findings and this type 
OT n e a n n g LOSS COUla p igU r e 5 F0r comparison a normally developed cochlea (left) and an example 
, , of an affected cochlea (right) showing absent apical turns in the axial plane. 
not yet be demon-
strated6,8. However, sensorineural thresholds were significantly higher in cases 
with enlargement of the endolymphatic duct and/or sac (authors' unpublished 
data). 
Reconst ruc t ive m i d d l e ear surgery 
The conductive component in the hearing impairment is mostly due to congenital 
anomalies of the ossicular chain. A predisposition for otitis media with effusion 
might be present. As a result of the branchiogenic origin of the ossicular chain all 
ossicles can be anomalous. Ankylosis of the stapes footplate as well as a too short 
long process of the incus are frequently present. Even the malleus handle can be 
missing9. A malleovestibulopexy can be needed to reconstruct the ossicular chain 
functionally. The curvature of the anterior bony canal is usually so severe that a 
canal-plasty in the same procedure is needed to allow crimping of the stapes-
incus replacing teflon-platinum prosthesis around the malleus handle17. 
Congenital anomalies of the middle ear can be severe; the round window niche 
can be missing and the facial nerve may cross the oval window or the 
promontory. Minor congenital ear anomalies causes reconstructive surgery of the 
ossicular chain in BOR syndrome to be less successful than usual. A preauricular 
sinus can be abnormally large and communicating with the middle ear cleft18. In 
case of chronic infection of a sinus excision can be necessary. 
Genet ics 
The EYAl gene (OMIM #601653) has been found to underlie the BOR syndrome19. 
This is the human homologue of the drosophilia 'eyes absent' gene one [eyai) 
and is localised on human chromosome 8qi3.319'22. EYAl, consisting of 16 exons 
with a genomic interval of 156 kB, forms part of a gene family comprising at least 
3 other isoforms (EYA2, EYA3 and EYA4)22. So far three different transcripts of the 
EYAl gene have been identified to result from alternative splicing of mRNA 
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transcripts. The gene encodes a 559-amino acid polypeptide and contains a highly 
conserved region called the eyes absent homologous region (eyoHR), encoded by 
exons 9-16, which has an essential role in normal gene function. Many different 
types of disease-causing mutations have been identified and most of these cluster 
in eyoHR, which is therefore the region of major interest for mutation analysis of 
this gene. 
EYAlGENE 
ƒ EYAlB \ 
- 1 1 1 ' 2 3 4 5 6 7 8 9 10 1112 13 14 15 16 
' H F + ^ H - ^ — H — I MIMI * 
• · · · ν _ ^ 
eyoHR 
Y 
EYAlC 
Figure 7 Schematic representation of the EYAl gene structure (unsealed). All boxes are coding exons except 
for the black-filled boxes. The grey-filled boxes indicate the eyo-homologous region The dotted lines indicate 
how the different isoforms [EYAlA, EYAlB and EYAlQ are built up. 
In spite of positive linkage to the EYAl locus, mutations in this gene have been 
detected in only 25% of the patients with the diagnosis of BOR. This can be 
explained by mutations in yet unknown important structures of this gene, i.e. 
promoters or introns, which are not recognised with the present methods and 
knowledge. A second gene has recently been discovered on chromosome i q 3 i in 
a family without signs of second-branchial arch cervical fistulas23. It is not yet 
known what proportion of BOR cases is caused by mutations in this gene. 
Involvement of this second gene together with the various different mutations in 
the EYAl gene is evidence of the genetic heterogeneity of BOR syndrome. 
Recently Rickard et al.24 proposed to limit the screening of the FVAigene to cases 
of classical BOR syndrome, until mutation-detection strategies yield higher 
detection rates. Although positive mutation analysis can provide tools to predict 
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the risk of recurrence in a given family, it does not allow for the prediction of 
phenotypic features due to the variable expressivity of the syndrome. This, 
together with our lack of knowledge regarding genotype-phenotype correlations, 
makes genetic counselling a difficult task. Further research on the BOR syndrome 
will have to clarify the factors and genes that influence the phenotypic variability 
of BOR patients. 
Animal models 
In Drosophila the eya gene is involved in the formation of the compound eye, 
whereas the expression pattern of the murine orthologue, Eyal, suggests a role in 
the development of major inner-ear components and metanephric cells22. Johnson 
et al.25 described a spontaneous mutation in the Eyal gene causing an autosomal 
recessive phenotype of deafness in a mouse model with circling and head-
bobbing behaviour. Subtle developmental anomalies in the superior part of the 
labyrinth, including foreshortening and narrowing of the lateral semicircular 
canals and incomplete formation of the common crus, were noted. Xu et al.26 
inactivated the Eyal gene in mice and reported that £yoi v heterozygotes showed 
conductive hearing loss associated with middle ear malformations. Similar to the 
BOR syndrome, these mice showed renal defects at low penetrance, including 
renal hypoplasia and unilateral agenesis. Inner-ear abnormalities in these 
heterozygotes included the vestibular labyrinth, but no specific details were given. 
Fyol7' homozygotes lacked ears and kidneys due to defective inductive tissue 
interactions and apoptotic regression of the organ primordia. 
Animal models provide insight in the way the genotype affects the phenotype. 
They enhance our understanding of the BOR syndrome and its underlying 
mechanism. Therefore, more well-designed animal models are needed to unravel 
this syndrome. 
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Abstract 
Objective: To study the results of petrosal bone imaging and audiometrie long-
term follow-up of two patients with branchio-oto-renal (BOR) syndrome and 
relate them to the clinical features, including caloric responses. 
Study design: Longitudinal case study. 
Setting: Tertiary referral center. 
Patients: A father and son with the BOR syndrome. 
Main outcome measures: Both patients underwent imaging studies to detect and 
evaluate inner ear anomalies. Longitudinal audiometrie analysis of the hearing 
threshold data over the previous 23 years was performed. Caloric tests were 
performed at various ages. 
Results: The son had a short, wide internal acoustic canal, a hypoplastic cochlea, a 
plump vestibule and a wide vestibular aqueduct on both sides; the semicircular 
canals and endolymphatic sac were of normal size. He showed progressive, 
fluctuant sensorineural hearing loss. Caloric tests disclosed hyporeflexia on the 
left side. The father had a plump internal acoustic canal and hypoplastic cochlea 
on both sides. The left vestibule was hypoplastic and the left vestibular aqueduct 
was marginally enlarged. He showed severe hearing impairment, without 
substantial progression or fluctuation, and caloric areflexia on the left side. 
Conclusion: These findings suggest a correlation between progressive, fluctuant 
sensorineural hearing loss with caloric hypofunction and the presence of an 
enlarged vestibular aqueduct in the BOR syndrome. Additional longitudinal case 
studies are needed to further evaluate such a correlation. 
51 
Chapter 2 
Introduction 
The branchio-oto-renal (BOR) syndrome is an autosomal dominant inherited 
syndrome, in which affected individuals may have sensorineural, mixed or 
conductive hearing loss, preauricular pits and structural defects of the outer, 
middle and inner ear. Other features include lacrimal duct stenosis, branchial 
fistulas or cysts of the second branchial arch, and renal anomalies ranging from 
mild hypoplasia to complete agenesia. A long and narrow face with a high-arched 
palate and deep overbite are less frequent symptoms14. Hearing loss, branchial 
clefts and earpits are most frequently expressed. Hypoplasia of the cochlea is 
another feature of the BOR syndrome2,5,6. The penetrance of relevant clinical 
features has been reported previously3,4. The estimated general prevalence of the 
BOR syndrome is 1:40,000; in profoundly deaf children the relative prevalence is 
2%7. 
The first gene underlying the BOR syndrome has been identified as the human 
homologue of the drosophila eyes absent gene 1 (EYAi)aia. Expression of the 
murine orthologue Eyai occurs in all components of the inner ear and in the 
metanephric cells surrounding the ureteric branches, which suggests a role in the 
development of inner ear and kidney9. The BOR syndrome shares important 
features with other branchial arch syndromes11,12; it shows high penetrance but 
very variable expression, part of which may be explained by genetic 
heterogeneity1,1315 A second gene has been identified recently16. 
An enlarged vestibular aqueduct (VA) and a hypoplastic cochlea are common 
radiological findings in Pendred syndrome1719. The hearing loss found in this 
autosomal recessive inherited syndrome varies in severity and progression1719. 
MRI of the petrosal bones and audiometrie follow-up studies showed a correlation 
between a widened VA and this progressive hearing loss17,18. Recently, several 
mutations have been identified in the gene underlying Pendred syndrome 
(PDS)171"2021. Mutations in the PD5 gene and bilaterally enlarged VAs were also 
found in three individuals with congenital profound non-syndromic autosomal 
recessive hearing loss (DFNB4)22. The Perchlorate test was not performed on the 
affected members of this family and therefore Pendred syndrome has not been 
excluded. 
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An enlarged VA and hypoplasia of the cochlea have also been reported in the 
sensorineural deafness-oligodontia syndrome and in the BOR syndrome1,5,23·24. In a 
histopathologic study of the temporal bones of a BOR patient Fitch et al.5 found 
enlarged VAs and cochlear hypoplasia. Daggilas et al.23 and Chen et al.1 were the 
first to demonstrate enlarged VAs on CT scans of BOR patients. In this study 2 BOR 
patients, who had already been followed-up for a long time with repeated 
audiometry and caloric tests, underwent imaging studies to find out whether they 
had similar inner ear anomalies underlying their specific functional features. 
Material and methods 
We investigated a 3-generation family in which three members were affected by 
the BOR syndrome. A mutation in the EYAi gene was found in these 
patients.(authors' unpublished data) Patient A has been previously indicated as 
case C-201 or C-13 4•2527 and patient Β as case C-302 or C-144'25'27. Both patients 
underwent high-resolution CT scanning (Siemens Somiton plus 4, Siemens, 
Forchheim, Germany) in the axial plane, as well as high-resolution heavily T2 
weighted 3D MR imaging of the temporal bones (Magneton Vision, 1.5 Tesla, 
Siemens, Erlangen, Germany). This MRI technique enables 3D reconstruction in 
every desirable plane to study abnormalities of the inner ear structures. Because 
of the presence of endolymph these structures have a high signal intensity on T2 
weighted images. A VA is considered to be widened when the middle part is 
wider than the posterior semicircular canal (SCC) and measures more than 1.5 mm 
on CT and/or MRI28. 
Audiograms were obtained in a sound-treated room, according to common 
clinical standards. Binaural caloric tests were performed with 
electronystagmography (eyes open in the dark) and computer analysis. Statistical 
analyses (Prism PC program, version 2, GraphPad, San Diego, CA, USA) comprised 
linear regression analysis of the longitudinal hearing threshold data and the 
threshold shifts between consecutive audiograms obtained for each frequency; 
this analysis included a runs test on the validity of the (linear) regression model. 
Progression was called "significant" if it could be linked to correlation coefficients 
that were significantly greater than zero at a sufficient number of frequencies 
(binomial distribution statistics). Cofluctuation analysis consisted of performing 
correlation analysis between any relevant pair of synchronous threshold shifts. 
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Cofluctuation was called "significant" if it was linked to a sufficiently high 
number of significant correlations between pairs of synchronous shifts. The 
probability level used in any test was Ρ = 0.05. 
Case s t u d i e s 
Patient A, a 55-year-old man, was seen for the first t ime in 1976 at age 33 years, 
because of bilateral discharging cervical fistulas and 
preauricular sinuses. A cleft palate had been treated surgically 
in childhood. On examination, bilateral cervical fistulas and 
preauricular sinuses were seen (Figure l ) . A preauricular tag 
was noted in front of his left ear. Examination of the 
tympanic membranes showed no anatomical abnormalities. A 
previous intravenous pyelogram had revealed a renal 
malformation2 7. Bilateral mixed hearing loss of 90 dB was ^ u r e 3 
, , , - _ , . , , formed right auricle and 
present25. Calorie tests were performed at age 32 and 44 years preauricular sinus (ar-
and disclosed vestibular areflexia on the left side. The bilateral 
cervical fistulas were removed surgically, as well as the preauricular fistula, which 
communicated with the tympanic cavity26. Exploratory tympanotomy was not 
performed. 
Figure 2 Patient A: CT scan of the 
right ear in the axial plane. 
Widened 1AC ("X") and hypo­
plastic cochlea (arrowhead), the 
vestibule is widened, the lateral 
SCC is slightly too small (arrow). 
Computed tomography of the temporal bones 
demonstrated a wide, plump internal acoustic canal 
(IAC) and a hypoplastic cochlea on both sides. The left 
vestibule appeared to be hypoplastic. The lateral SCC 
was slightly too small (Figure 2). MR! showed a 
marginally widened left VA. The right VA was not 
abnormally wide. No endolymphatic sac could be 
visualised. (Figure 3). 
Figure 3 Patient A: Coronal reconstruction MR1 through the endolymphatic ducts on the right (A) and left side 
(B). The left endolymphatic duct is abnormally wide, whereas the right one is of normal size (arrows). No 
endolymphatic sac could be visualised. 
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Increasing bilateral hearing loss from about 90 dB in 1976 to 100-105 dB in 1998 
was evident in the 22-year audiometrie follow-up data of this patient (n=6 
audiograms, age 32-54 years) (Figure 4). Progression was significant at all 
frequencies, except at 1 and 4 kHz in both ears and at 0.25 kHz in the right ear. 
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Figure 4 Patient A air conduction thresholds plotted against age (R, nght, L, left) These longitudinal threshold 
data show only limited progression, well within the normal limits of presbyacusis (see text) The data are not 
suitable for fluctuation analysis 
However, the slopes were fairly similar to those on plots that were prepared (not 
shown) using median presbyacusis threshold data according to ISO norms at 
similar ages29. The apparent progression vanished at all frequencies when the 
threshold levels were corrected for median presbyacusis. Progression could 
therefore be attributed to presbyacusis. Analysis of fluctuations was impossible 
because of an insufficient number of observations. The air-bone gap (ABG) lies 
between about 50 dB at 0.5 kHz and about 30 dB at 2 kHz. The bone conduction 
threshold increased by about 10 dB between the age of 32 and 54 years, which 
seems to be in line with the threshold increase associated with presbyacusis. This 
patient clearly stated that his hearing had been much better during childhood and 
adolescence. Audiograms obtained at that age could not be retrieved. 
Patient Β is the 30-year-old son of patient A. At his first examination (age 7 years) 
he was found to have a 50 to 80 dB mixed hearing loss. Physical examination 
revealed bilateral cervical fistulas as well as preauricular sinuses (Figure 5). There 
were no preauricular tags but his auricles were slightly cup-shaped. Some 
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retrognathia and a high-arched palate were present and otoscopy showed no 
abnormalities2 5. 
Figure 5 Left panel: Slightly malformed right auricle and preauricular sinus (arrowhead) of patient Β at 7 years 
of age. Right panel: Bilateral second branchial arch fistulas (arrows) of patient Β at 7 years of age. 
In 1976, temporal bone tomography had shown scarcely pneumatised mastoids. 
An abnormal configuration of the ossicular chain was seen, as well as a Mondini-
type cochlear dysplasia and a wide IAC bilaterally. Renal malformations were 
visible on a previously obtained intravenous pyelogram2 7. The cervical fistulas 
were bilaterally excised. Exploratory tympanotomy of the right ear revealed a 
dysplastic, plump long process of the incus and incomplete stapedial crurae. The 
oval niche could not be identified, but the niche of the round window was visible. 
The facial nerve was dehiscent and no ossicular chain reconstruction was 
performed. Five years later, grommets were placed twice in the left ear, because 
of recurrent otitis media with effusion. In 1990, myringoplasty of the left ear was 
performed to close the remaining perforation, however the perforation recurred a 
few years later. The patient also suffered from recurrent external otitis as a result 
of occlusion of the external ear canal by the mold of his hearing aid. 
CT scanning of the temporal bones (Figure 6, left panel) showed a short, wide IAC 
and a hypoplastic cochlea on both sides. MRI of the temporal bone (Figure 6, right 
panel) showed a plump vestibule with normal-sized SCCs. A wide VA and normal-
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sized endolymph sac were found bilaterally. Caloric tests were performed at age 
10 and 16 years; they revealed hyporeflexia on the left side. 
Figure 7 Left panel: CT scan of the left ear in the (transverse) axial plane of patient B. A widened internal 
meatus is visible ("X") as well as a plump vestibule (arrowhead). The vestibular aqueduct (arrow) is widened. 
Right panel: Coronal reconstruction of 3D high-resolution MRI showing an enlarged endolymphatic duct 
(arrows) on both sides of patient Β at the age of 28 years. 
The audiometrie follow-up data of this patient over 23 years (29 audiograms; age 
range, 6-29 years) (Figure 8) demonstrated clear progression of hearing loss. This 
consisted of an increase in the sensorineural component first noted in the right 
ear, which later on also developed in the left ear. Progression may have been 
most prominent early in the follow-up period, especially at the lower frequencies, 
but such an interpretation is questionable, because it was mainly based on the 
earliest audiograms, obtained at the age of 6-7 years. Regression analysis (after 
exclusion of the first audiogram) was performed for air conduction and showed 
that progression was generally significant at all frequencies. However, even after 
exclusion of the first audiogram, progression may have been nonlinear; the runs 
test was significant at 0.25-2 kHz in the left ear and at 0.25 kHz in the right ear. All 
frequencies showed considerable threshold fluctuations (Figure 8). 
Cofluctuation analysis comparing the separate frequencies in each ear showed 
that, with few exceptions, synchronous air conduction threshold shifts between 
consecutive audiograms generally covaried in the same direction. Both the right 
ear (positive, significant cofluctuation in 5 of 10 comparisons) and the left ear (13 
of 15 comparisons showed cofluctuation, 9 of those were significant) showed 
significant cofluctuation of the separate frequencies. Binaural cofluctuation in air 
conduction threshold was observed for the frequencies O.25, 0.5, l , 2 and 4 kHz 
(significant at 0.5 and 1 kHz). Shifts in air and bone conduction thresholds 
demonstrated a high degree of covariation. 
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Progression in bone conduction thresholds was significant at 0.5 and l kHz in 
both ears and at 2 kHz in the left ear. Independently of age, the ABC in both ears 
was 30 to 60 dB at 0.5 to l kHz and under 40 dB at the higher frequencies. Thus 
the ABC did not show any substantial progression, but it did show considerable 
fluctuation. 
It is obvious that ABG data depend on both the air conduction and bone 
conduction levels. We would have liked to evaluate the relationship between 
these variables, but as they are not stochastically independent, regression or 
correlation analysis is prohibited. We therefore only inspected the synchronous 
consecutive shifts in bone conduction level and ABG directly at a given frequency 
in a given ear. We observed a remarkable counterfluctuation (data not shown). 
Stochastical interdependency can be avoided by replacing one of the variables 
involved by the corresponding variable pertaining to the other ear. Following 
such a replacement, we could not detect any significant correlation between any 
of the variables involved. These findings suggest that the observed 
counterfluctuation of ABG and bone conduction threshold pertaining to the same 
ear was a trivial phenomenon. 
Discussion 
More than 20 years of audiometrie follow-up data and recent MRI and CT of the 
temporal bones were evaluated in a father and son with the BOR syndrome. The 
young patient (case B) showed progressive and fluctuant sensorineural hearing 
loss, which first started in the right ear and later affected the left ear. The older 
patient (case A) already had severe hearing impairment, but he clearly indicated 
that his hearing had been much better in the past. Therefore, we may have missed 
any progression and fluctuations in hearing threshold. The young patient, who 
showed clear progression and fluctuation, had a bilaterally wide VA and 
hypoplastic cochlea; caloric responses were diminished on one side only. The 
older patient had a hypoplastic labyrinth on one side with a marginally 
hypoplastic lateral SCC and a marginally wide VA. He showed caloric areflexia on 
that side, but hearing impairment was bilaterally severe and symmetric. 
Therefore, there was (incomplete) correlation between the imaging findings and 
functional performance in these two cases. 
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About 200 cases of the BOR syndrome have been reported in the literature. Only a 
few reports clearly described progressive hearing loss in individual cases330'32. In 
some cases it was recognised in childhood, while other patients reported to have 
had normal hearing before the age of 20. Fourman and Fourman mentioned that 
hearing impairment varied from mild to severe33. Mild head injury can lead to 
progression of hearing loss. This phenomenon appears to be especially related 
with an enlarged VA and has come to be known as the large VA syndrome 
(LVAS)3336. The audiometrie configuration in children with LVAS is usually 
downsloping. The LVAS was found to be an almost obligatory feature of the 
Pendred syndrome in recent imaging studies17"19; this syndrome is caused by a 
mutation in the PDS gene which encodes an chloride-iodide cotransport 
protein20,37. Recently, linkage was found to the PDS locus in several patients with 
an autosomal recessive inherited form of LVAS and no clinical evidence of the 
Pendred or BOR syndrome, whereas another family with the same trait had 
mutations in the PDS gene38,39. Although the cochlear malformation may underlie 
our patients' hearing impairment, it is perhaps more plausible that their 
progressive hearing loss, which was clearly fluctuant in one and accompanied by 
vestibular impairment in both of them, fits in with the LVAS. 
Conclusion 
Our findings suggest a correlation between progressive, fluctuant sensorineural 
hearing loss with caloric hypofunction, all of which constitute the LVAS as part of 
the BOR syndrome. Additional longitudinal case studies are needed to further 
evaluate such a correlation. 
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BOR Syndrome 
Abstract 
Objective: To summarize the syndromic features and evaluate the presence of 
inner-ear anomalies in 35 BOR patients from 6 families (A-F). 
Design: Retrospective evaluation of magnetic resonance imaging of the temporal 
bones and clinical features in patients with BOR syndrome. 
Setting: Tertiary referral center. 
Patients: The study population comprised 35 clinically affected patients with BOR 
syndrome from 6 families. Most of these families were followed for over 25 years. 
Main outcome measures: Twenty-four patients underwent high-resolution heavily 
T2-weighted 3D MR imaging of the temporal bones for evaluation of inner-ear 
anomalies. Special attention was paid to the endolymphatic duct and sac. 
Results: A total of 7 enlarged endolymphatic ducts and sacs (3 bilaterally, 4 
unilaterally) and 5 enlarged endolymphatic ducts only (2 bilaterally, 3 unilaterally) 
were observed. Nine hypoplastic cochleas and 6 hypoplastic labyrinths were seen 
bilaterally. Eight family members had normal inner ears. 
Conclusion: These findings suggest that inner ear anomalies are frequent but non-
obligatory features of the BOR syndrome. 
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Introduction 
The branchio-oto-renal (BOR) syndrome is defined as an autosomal dominant 
inherited disorder characterized by the following three essential clinical features: 
(l), hearing loss with structural defects of the external, including earpits, middle 
and/or inner ear;(2), second-branchial arch defects; and (3), renal anomalies, 
ranging from mild hypoplasia to aplasia, which can lead to varying degrees of 
renal failure. Accompanying features like lacrimal duct stenosis or a high-arched 
palate can also be present in these patients14. One gene underlying the BOR 
syndrome, EYAi (chromosome 8qi3.3) has been identified5"8. Recent linkage 
analysis provided evidence for a second gene on chromosome iq3 i 9 . This disorder 
has a high penetrance but variable clinical expression. The major clinical findings 
associated with BOR syndrome are branchial clefts, hearing loss and renal failure1 
''•
1
°·
11
. The general prevalence of BOR syndrome is 1 in 40,000 people, and it occurs 
in 2% of profoundly deaf children". 
Radiological and histological investigations have demonstrated the presence of 
congenital inner ear anomalies in patients with BOR syndrome413. Enlarged 
vestibular aqueduct and cochlear hypoplasia have been identified and may be 
important findings in BOR syndrome. 
The syndromic features of 35 patients with BOR syndrome from 6 families are 
described in the present article. Magnetic resonance imaging (MRI) of the 
temporal bones was performed in most of the patients to evaluate inner ear 
anomalies. Special attention was paid to a large endolymphatic duct and sac. 
Patients and methods 
We investigated 6 families with BOR syndrome (families Α-F) with 35 affected 
family members. The family members who participated in this study were seen at 
the outpatient clinic of the Department of Otorhinolaryngology, University 
Medical Center St Radboud, Nijmegen, the Netherlands. Most of these BOR 
families were followed for over 25 years3101417. Renal function tests, intravenous 
pyelography and/or ultrasonography of the kidneys have been performed to 
record any renal involvement in most patients11. Pedigrees were updated (Figure 
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l) and the results of the otorhinolaryngological examination were evaluated 
(Table l) . 
Twenty-four patients underwent high-resolution heavily T2-weighted 3D MR 
imaging of the temporal bones (Siemens Magnetom Vision, 1.5 Tesla; Siemens, 
Erlangen, Germany). This MRI technique enables 3-dimensional reconstruction in 
any desirable plane to study abnormalities of the inner ear structures. Owing to 
the presence of endolymph these structures have a high-signal intensity on T2-
weighted images. Thin-section MR imaging technique enables us to visualize the, 
often invisible, endolymphatic duct and sac, especially if they are enlarged18. The 
endolymphatic duct is considered to be dilated when its diameter, at the midpoint 
between the common crus and its external aperture, is 1.5 mm or more on thin 
section images19. 
Linkage analysis and/or mutation analysis of the EYAi gene is performed in all 6 
families 
Results 
The pedigrees of the families A through F are shown in Figure 1 and relevant 
clinical information is presented in Table 1 for each affected family member 
separately. The number of affected individuals in each generation conformed to 
an autosomal dominant pattern of inheritance with close to 100% penetrance in 
almost each family, i.e. including the ones indicated as 'affected by history', 
whose children were affected. The only possible exception was the second 
generation of family E (P= 0.04 in binomial distribution). Male-to-male 
transmission was documented in families A, C and D. 
Clinical features present in about 32 cases (95%), were malformed auricles, 
preauricular sinus and/or pit, second-branchial arch fistula and hearing 
impairment. Renal malformation was fairly common (13 patients [37%]), whereas 
preauricular tags and lip pits (6 patients [17%]) were less common. The 
penetrance of these features did not differ significantly in any of the separate 
families from the average penetrance calculated for the combined families. 
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Figure 1 Overview of the pedigrees of the 6 
participating with branchio-oto renal (BOR) 
syndrome (families Α-F) The clinical features 
of the persons affected by BOR syndrome 
are presented in more detail in Table 1 
. Open symbols represent unaffected cases, 
Jf ^ whereas filled symbols are affected by the 
2 *• BOR syndrome Probands are indicated by a 
black arrow, MRI of the petrosal bones was 
performed in patients indicated by a plus 
sign, possibly affected cases are indicated by 
a question mark Slashed symbols have 
deceased, and double slashes, separated or 
divorced relationships SB sindicates 
stillbirth,SE, spontaneous abortion 
Most of the patients had had their second branchial arch fistulas surgically 
removed. Preauricular sinus and/or pits or tags had only been removed 
incidentally. Surgical intervention is often indicated because of recurrent infection 
of these anatomical variations. Aesthetic surgical correction of malformed auricles 
has been performed in a few cases (Table i ) . Nine patients (38%) required middle-
ear surgery. Cremers et al.1 0 1 4 1 6 and Kemperman et al.17 described the results and 
details of these interventions and, based on these data, discussed the impact of 
syndromic diagnosis, including BOR syndrome, on the outcome of reconstructive 
ear surgery20. 
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Table l Clinical features in family A-F. 
Family 
^3,10,11,18 
„3,10 
£11,14,16,17 
D6,16 
E7 
F 
Case 
11-7 
III-3 
III-5 
111-11 
111-13 
IV-2 
IV-3 
IV-6 
IV-10 
IV-11 
IV-12 
IV-17 
IV-23 
V-5 
11-2 
III-2 
III-6 
III-7 
IV-1 
IV-2 
IV-7 
IV-9 
l l - l 
III-2 
IV-1 
11-6 
III-4 
III-5 
IV-1 
11-4 
III-4 
IV-1 
1-2 
l l - l 
11-2 
Malformed Preauricular Sec.branchial Hearing Renal . . . . . . . 
aundes sinus/pit/fistula arch fistula loss malformation Additional information 
R+L R+L R+L + 
R+L L + 
R+L R+L R+L + R+L R preauricular tag 
na na na na na Died from renal failure 
R+L R R+L* + 
R+L R+L R+L+M* + R+L 
R+L - + R+L Severe renal failure-»Kidney transplantation; 
R+L R+L R+L + 
R+L R+L R+L + 
R+L R+L R+L* + 
na na na na na Died from renal failure 
R+L L - + + R lip pit 
R+L R*+L* R+L* + na Bilateral reconstruction of external auditory canal atresia 
R R+L R*+L* + L Born with inspiratory stridor caused by bilateral recurrent nerve palsy 
R+L R*+L* + IVP normal Hearing worse after giving birth to daughter;reduced renal function 
R R*+L + L hypopl kidney Diminished renal function 
+ R+L R*+L* + - Dolichocephal skull; Bilateral surgical correction of malformed auricles 
+ R+L L* + - High-arched palate 
R+L - - na 
+ R+L R*+L* + na 
R+L L R*+L* - - Bilateral lacrimal duct aplasia; dolichocephal skull 
R+L R+L - + - H ip pit; Bilateral surgical correction of malformed auricles 
R+L* R*+L* + + Normal renal function;L preauric tag*; Surgical treatment of cleft palate 
+ R+L R*+L* + + Myringoplasty L ear 
+ R+L R+L + + 
R+L R+L + - R lip pit 
+ R+L R* + - R external auditory canal atresia; Lear microtia 
R+L L + - R lip dimple;L lippit;R+L preauric. tags*;R+L surgic correction auricles 
L - na - Small accessory ear L 
+ - R+L + 
+ R+L - - High-arched palate 
R*+L* R*+L* + High-arched palate; Surgical correction of Fallot's tetralogy 
R+L R*+L* + 
R R*+L* R*+L* + L dysplastic 1. R sided hemifacial microsomia with normal facial nerve function 
kidney 2. Submucosal defect of lateral R part of orbicularis oris muscle 
3. Severe renal failure. Kidney transplantation planned 
4. Bilateral fistulas in medial eye canthus 
R+L R* + 
R, right; L, left; M, median; +, present; -, not present; na, not available; *, surgically removed; IVP, intravenous pyelography. Probands are in boldface 
Table 2 MRI findings of the temporal bones and serial audiometry in 6 BOR families (Α-F). Probands in bold print 
Case: 
Alll:3 
Alll:5 
AIII:13 
AIV:2 
AIV:3 
AIV:6 
AIV:17 
AIV:23 
Bll:2 
Blll:2 
Blll:6 
Blll:7 
BIV:2 
BIV:7 
BIV:9 
Cll:l 
Clll:2 
Dll:6 
Dlll:4 
Dlll:5 
Ell:4 
Elll:4 
EIV:l 
Fl:2 
FILI 
Fll:2 
MRI 
Bilateral hypoplastic cochlea; LEDS left; LED 
right 
n a * 
LEDS right; mild bilateral cochlear and 
vestibular hypoplasia 
LED bilateral 
Normal 
Normal 
Bilateral hypoplastic cochlea and 
dysplastic semicircular canals 
LEDS bilateral; mild bilateral cochlear and 
vestibular hypoplasia 
n a · 
Mild bilateral cochlear and vestibular 
hypoplasia 
LEDS bilateral 
LEDS right; mild LED left; subtle bilateral 
hypoplastic labyrinth 
Plump internal acoustic canal (right more 
than left); bilateral hypoplastic cochlea and 
vestibule; LEDS bilateral 
Normal 
Bilateral mild hypoplastic cochlea and 
labyrinth 
LED left 
Plump vestibule; LED bilateral 
Normal 
Bilateral wide internal meatus 
Normal 
Plump internal acoustic canal; 
Normal 
Fluid in middle ear and mastoid; normal 
Bilateral plump internal meatus; bilateral 
hypoplastic cochlea; LEDS right 
Normal 
Bilateral hypoplastic cochlea 
Relative frequencies of anomalous findings on 
T o O f e c £ndZ7ahcatÌC Other 
4/7 4/7 3/7 
4/6 3/6 4/6 
0/2 2/2 1/2 
0/3 0/3 1/3 
0/3 0/3 1/3 
2/3 1/3 1/3 
MRI of: 
Any 
5/7 
ζ / β j ' v 
2/2 
1/3 
1/3 
2/3 
Serial audiometry 
Progressive hearing loss 
Progressive fluctuant hearing loss 
na 
Progressive fluctuant hearing loss 
Progressive fluctuant hearing loss 
na 
Progressive fluctuant hearing loss 
na 
Progressive fluctuant hearing loss 
Progressive hearing loss 
na 
Progressive hearing loss 
No progressive fluctuant hearing loss 
Progressive fluctuant hearing loss 
na 
No progressive fluctuant hearing loss 
Progressive fluctuant hearing loss 
na 
na 
Fluctuant hearing threshold 
na 
na 
No progressive fluctuant hearing loss 
No progressive fluctuant hearing loss 
na 
Progressive hearing loss 
LED, large endolymphatic duct; LEDS, large endolymphatic duct and sac; LES, large endolymphatic sac; na, not available; *, CT scans performed (outside present scope) 
BOR Syndrome 
The MRI findings in the 6 BOR syndrome families are given in detail in Table 2, 
together with the findings of serial audiometry, and the relative frequency of 
anomalous MRI findings by structure are summarized in Table 3. In 7 patients a 
large endolymphatic duct and sac (LEDS) (3 bilaterally; 4 unilaterally) and in 5 
others a large endolymphatic duct (LED) (2 bilaterally; 3 unilaterally) were 
observed. 
Table 3 Summary of anomalous MRI findings by structure in 6 BOR families (A-F) 
Anomalous findings in 
Cochlea 
Endolymphatic duct/sac 
Other 
Total 
Relative frequency 
9/24 
10/24 
10/24 
16/24 
Nine hypoplastic cochleae and 6 bilateral hypoplastic labyrinths were present 
(Table 2). We did not find any congenital defects in 8 affected BOR patients. 
Figure 2a MRI of the temporal bones of case BIII-6 showing a bilaterally enlarged endolymphatic duct. 
In most cases the type of hearing loss was mixed. Long-term audiometrie follow-
up analysis (threshold data not shown) demonstrated that progressive, fluctuant 
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sensorineural hearing loss is not uncommon in the BOR syndrome (Table 2); we 
were unable to confirm this feature in all BOR patients17,21. 
Although a considerable proportion of cases exhibited anomalous findings, we 
were unable to find a clear relationship between these and any of the features of 
hearing impairment (progressive and/or fluctuant). 
Figure 3 MRI of the temporal bones of case BIV-2 showing a bilaterally plump internal acoustic canal, 
bilateral hypoplastic cochleas and vestibules with an enlarged endolymphatic duct on both sides. The 
endolymphatic sac is also bilaterally enlarged (not shown here). 
Figure 4-/e/t panel: MRI of the right temporal bone of a normal individual showing the normal configuration 
of the cochlea, the vestibule and the lateral semicircular canal. Right panel: MRI of the left temporal bone of 
case FII-2, showing a hypoplastic cochlea. 
Linkage to the EYAl locus was found in family A22 and family B, however no 
mutations were detected by mutation analysis (author's unpublished data, 1999)· 
In family C a mutation (IVS-9 G>C at -l) (author's unpublished data, 1999) was 
found which probably results in aberrant splicing of the gene. Mutation analysis 
in family D showed the presence of a missense mutation (T-to-C transition at 
position 1,360) in exon 13, resulting in a Ser454Pro substitution in the EYAl 
protein6. Family E has a delC at position 1592 of exon 15 causing a frameshift 
mutation7. No mutation has been detected in family F yet. 
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Discussion 
Inner-ear abnormalities can be regarded as common findings in patients with BOR 
syndrome. Recently the presence of such abnormalities in combination with 
progressive hearing loss has been demonstrated in Pendred syndrome. In 
particular, the presence of an enlarged vestibular aqueduct was an almost 
obligatory finding in these patients23,2". The autosomal recessively inherited large 
vestibular aqueduct syndrome (LVAS) is a distinct clinical entity, although 
mutation analysis has shown that the LVAS and the Pendred syndrome both share 
mutations in the pendrin gene (PD5)25. 
The present study shows that inner-ear anomalies, such as cochlear hypoplasia and 
large endolymphatic duct and sac are frequent features of the BOR syndrome. This 
syndrome shares these features as well as progressive, fluctuant hearing loss with 
the Pendred syndrome. However, although such features were non-obligatory, but 
frequently present in our BOR patients, they were not clearly correlated to one 
another. The latter result was obtained by testing on possible correlations of the 
pooled data of all families. This procedure is, obviously, not permitted if there is 
genetic heterogeneity between the present families. Unfortunately we have 
insufficient information on form (MRI), impaired function (progressive and/or 
fluctuant hearing impairment) and linkage/mutation analysis to test for such a 
correlation in each family, even the largest ones, separately. 
Because of the pathognomic presence of an enlarged vestibular aqueduct, 
computed tomographic scanning of the temporal bones can function as a 
diagnostic procedure in Pendred syndrome. We know from our experience that 
the branchiogenic origin of BOR syndrome can cause a wide range of anatomic 
malformations of the outer-, middle- and inner ear structures. Indeed, many 
different forms of inner-ear anomalies were present in our patients, however none 
of them seems to be pathognomic for BOR syndrome. Nevertheless MRI remains a 
useful additional tool that can visualize the neuronal tissues and the endolymphatic-
and perilymphatic filled structures, such as the cochlea and endolymphatic duct. It is 
clear that this technique refines our knowledge of the inner-ear anatomy in general 
and specifically in BOR patients. 
Until now many mutations in the EYAl gene have been described57 and recent 
linkage analysis provided evidence of involvement of another gene underlying the 
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BOR syndrome9. No mutations are detected in the coding sequence of EYAi in 
approximately 70% of families with the BOR-phenotype. It would be interesting to 
perform further linkage analysis in such families. This would enable us to study 
the possible correlations between imaging findings, audiometrical follow-up 
results and linkage results. 
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BOR Syndrome 
Abstract 
We retrospectively analysed long-term serial audiometry data in patients with the 
branchio-oto-renal (BOR) syndrome to show the features of progression and 
fluctuation in hearing impairment and relate the findings to the patient's age and 
magnetic resonance imaging (MRI) findings in their petrosal bones. 32 clinically 
affected BOR patients from 6 Dutch families (Α-F) were included. Audiograms were 
available in 24 cases, covering follow-up intervals of between 3 and 30 years, and 
suitable for individual statistical analysis in 16 of them; 14 cases also had MRI 
findings. Significant progression in hearing impairment was found in 10 cases, while 
findings of significant fluctuation were made in 7 cases. These findings did not 
clearly correlate with MRI findings. Substantial fluctuation occurred only in cases 
followed at a relatively young age. Patients with an enlarged endolymphatic duct 
and/or sac showed significantly higher sensorineural hearing thresholds than those 
with either normal MRI findings or cochlear/labyrinthine hypoplasia with or without 
enlarged duct or sac. We conclude that progressive, fluctuant hearing loss occurred 
in some of BOR patients, however, only young patients showed substantial 
threshold fluctuation. BOR patients with an enlarged endolymphatic duct and/or sac 
on MRI seemed to be predisposed to developing more severe hearing impairment. 
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Introduction 
The autosomal dominant branchio-oto-renal (BOR) syndrome shows a broad 
spectrum of clinical manifestations comprising various combinations of branchial-
arch, otic and renal anomalies. The four most characteristic clinical features are: 
(l) second-branchial arch cleft or sinus; (2) hearing loss; (3) malformations of the 
outer, middle and/or inner ear, including earpits; (4) renal anomalies, ranging 
from mild hypoplasia to complete agenesis13. Other features, such as facial and/or 
palatal abnormalities, have also been associated with BOR syndrome". Although 
this disorder shows high penetrance, expression can be quite variable13. BOR 
syndrome, occurring in 2% of profoundly deaf children, has an estimated general 
prevalence of 1:40,00ο5. 
Mutations in the EYAl gene (8qi3.3) were found to underlie this classical 
syndrome69. ΕΥΑ genes form a family of transcription activators that interact with 
other proteins to regulate early embryonic development1011. Interestingly, in 
approximately 70% of families with the BOR phenotype no mutations are detected 
in the coding sequence of EYAi"12. In a large family with an almost similar clinical 
syndrome Kumar et al.13 identified linkage to chromosome i p 3 i using a genome 
wide search. 
The type of hearing loss associated with the BOR syndrome can be conductive, 
sensorineural or mixed. Until recently, hearing impairment has generally been 
assumed to be stable; progressive hearing loss has only been reported in a few 
cases, without specific details1416. Recent long-term serial audiometry and 
magnetic resonance imaging (MRI) of the inner ears in BOR patients 
demonstrated the presence of progressive sensorineural hearing loss and inner 
ear anomalies, including an enlarged vestibular aqueduct, suggesting that these 
findings have a causative relationship1718. The combination of progressive, 
fluctuant sensorineural hearing loss and a wide vestibular aqueduct has already 
been demonstrated in Pendred's and the enlarged vestibular aqueduct (EVA) 
syndrome19,20. 
In this study we present the results of an audiometrical long-term follow-up analysis 
performed in 32 BOR patients from 6 Dutch BOR families (Α-F), especially focusing 
on the features of fluctuation and progression and their possible relationship to 
80 
BOR Syndrome 
inner-ear morphology. The patient's age during follow up and the various types of 
MRI findings were also related to the sensorineural hearing threshold. MRI of the 
temporal bones in 24 affected family members from the same families 
demonstrated that inner ear anomalies are frequent, but non-obligatory features 
of the BOR syndrome21. 
Patients and methods 
We included 32 BOR patients from 6 Dutch families (Α-F) in this study. All patients 
participating in this study underwent ORL examination. Anamnestically special 
attention was paid to exclude other possible reasons for hearing impairment. 
Clinical features, details on middle-ear surgery, inner-ear findings obtained with 
MRI as well as some genetic analysis results have been reported in detail 
previously3,78'18212'1. Collected blood samples were sent to Boys Town National 
Research Hospital for genetic evaluation, which involved linkage analysis to the 
EYAi locus. Mutation analysis of the EYAl gene was performed when positive 
linkage was found. Previously obtained audiograms were retrieved for dedicated 
statistical analysis. Special attention was paid to the features of progression, i.e. 
threshold increase, and fluctuation, i.e. cyclic threshold changes. Comparing any 
two modulating thresholds at a given frequency, the feature of simultaneous in-
phase changes (both either deteriorating or improving) was called cofluctuation, 
whereas the feature of simultaneous changes in counterphase (one deteriorating, 
the other improving) was called counterfluctuation. 
Statistical analysis 
Individual serial audiograms were used to plot threshold (dB hearing level = HL) 
against age for air conduction (AC), bone conduction (BC), as well as air-bone gap. 
Statistical analysis was performed using the Prism program (PC version 3.02, 
GraphPad, San Diego, CA, USA). Linear regression analysis was employed to evaluate 
any age trend in hearing impairment in unoperated ears. Progression was called 
significant if a significant positive regression coefficient (P < 0.025) was found. 
Systematic significant progression was concluded to exist if the relative frequency of 
significant findings in a given data subset, i.e. the relative number of "hits" was high 
enough to show significantly low tail probability (P < 0.05) in the corresponding 
binomial distribution. Cofluctuation was evaluated by analysing the residues after 
linear regression in pairwise comparisons and establishing the correlation matrix for 
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all the relevant parameters (AC or BC in the R or L ear) pertaining to the separate 
octave frequencies 0.25-8 kHz. Pairwise comparisons involving a set (or sets) of 
residues with insufficient data (id) or residues at error level (el) were not tested (nt) 
on significant correlation. Significant positive correlation coefficients were related to 
eight different categories of pairwise comparisons involving: (1, 2) ipsilateral (R or L) 
AC thresholds; (3) contralateral (R and L) AC thresholds; (4, 5) ipsilateral (R or L) AC 
and BC thresholds; (6, 7) ipsilateral (R or L) BC thresholds; (8) contralateral (R and L) 
BC thresholds. Cofluctuation was concluded to exist if the finding of a significant 
positive correlation coefficient occurred significantly more often (P < 0.05) among 
the relevant tests than predicted on the basis of the appropriate binomial 
distribution statistics, provided that all data pertained to substantial fluctuation, i.e. 
the presence of residues > 5 dB in the regression analyses. Similarly, a significant 
high prevalence of the finding of a significant negative correlation coefficient was 
taken to substantiate the phenomenon of counterfluctuation. MRI findings and 
variables or features such as the patient's family, age, sensorineural hearing (BC) 
threshold, progression and fluctuation in threshold were evaluated for possible 
intercorrelations. The possible correlation between family, BC threshold, MRI 
findings and progression and/or cofluctuation was evaluated using contingency 
tables including all relevant findings in the available cases; tables were reduced to 
2x2 tables where appropriate and Fisher's exact probability test was applied. Age 
was taken into account, as illustrated below (Figures 3 and 5), if these tests 
involved age-dependent variables, such as the BC threshold. Student's t test was 
used for comparisons between (sub)groups and included Welch's correction if 
Bartlett's test detected unequal variances. 
Results 
The pedigrees of the participating families (Α-F) are shown in Figure 1. Although 
positive linkage to the EYAl locus was found in all 6 families, mutation analysis so 
far identified EYAl mutations in the families C (IVS-9 G>C at -l) (authors' 
unpublished data), D (Ser454Pro)7 and E (l592delC)8. Serial audiograms of 24 
affected BOR patients were available in these families, however, only 16 cases 
were suitable for longitudinal analysis (Tables 1 and 2). We analysed progression 
(BC) and fluctuation in hearing (AC and BC) threshold in these cases and were able 
to demonstrate significant progression in 10 out of 16 testable cases. 
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Figure l Pedigrees of the 6 participating BOR families (Α-F). Long-term audiometrie follow up was suitable for 
analysis in persons indicated by a side cross (V); α man; o, woman; affected persons in black (•,·); +, MRI 
performed; ?, affected by history, SB, stillbirth; O, sex unknown. 
The presence or absence of progression is shown together with the outcome of 
MRI of the inner ears in Table i. There was no significant correlation between the 
absence/presence of progression and the type of MRI findings. 
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Table l Threshold progression and detailed MRl findings in 16 affected patients 
Follow-up Significant 
interval Ν progression MRl findings 
Fam Case (age m years) R L 
III-3 
III-5 
A IV-2 
IV-3 
IV 17 
11-2 
III-2 
Β III-7 
IV-2 
IV-7 
ll-l 
c 
III-2 
D III-5 
E IV-1 
1-2 
F 
11-2 
35-57 
54-73 
17-39 
14-37 
6-35 
49-79 
18-47 
11-40 
6-17 
3-19 
32-55 
6-29 
15-27 
13-16 
35-47 
4-21 
4-5 
4-10 
6-23 
6-15 
8-22 
3-12 
5 
3-12 
3-8 
4-24 
4-6 
3-29 
4-12 
4-8 
3-4 
6-16 
yes yes Hypo cochlea R/L, LEDS L, LED R 
yes na na* 
na yes LED R/L 
no no Normal 
yes na hypo cochlea R/L, dysplastic SCCs R/L 
no yes na* 
no no hypo cochlea, vestibule R/L 
yes na LEDS R, mild LED L, subtle hypo labyrinth R/L 
no no Plump IAC (R>L),hypo cochlea R/L,hypo vestibule R/L,LEDS R/L 
yes yes Normal 
no no LED L 
yes yes Plump vestibule, LED R/L 
na na Normal 
no no Normal 
yes yes Plump IAC R/L, hypo cochlea R/L, LEDS R 
no yes Hypo cochlea R/L 
n, number of available longitudinal measurements (variable across frequency), hypo, hypoplastic, IAC, 
internal acoustic canal, L, left, LED(S), large endolymphatic duct (and sac), R, right, SCCs, semi-circular canals, 
na, not available, *, CT scans performed (beyond present scope) 
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Table 2 Relative frequency of pairwise threshold residue comparisons showing significant positive correlation indicating cofluctuation, shown with overall MRI findings. 
Studied cases with centre age < 25 in bold. Significantly high relative frequencies in italics. Relative frequencies of comparisons with significant negative correlation indicating 
counterfluctuation are also included 
Family-ïCase Centre Fluctuation findings MRI findings 
age" (y) Pairwise comparison by AC threshold Pairwise comparison byAC&BC thresholds Pairwise comparison by BC threshold 
Ipsilateral Contralateral Ipsilateral Ipsilateral contralateral 
R( l ) * L(2) (3) R(4) L(5) R(6)· L(7) (8) R L 
II1-3 
II1-5 
A-» IV-2 
46 
63.5 
28 
IV-3 25.5 
IV-17 20.5 
11-2 
III-2 
B-> III-7 
IV-2 
IV-7 
l l - l 
c^ 
III-2 
D-» III-5 
E^ IV-1 
1-2 
F-» 
11-2 
64 
32.5 
25-5 
11.5 
11 
43-5 
17.5 
21 
14.5 
41 
125 
Relative f req of tested 
cases with S fluctuation 
Cofluctuation 
Counterfluctuation 
id 
el 
na 
1/15 
10/15 
el 
el 
el 
J/15 
11/15 
el 
7/10 
na 
id 
el 
15/15 
5/6 
id 
na 
4/15 " 
5/15 
na 
el 
el 
na 
7/15 
7/15/J/151 
el 
8/15 
na 
id 
el 
15/15 
6/6 
1/6 
nt 
nt 
na 
5/36 
na 
nt 
nt 
na 
12/36 
2/36 
nt 
S/30l7/30c 
na 
nt 
nt 
30/36 
4/5 
1/5 
nt 
nt 
na 
nt 
2/30 
nt 
nt 
nt 
0/30 
S/36 
na 
6/20 
na 
nt 
nt 
nt 
2/4 
na 
na 
3/30 
0/30 
na 
nt 
nt 
na 
nt 
1/36 
na 
2/18 
na 
nt 
nt 
nt 
1/4 
id 
el 
na 
el 
7/10 
id 
el 
id 
3/10 
3/14 
na 
5/6 
na 
id 
el 
el 
4/4 
na 
na 
2/10 
2/10 
na 
el 
id 
na 
id 
1/14 
na 
1/6 
na 
na 
el 
el 
2/4 
na 
na 
na 
nt 
na 
nt 
nt 
na 
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abn 
na 
abn 
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abn 
na 
abn 
abn 
abn 
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na 
abn 
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abn 
na 
abn 
abn 
abn 
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abn 
abn 
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norm 
abn 
abn 
AC, air conduction (threshold); BC, bone conduction (threshold); el, error level; id, insufficient data; na, not available; nt, not tested; ', mean of minimum and maximum age 
during follow up;b, η,/nj (relative frequency) indicates n, pairwise comparisons showing significant correlation among n2 pairwise comparisons; c, relating to significant 
negative correlation indicating counterfluctuation (AC); S, significant; *, numbering of pairwise comparisons presented in Patients and Methods 
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Figure 2 illustrates the clear fluctuations in case Fll-2 with a series of the most 
elaborate audiograms. The fluctuations can be appreciated from this figure by 
looking at the striking consecutive changes in (AC and BC) threshold 
configurations and the associated changes in the extent and pattern of the air-
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Figure 2 Illustration of fluctuation in case Fll-2. 
Consecutive audiograms (age in years) with sufficient 
data pertaining to air conduction (square symbols) and 
bone conduction (circles) are shown (R and L ear in 
juxtaposition) from top left downwards. The 
crosshatched area highlights the consecutive changes 
in air and bone conduction levels and the resulting 
variation in extent and shape of the air-bone gap. 
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bone gap (Figure 2, crosshatched areas). Large longitudinal variations occurred in 
either ear, anywhere within the audio frequency range. Similar such variations 
were observed in all our follow-up cases. Remarkably, the extent of the air-bone 
gap during follow up varied between o and about 30-60 dB; it did not show a 
consistent, significant age-related trend (data not shown). There was a clear, 
significant relationship between age during follow up and the finding of 
significant cofluctuation (Table 2). The 8 studied cases with évaluable fluctuation 
and a centre age, i.e. the mean of minimum and maximum age during follow up, 
of > 25 years bilaterally showed fluctuations only at error level, i.e. about ±5 dB, 
with few exceptions, and could not be called substantial. MRI findings obtained in 
6 of these cases were normal in only one of them. The 5 cases with centre age < 
25 years (highlighted in bold in Table 2) showed significant cofluctuation and 
abnormal MRI findings, except for one case. This is illustrated in Figure 3 with 
data pertaining to the right ear; it was checked that similar findings were 
obtained for the BC thresholds pertaining to the left ear. "Fuzzy" and "noisy" 
superposition plots in Figure 4 are associated with a lack of cofluctuation in most 
cases. It can also be noted that the non-significant fluctuation in left BC threshold 
(comparison (7) in Table 2, relative frequency 1/6) makes the other pairwise 
comparisons involving the left BC threshold, i.e. (5) and (8) also non-significant. 
The same applies to patient BIV-7 (Table 2). 
In some cases, fuzziness may be due to the combination of significant 
cofluctuation and counterfluctuation (Table 2 and Figure 4). Significant 
BC R 2 kHz 
Age (year) 
Figure 3 BC threshold (R ear) at 2 kHz plotted against age for the right ear in all cases, illustrating the 
finding that significant fluctuation above error level (highlighted by bold lines) only occurred at age < 25 
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counterfluctuation did not occur sufficiently more often among the cases than 
could be expected on the basis of chance alone according to binomial distribution 
statistics (Table 2, bottom row). This also applies to contralateral cofluctuation in 
bone conduction threshold and cofluctuation of the air and bone conduction 
threshold ("AC & BC") in the left ear. All the other types of cofluctuation indicated 
could be called substantial (Table 2). Remarkably, these included contralateral 
cofluctuation of air conduction thresholds. 
The features of cofluctuation and type of MRI finding (alone or in any 
combination) did not show any significant correlation. Figure 5 shows clear 
threshold separation at 1-4 kHz between the cases with enlarged endolymphatic 
duct (LED) and/or sac (LEDS) alone on MRI and the others. The finding of 4 such 
cases, all showing relatively poor thresholds, compared to 9 other age-matched 
cases with different MRI findings, all showing relatively more favourable 
thresholds, was significant (Fisher's exact probability test). Similar plots as shown 
in Figure 5 were prepared highlighting the different families. The only significant 
family-related finding (taking age into account) was that family A showed 
remarkably favourable BC thresholds. The two family C cases showed remarkably 
high thresholds; both these cases pertain to the LED(S) category. 
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BC R 0,5 kHz 
BC R ? kHz 
0 -I 1 * 1 ^ t " " — ι 1 1 1 r 
O 10 20 30 40 50 60 70 80 
o 10 20 30 40 30 60 70 Θ0 
Figure 5 BC threshold (R ear) plotted against age for the 0.5-4 kHz frequencies. The other frequencies have 
not been consistently measured in all cases. The highlighted cases (bold lines) are those showing only 
LED(S) on MRI. Family A is indicated by asterisks and dashed lines. 
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Discussion 
The analyses performed in this study unequivocally substantiated progression in a 
number of BOR cases that could be evaluated. Substantial cofluctuation was found 
in a number of cases, mainly the younger ones (< 25 years). However, there was an 
obvious bias present: Figure 3 shows a much higher sampling rate for the cases 
aged <25 years than for the older ones. Fluctuations at a more advanced age may 
have been missed by undersampling. It is possible that fluctuations tend to occur 
predominantly in the first decades of life, but this issue can only be settled by 
performing uniform sampling over the whole age range at a sufficiently high rate. 
There was no significant correlation between progression and age or MRI findings, 
or cofluctuation and MRI findings. Remarkably, patients with LED(S) alone on MRI 
showed significantly poorer thresholds in appropriate comparisons than patients 
with different MRI findings. This finding suggests that an enlarged endolymphatic 
duct and/or sac predispose towards more severe hearing impairment in BOR 
syndrome. However, we have no explanation for the present observations that 
patients having combinations of cochlear/labyrinthine hypoplasia and LED(S) did not 
show significantly poorer thresholds than either patients with normal MRI findings 
or hypoplasia alone, and better thresholds than patients with LED(S) alone. It should 
be emphasised that significant progression and/or cofluctuation was also found in 
cases with only cochlear hypoplasia or even normal MRI findings. 
According to a literature review concerning the degree of hearing impairment in 82 
BOR patients performed by Stinckens et al.17 the median values for air conduction 
threshold, bone conduction threshold and air-bone gap were 50 dB, 30 dB and 20 
dB, respectively. These findings seem to be in line with those of our families, except 
for our LED(S) cases who showed greater impairment at most frequencies (Figure 5). 
A substantial air-bone gap may be also present in patients with large vestibular 
aqueduct syndrome (LVAS)25. We have no idea about the possible pathophysiologic 
mechanism underlying the longitudinal individual variations in air-bone gap. Xu et 
al." inactivated the Eyai gene in mice and reported that Eyai*'' heterozygotes 
showed conductive hearing loss, with a remarkable amount of variation, associated 
with middle-ear malformations. These malformations comprised ossicular chain 
anomalies, including discontinuity. However, we are not aware of middle-ear 
malformations being associated with fluctuations in conductive hearing impairment. 
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The present study demonstrated significant fluctuation (at least in the young BOR 
patients). A great variation in audiogram configuration has been noted to exist 
between different BOR patients in several studies involving either cross-sectional 
analysis or presentation of selected audiograms26. In light of the present findings, it 
should be realised that individual longitudinal threshold data may entail such large 
fluctuations that the validity of "snapshot" intersubject threshold comparisons can 
be questioned. Besides this, Anderson et al.27 described congenitally hearing 
impaired children with pseudo-mixed hearing loss mainly present at 0.25 - 2 kHz. He 
proposed that the observed air-bone gap was an artifact of measurement due to 
subtle congenital malformations of the ossicular chain, subsequently changing its 
inertial mass without restricting its transmission function. The air-bone gap is thus 
regarded as a manifestation of an increased inertia component of the bone-
conduction apparatus27. Perhaps in the line of this, concern has recently been 
expressed about systematic errors in BC conduction audiometry, especially in case of 
conductive loss, resulting in a pattern of 'notching' at 2 kHz28. As fluctuations in our 
patients not only aff ected this frequency, but also other frequencies, as well as the 
AC threshold, these effects cannot explain all the present findings. 
It might seem possible that the air-bone gap and threshold fluctuations findings 
are related to otitis media with effusion (OME). OME certainty forms part of the 
clinical picture of branchio-oto-renal syndrome in many cases. We have 
retrospectively screened the clinical notes related to the occurrence of OME and 
tympanometric data, especially in the patients with clear fluctuations. Owing to 
the fact that only incidental observations and measurements were found, we 
were unable to evaluate the possible effects of OME. However, it is very difficult 
to reconcile OME with finding such as contralateral fluctuations as well as 
fluctuations in bone conduction thresholds. 
Apart from BOR syndrome and the autosomal recessive LVAS, progression of 
sensorineural hearing loss combined with the presence of an enlarged 
endolymphatic duct/enlarged vestibular aqueduct has also been demonstrated in 
Pendred's syndrome20. In comparison to BOR syndrome, however more rapid 
progression at a younger age ultimately leads to higher thresholds in the Pendred 
syndrome19. Mutation analysis of the involved SLC26A4 gene in such patients 
produced evidence that the LVAS is a clinical variant of the classical Pendred 
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syndrome and therefore the correlation between progressive hearing loss and the 
inner-ear anomalies are thought to have the same molecular-based aetiology29. The 
Eyai gene shows expression in early stages of the murine otic vesicle and later on in 
the floor of the cochlear duct, the area that gives rise to the organ of Corti10. It may 
therefore be an attractive hypothesis that congenital defects in man are caused by 
EYAi mutations that predispose towards increased cochlear vulnerability to damage 
later in life. Lacking mutation data and the still relatively small numbers of 
observations in our BOR families however, prohibit a major genotype-phenotype 
correlation analysis to be performed. 
The association of mild head injury and worsening of hearing impairment, which 
has often been observed in LVAS and BOR syndrome30"33 emerged from the 
medical history in only one of our patients. Unfortunately we did not perform a 
formal enquiry to address this issue. 
We have no plausible explanation for the intriguing finding of contralateral 
cofluctuation. Neither of the findings of substantial cofluctuation and progression 
was related to the MRI findings. It can be speculated that (endocrine?) 
homeostatic control factors have a synchronous, bilateral deleterious effect on 
the function and/or morphology of the membranous labyrinth in BOR. If 
labyrinthine morphology, indeed, is involved, it may have escaped detection by MRI. 
Such a possibility is inherent to any method with given limitations, including MRI; an 
unrelated example has been reported recently34. Hopefully, new developments in 
imaging methods may favour our understanding of mechanisms underlying the 
intriguing features of auditory threshold progression and fluctuation. We feel that 
the present study has succeeded in substantiating such features of hearing 
impairment. However given the small numbers of observations within each 
category of consistent MRI findings, it was not possible to pinpoint any significant 
correlations between these findings and the hearing impairment features of 
progression and fluctuation. Therefore careful collection of suitable families and 
cases is certainly needed for further study, including substantiation in all relevant 
details. 
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DFNA9/C0CH 
Introduction 
The cochlear and vestibular structures are embryologically, anatomically and 
functionally closely related. The number of hereditary disorders that affect both 
cochlear as well as the vestibular function is very small, contrary to the large 
variety of hereditary cochleovestibular disorders in mice. DFNAg (OMIM #601369) 
is until now the only autosomal dominant type of non-syndromic sensorineural 
hearing impairment (SNHI) in human, exhibiting concomitant vestibular 
dysfunction1. Linkage analysis in an American family mapped the DFNAg locus to 
chromosome I4qi2-qi3 in 19962 Histopathological temporal-bone studies of 
affected persons revealed characteristic depositions throughout the labyrinth with 
concomitant degeneration of cochlear and vestibular sensory structures. These 
depositions, corresponding to the expression pattern of an inner ear-specific gene 
in chicken, have helped to identify the disease-causing COCH gene in 1998. Since 
then three different mutations were found in all three American families, as well 
as one specific mutation in fifteen Dutch and Belgian families, most of which were 
shown to have a common founder3·4. The latest report on a new DFNAg family 
harbouring a novel mutation in the COCH gene originates from Australia5. 
Audiometry 
Affected American individuals suffered from progressive high-frequency hearing 
loss, with an average age of onset of 20 years in two and 40 years in one family, 
leading to profound deafness in a period of 20-30 years time6. The low and the 
mid frequencies followed the first drop at the high frequencies, resulting in an 
overall picture of a flat progressive loss in the low to mid frequencies coupled 
with a high-frequency slope6,7 Three different disease-causing mutations in the 
COCH gene were identified in these families3 (see below) 
Dutch and Belgian DFNAg families all carry a specific mutation of the COCH gene8 
(see below). After the first clinical description of a Dutch family (OMIM #ig3005) 
in ig88, a number of additional families with a similar type of impairment have 
been identified818. Hearing loss, progressing to profound deafness in the 6,h-7th 
decade, predominantly involved the high frequencies. The age of onset was 
determined at ~40 years in all of these families1020 and a particularly high 
prevalence of vascular disorders was noted in two Dutch families1014. The natural 
history could be further outlined by performing extensive genotyping and 
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longitudinal as well as cross-
sectional threshold-on-age 
regression analyses in a large 
Dutch family101119. 
It appeared that significant 
sensorineural hearing impairment 
(SNHI) at 4 and 8 kHz was already 
present at a very young age and 
might have been congenital. 
Significant progression in SNHI did 
not start before the age of ~40 
8 kHz years. Progression of hearing 
Figure I Age-Related typical audiograms (ARTA) of a 
large Dutch DFNA9 family. Italics indicate age in years 
impairment of ~3dB/year 
appeared to be concentrated in a 
relatively short period of time of ~20-25 years. Anamnestically a high prevalence 
of Ménière-like symptoms was noted in about one third of the patients41218,20. 
SNHI in affected individuals from the Australian DFNA9 family initially starts with 
high-frequency loss in the 2nd-3rd decade and progressed to severe/profound loss 
across all frequencies in the 6th-7th decade5. Cochlear implantation has been 
successful in some American and European patients721. 
Speech recognition scores in an American family showed generally good results 
until the age of ~35 years, when a fairly rapid decline sets in that was supposed to 
be excessive given the pure-tone thresholds7. The benefit from using hearing aids 
was reported to be unsatisfactory in this stage of the disease. Forty-two affected 
individuals from several Dutch DFNAg families, showed relatively poor speech 
recognition scores compared to age and hearing level, contrary to DFNA2 patients 
in the same study showing relatively good speech recognition scores22. Speech 
recognition scores in the Australian family are not available5. 
Detection of vestibular impairment requires specific vestibular function tests, 
otherwise it may go clinically undetected due to compensation by other systems 
involved in maintaining balance. So far only two forms of hereditary purely 
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vestibular impairment, i.e. with normal hearing, have been identified23,24. 
Uniquely, vestibular symptoms in DFNAg developed simultaneously with hearing 
deterioration. Initially progressive vestibular failure was demonstrated in one 
American family member25. More recently vestibular impairment has been 
reported in three additional American patients and a comprehensive 
audiovestibular questionnaire disclosed vestibular symptoms in a few more of 
them26. All Dutch and Belgian families and the Australian family showed a fairly 
similar type of vestibular impairment, including failure of otolith reflexes16, 
progressing to vestibular areflexia4'51018'20. Simultaneous fluctuation in hearing 
thresholds and vestibular impairment were associated with Ménière-like 
symptoms in some European patients412·1718'20. 
Genetics 
The COCH gene (OMIM #603196), formerly known as hCoch-5B2, was found and 
characterised with the use of a cDNA library, which contained transcripts of genes 
expressed specifically within the fetal cochlea. COCH resides within the locus for 
DFNAg on human chromosome 14 (I4qil.2-qi3)27'28 This gene, consisting of 12 
exons, is strongly expressed in the cochlear and vestibular labyrinthine 
compartments, supporting structures and neural channels surrounding the inner 
ear and encodes a protein named cochlin. Three characteristic domains can be 
identified in this protein: (1), a signal peptide; (2), a cysteine-rich domain with 
homology to the factor C domain of the horseshoe crab Limulus (FCH domain) 
and (3), two regions with homology to the von Willebrand factor A (vWFA) 
domains. The latter are present in many extracellular matrix components and 
secreted proteins involved in various host-defense systems, such as haemostasis, 
the complement system and the immune system3. The true function of the gene 
and its protein is still unknown. 
Three mutations were found in the American families, e.g. V66G, G88E, and 
W117R, one specific P51S mutation in all Dutch/Belgian families and a novel I109N 
mutation in an Australian family4-5·11-29'32. All reported mutations occur in the FCH 
domain of the COCH gene. Haplotype analysis in the Dutch and Belgian families 
revealed the presence of a common founder in this part of Europe8. Interestingly, 
one patient presenting with a homozygous P51S mutation demonstrated an 
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earlier onset (at 25 years) and more rapid progression than the heterozygous 
mutation carriers" (Table 1). 
Table 1 overview of DFNA9/COCH families reported in literature 
Famtly 
3 US families 
15 Dutch/Belgian 
families 
1 Australian 
family 
Type of mutation 
1 missense mutation V66G30 
1 missense mutation G88E31 
1 missense mutation W I J J R 3 1 
1 missense mutation P51S29 
1 missense mutation I109N 
Fxon 
4 
5 
5 
4 
5 
Reference 
Manolis et al !, Robertson et al3, 
Ketharpal et al6 !S !6, Halpin et al7 
Verhagen et al1318, De Kok et a l " , Born et 
a l 1 0 1 9 " , Fransen et al«8, Lemaire et al12 
Kamannos et al5 
Histopathology and pathogenesis 
Histopathological temporal bone studies showed peculiar, specific acidophilic 
deposits in the cochleas, maculas and cristas of DFNA9/COCH patients with severe 
degeneration of vestibular and cochlear sensory elements and dendrites625. Very 
recently a highly branched non-banded microfibrillar substance decorated with 
glycosaminoglycan-like granules was identified with electron microscopy26. These 
findings were thought to be typical of the deposits anywhere within the labyrinth. 
The type II collagen bundles, that are normally abundant in the spiral ligament, 
were conspicuously absent26. 
Cochlin expression at fairly similar sites in the chicken inner ear have lead to the 
hypothesis of "strangulation" of cochlear and vestibular nerve endings by the 
deposited substance3"8. Consistent with the observations that various COCH 
mutations cause misfolding of cochlin, which may lead to deposition of this 
protein, the possibility was suggested that normal fibrillogenesis is disrupted by 
an excess of microfibrillar substance, resulting in degradation of collagens and 
extracellular matrix components626. In addition, it was postulated that expression 
of the COCH gene in the stroma underlying the sensory structures of the inner ear 
may indicate a possible role of this gene in ion homeostasis4. The special 
vulnerability of hair cells in the basal turn might be explained by the relatively 
high levels of ion flux required in this part of the cochlear duct. Failure in ion 
homeostasis might be an appealing hypothesis because of the Ménière-like 
symptoms experienced by some of the COCH patients. Furthermore, based on the 
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structure of cochlin, COCH may even be involved in a host-defensive, rather than 
an architectural role, making DFNAg patients more vulnerable to infection and/or 
cardiovascular disease6,33. However, the specific function of COCH and the 
pathogenesis of DFNAg still needs to be further unravelled. 
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DFNAg/COCH 
Abstract 
Objective: To perform genetic analysis and to analyse cochleovestibular 
impairment features in a newly identified Dutch family with DFNAg. 
Design: Genetic analysis was performed using microsatellite markers and SNPs. 
Audiometrie data were collected and analyzed longitudinally. Results were 
compared to those obtained in previously identified P51S COCH mutation carriers 
(n = 74). Special attention was also given to a comparison of age-related features 
such as progressive hearing and vestibular impairment. 
Subjects: G88E COCH mutation carriers from a Dutch family. 
Results: Pure tone thresholds, phoneme recognition scores and vestibular 
responses of the G88E mutation carriers were essentially similar to those 
previously established in the P51S mutation carriers. Hearing started to 
deteriorate in G88E mutation carriers from age 46-49 years onwards, whereas 
deterioration of vestibular function started from about age 46. In the P51S 
mutation carriers vestibular impairment started earlier, at about age 34 years. 
However, the difference in age of onset with the G88E mutation carriers was not 
significant. Remarkably, the proportion of patients who developed complete 
vestibular areflexia within the age range of 40-56 years was significantly lower for 
the G88E mutation carriers than for the P51S mutation carriers. 
Conclusions: Apart from a significantly lower frequency of vestibular areflexia 
between the age of 40-56 years, there are no phenotypic differences between 
carriers of the G88E and P51S mutations in the COCH gene. 
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Introduction 
Since the early nineties of the past century, 51 different loci and 18 different 
genes have been identified to be associated with non-syndromic autosomal 
dominant hearing impairment (DFNA)1. DFNA9 is the ninth discovered non-
syndromic form of autosomal dominant hearing loss, which was linked to I4ql2-
qi3 in 19962. Remarkably, DFNA9 is, apart from DFNAll3, the only type of DFNA 
exhibiting concomitant vestibular dysfunction. Soon after genetic linkage was 
established the underlying disease-causing gene was identified as COCH4. This 
gene contains 12 exons encoding a protein named cochlin. It is strongly expressed 
in the human fetal cochlea and the vestibular labyrinth5. The function of the 
protein is still unknown. So far six different mutations have been identified. Three 
of them originate from North America (V66G, G88E and WliyR)", one specific 
founder mutation (P51S) is present in many Dutch/Belgian families6'7,in Australia 
an I109N mutation has been identified8 and recently an A119T mutation was 
reported in Japan9. 
In this report we describe the phenotype of the first Dutch DFNA9 family with 
hearing loss and vestibular impairment caused by a G-to-A transition at nucleotide 
319 in exon 5 of the COCH gene, resulting in a change of codon 88 from GGA (gly) 
to GAA (glu). The clinical features are compared with the available data of the 
American DFNA9 family carrying the same mutation and to those established in 
patients carrying the P51S founder mutation from a number of previously 
described Dutch families. 
Patients and methods 
In 1999 we ascertained and investigated a Dutch family (W99-101) with a pedigree 
spanning five generations. Written informed consent was obtained to perform 
this study. The study was approved by the local medical ethical committee. 
Thirteen family members were affected (by history) by progressive hearing loss 
with, in some cases, concomitant vestibular impairment. Medical history was 
taken and anamnestically non-hereditary causes of hearing loss were excluded. 
Participating individuals underwent otological examination, paying special 
attention to the presence of any syndromic features, pure tone audiometry and in 
some cases speech audiometry. Vestibular function was tested in 10 patients. One 
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affected person underwent computerized tomography (CT) of the temporal bones. 
Blood samples were collected from six presumably affected and 36 presumably 
unaffected persons for the purpose of linkage and mutation analyses. 
Genetic analysis 
DNA was isolated from peripheral blood according to Miller et al.10. Because of 
the apparent similarity of the present type of hearing loss to DFNA9 we first 
searched for mutations in the COCH gene, with special attention for the known 
mutations. 
Sequence analysis 
We used primers, designed to flank the exons of the COCH gene6 to amplify and 
sequence exons 2-12. Prior to sequencing, PCR fragments were purified using the 
Qiaquick gel extraction kit (Qiagen, Hilden, Germany). Sequence analysis of PCR-
amplified exons 2-12 was performed using DNA from two family members (II-13 
and II-14) and an unaffected unrelated control individual (ABI PRISM Big Dye 
Terminator cycle sequencing \/2.0 ready reaction kit and an ABI PRISM 3700 DNA 
analyser (Applied Biosystems)). For testing the segregation of the detected 
mutation in family W99-101, exon 5 was amplified with the primers 5' 
TCTTTAGATGACTTCCCTGATGAG-3'and S'-TCACAGGTTTTTCCATCAAGGTTA-S'. PCR 
products were digested with Avail (New England Biolabs), which cuts the wild-
type PCR product into fragments of 154 and 214 bp. After digestion, DNA 
fragments were separated on a 2% agarose gel and stained with ethidium 
bromide. 
Haplotvpe analysis 
We studied the possible presence of a common ancestor for both the original 
American family and the present family using haplotype analysis. For this purpose 
we used polymorphic markers flanking the COCH locus (D14S262, D14S975, 
D14S1021, D14S257 and D14S1040) and single nucleotide polymorphisms (SNPs) 
present within the COCH gene (RS#223958l, RS#2239580 and RS#2295127). 
Analysis of the microsatellite markers was performed as described by Kremer et 
al." The SNPs were analysed by sequencing. 
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Audiometry and data analysis 
Pure tone audiometry was performed in a sound treated room, conforming to the 
International Standards Organisation (ISO)12·13. The individual 95lh percentile 
threshold values of presbyacusis (Pg5) in relation to the patient's sex and age were 
derived for each frequency using the ISO 7029 method14. Persons were considered 
affected if the best hearing ear showed thresholds beyond the P95. Similar to the 
previously reported analysis of the P51S COCH mutation carriers15, cross-sectional 
binaurally averaged threshold data (air conduction level in dB HL) were plotted 
against age for each frequency and analyzed using nonlinear regression analysis 
(threshold on age) fitting a sigmoidal response curve with a variable slope (Prism 
3, GraphPad, San Diego, CA, USA). Student's t test was used to compare between 
the associated parameter values fitted for the P51S mutation and the present 
G88E mutation. This test included Welch's correction if Bartlett's test identified 
unequal variances. The level of significance used in all tests was Ρ = 0.05- The 
fitted curves were used to construct age-related typical audiograms (ARTA). 
According to a previously described method16, the ARTA for the present G88E 
mutation carriers and previously described P51S mutation carriers were 
compared. 
Speech audiometry was performed under the above-mentioned conditions using 
phonetically balanced standard Dutch consonant-vocal-consonant word lists. The 
maximum phoneme recognition score (%Correct, mean for both ears) was 
obtained from monaural performance-intensity curves and was analyzed in 
relation to age and pure tone average (mean for both ears) at the frequencies 1, 2 
and 4 kHz (PTA12i| k H z). Linear regression analysis was performed to fit individual 
longitudinal scores for the present G88E carriers. These scores were compared to 
those used for a previously performed similar cross-sectional analysis of P51S 
mutation carriers (scores for right ear) from seven different families, to which a 
sigmoidal curve with variable slope had been fitted17. 
Vestibulo-ocular examination, data analysis and imaging techniques 
Eleven affected family members and mutation carriers underwent vestibular and 
ocular motor tests. These included evaluation of the vestibulo-ocular reflex (VOR), 
using electronystagmography with computer analysis and saccadic, smooth 
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pursuit and optokinetic nystagmus responses. Vestibular stimulation comprised 
rotatory and caloric tests. Details and normal values have been previously 
described18. The analysis of the VOR focused on the time constant (T, in seconds) 
derived from (907s) velocity-step test responses in either direction. As this 
parameter shows a log normal distribution19, the geometric mean for both 
nystagmus directions was used for further evaluation; the 90% (P5-P95) 
confidence interval for Τ was 13-23 seconds. An arbitrary zero (T = 0) was assigned 
to rotatory responses showing vestibular areflexia with no or just a few 
nystagmus beats. The above-mentioned procedure for fitting a sigmoidal curve 
was also applied to the Τ vs. age data. For comparison, we retrieved similar data 
from 74 P51S mutation carriers from eight previously reported different Dutch 
families, as well as from a recently studied, newly identified DFNA9 family20. 
Comparisons between fitted sigmoidal curves were performed as described above 
by applying Student's t test to the fitted parameter values. Fisher's exact 
probability test was used to compare the relative frequency of complete vestibular 
areflexia (T = 0-3 sec) between the groups of G88E and P51S mutation carriers, as 
well as between subgroups of the respective mutation carriers within various age 
classes. 
A CT scan of the petrosal bones of patient III-26 was performed (Siemens 
Somatom Plus 4, Siemens, Forchheim, Germany). Magnetic resonance imaging 
(MRI) results of the posterior fossa of patient III-8 in 1998 were retrieved from 
elsewhere. 
Results 
For the sake of clarity and privacy matters a pedigree containing three 
generations was deduced from the original pedigree with five generations (Figure 
1). Thirteen persons were affected by history. Six of them were alive. Blood 
samples were obtained from 42 individuals for genetic analysis (see below). 
Audiometry was performed and/or could be retrieved from elsewhere in 42 
individuals, some of which concerned presumably affected individuals who 
already had deceased prior to the start of this study. An autosomal dominant 
pattern of inheritance is apparent, especially from the oldest generations of the 
pedigree. The case histories and physical examinations excluded syndromic 
involvement. All clinically affected individuals reported bilateral slowly 
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progressive hearing loss with onset age in the range of 40 - 68 years. Varying 
vestibular symptoms were noted in six of them (11-13, 11-14, II-16, III-8, III-19, 111-26), 
including instability in the dark, vertigo and a tendency to fall. We did not note a 
high incidence of cardiovascular disease or Ménière-like symptoms. 
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Figure 1 Simplified pedigree of family W99-101 with non-syndromic autosomal dominant hearing loss and 
vestibular impairment. Open symbols, anamnestically unaffected; solid symbols, anamnestically affected; 
deceased individuals are slashed 
Genetic analysis 
Sequence analysis 
The prosiser (P51S) mutation (exon 4) was not present. Further DNA sequence 
analysis of the COCH gene in cases II-13 and II-14 revealed a heterozygous guanine 
(G) to adenine (A) alteration at nucleotide position 263 of the protein coding 
region (C.263G>A) in exon 5. This missense mutation results in the substitution of 
a glutamic acid for a glycine at amino acid residue 88 of cochlin (G88E). No other 
mutations were identified in the protein coding sequences of exons 2-4 and 6-12. 
This G to A mutation destroys an AvaW restriction site, which was used to analyze 
co-segregation of this mutation within this family. The wild-type allele, without a 
G to A mutation, will be digested into two fragments of 154 and 214 bp, as 
illustrated for part of the digested samples in Figure 2. 
Based on this restriction enzyme analysis 16 mutation carriers were identified, 
which included all six clinically affected individuals from the 2nd and 3rd generation 
with ages varying from 51-82 years (solid figures in Figure 1). Six unaffected 
individuals from the 3rd generation (ages from 39-53 years) and four unaffected 
family members in their offspring (ages from 22-29 years) turned out to be 
mutation carriers as well. For privacy reasons we did not include the pedigree 
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numbers of these unaffected cases. All other family members were homozygous 
for the wild-type allele. Restriction analyses of genomic DNAs from 100 healthy 
unrelated control individuals did not reveal this mutation (data not shown). 
Haplotype analysis 
Using 0145262, D14S975, D14S257 and D1451040 did not reveal a common 
disease-associated haplotype in the Dutch and the American family. Only for the 
polymorphic marker D1451021 there was a common allele, however this allele is 
too frequent to draw any conclusions. Through testing of the SNP RS#223958l 
which is located very close to the mutation, a new polymorphism was detected 
(IVS4+8odelT). In the Dutch and American families the disease-associated 
haplotype differed with regard to this polymorphism. Alleles of all three other 
SNPs in the COCH gene are the same for both families. However, again the most 
common alleles are associated with the mutation. Based on these results (data not 
shown) a common origin of the mutations seems unlikely, but could not totally be 
excluded. 
+ + + η + 
11-13 11-14 
— 368 bp 
I — 214 bp 
^ 154 bp 
Figure 2 Part of the AvaW restriction analysis of PCR-amplified exon 5 of the COCH gene of family W99-IOI. 
Normally, digestion of exon 5 results in two DNA fragments of 154 and 214 bp; digestion of exon 5 containing 
the G>A alteration prevents this restriction and yields a single fragment of 368 bp. Partial ΛνοΙΙ digestion is 
present in the cases indicated with a "+", identifying them as heterozygous mutation carriers, n, digested 
DNA sample from an unaffected family member. Bp, basepairs. 
Audiometry 
Pure tone thresholds related to age 
Figure 3 shows the cross-sectional analysis of the threshold against age data for 
the G88E mutation carriers. The threshold data included in the nonlinear 
regression analysis represent either a single snapshot measurement or, if serial 
audiometry was available -which was the case in seven mutation carriers- the last 
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visit at which a reasonable number of thresholds was still measurable. Individual 
longitudinal threshold measurements are also included; they seemed to conform 
reasonably well to the fitted sigmoidal curves, except at 8 kHz and possibly also at 
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Figure 3 Cross-sectional analysis (binaural mean air conduction threshold) for the present family Threshold data 
(unconnected open circles, last measurable threshold in dB HL) vs age (in years) for all frequencies in 16 C88E 
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the P51S mutation in a single, large family15 (uppermost dashed curve), and the same curve corrected for zero 
offset threshold at age zero (lowermost dashed curve) 
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4 kHz. It should be realised that for the longitudinal data the threshold was fixed 
at 130 dB (before averaging) for out-of-scale thresholds, whereas such thresholds 
had been excluded for the fitt ing procedure. For this reason, especially the curves 
fitted for 4 and 8 kHz were certainly biased in a downward direction, which 
presumably has influenced especially the fitted top level and perhaps also the 
maximum slope of the curve and apparent onset age. 
Maximum slope of the sigmoidal curve (Figure 3, bold line in each panel) was 
visually estimated by drawing a tangent through the inclination point of the 
curve; this is an indication of maximum annual threshold deterioration (ATD, in 
dB/year). ATD was in the range of 3.6-4.6 dB/year. Onset age (X1015) was estimated 
at 46-49 years only at 0.25-2 kHz; we did not include 4 and 8 kHz because of the 
presumed bias. For the sake of comparison, the fitted sigmoidal curves of P51S15 
are included without any change, as well as corrected for presumed zero offset at 
age zero (dashed curves). The latter was closer to the presently f itted (continuous) 
curve at each frequency. Student's t test comparing between the parameter values 
fitted for the respective sigmoidal curves only detected a significant difference 
between the uppermost dashed curve and the continuous one at 4 and 8 kHz: at 4 
kHz the ages of onset and at 8 kHz the bottom levels differed significantly. 
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Figure 4 ARTA of the phenotypically and genotypically affected family members of family W99-101 (left 
panel) and affected Dutch DFNA9 family members (W98-011) carrying the P51S mutation (right panel). Italics 
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have been underestimated (Patient and Methods) 
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Figure 4 shows the ARTA derived for the present mutation carriers and those 
previously derived for the P51S mutation carriers in juxtaposition. Using the 
method described elsewhere16, we did not find any significant difference in ARTA 
between the two groups of COCH mutation carriers. 
Speech recognition scores related to age 
Figure 5 shows the single snapshot measurements and the longitudinal 
measurements of phoneme scores in the present G88E mutation carriers. These 
scores seemed to compare reasonably well with the scores previously measured 
for monaural presentation to the right ear in P51S mutation carriers from 
different families17 to which the sigmoidal curves had been fitted (in cross-
sectional analysis) as far as the impairment-performance plot (Figure 5B) was 
concerned. In the age-performance plot (Figure 5A) it would seem that the G88E 
mutation carriers had a tendency to show relatively high scores in the age range 
of 40-60 years, which might be associated with a higher age of onset. It should be 
kept in mind, however, that the present scores were averaged for the monaural 
responses in two ears and that many of the scores pertained to longitudinal 
measurements, which prohibited statistical testing of these scores against the 
previous cross-sectional, monaural measurements. 
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Figure 5 Mixed single snapshot and longitudinal individual measurements (large symbols connected by 
hairlines) of binaural mean speech recognition scores at last visit against age (A) and against binaural mean 
PTA j
 2 „ k H z (B) in 10 G88E mutation carriers. Different symbols pertain to different carriers. Straight lines are 
individual linear regression lines. For the sake of comparison, the cross-sectional data of P51S mutation 
carriers (monaural score for right ear) from 7 different families are included (small asterisks), along with the 
bold, dashed sigmoidal curve that was fitted to those scores; horizontal and vertical dashed hairlines and 
italic figures indicate onset age (A) and onset level (B) fitted for those data1 7 
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Vestibulo-ocular examination and imaging 
Two mutation carriers showed vestibular areflexia at age 75 and 49 years, 
respectively. The youngest of them, who had no significant hearing loss at that 
age, exhibited an enhanced cervico-ocular reflex. One hearing impaired individual 
(III-8) revealed bilateral caloric weakness, whereas patient III-15 exhibited 
asymmetrical responses to caloric testing (left areflexia, right hyporeflexia). 
Vestibular testing in six other clinically unaffected mutation carriers at ages 
between 24 and 55 years, revealed no abnormalities. 
Figure 6 shows the cross-sectional analysis of mean Τ in relation to age for the 
G88E mutation carriers (asterisks and bold curve), compared to a similar analysis 
for the P51S mutation carriers (open circles and thin curve). 
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Figure 6 Mean VOR time constant (T in sec, left axis) plotted against age (years) for 10 of the present G88E 
mutation carriers (asterisks and bold sigmoidal curve) and 74 P51S mutation carriers20 (open circles and thin 
curve) Complete vestibular areflexia (found in 2 patients) is represented by an arbitrary zero. The 5' and 95' 
normal percentile values are shown as dashed horizontal lines. Dashed vertical hairlines indicate onset age 
(X90. years) for C88E (bold figure) and P51S (italic figure). For comparison, the dashed sigmoidei curves 
(threshold level, right axis) are included, which are the same curves as the continuous ones in Figure 3 fitted 
to the present threshold data at 0.25-2 kHz 
Although the G88S mutation carriers seemed to have later onset (age 46) than the 
P51S carriers (age 34), we could not find any significant difference between 
corresponding parameter values fitted for the two groups of mutation carriers. 
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There was, however, a striking, significant difference between the two groups of 
mutation carriers: only two of the ten G88E mutation carriers showed complete 
vestibular areflexia (T = 0-3 sec), whereas 52 of the 74 P51S mutation carriers 
showed this feature (P = 0.0033). Restricting the comparison to mutation carriers 
aged 40 years and over, the significant difference was even more clear: two of 
eight vs. 52 of 64 (P = 0.0024). As the group of G88E mutation carriers included 
only one patient aged > 56, it might have been that the significant difference was 
caused by differences in age distribution between the groups of mutation carriers 
(Figure 6). However, there was also a significant difference found within the age 
class of 40-56 years: one of six vs. 25 of 37 (P = 0.013). Of course, this does not 
exclude the possibility that all or most of the G88E mutation carriers develop 
vestibular areflexia at ages of > 56 years. Within the present group of G88E 
mutation carriers, it was tested as to whether there was a significant difference in 
age of onset estimated (fitted) for progressive deterioration of vestibular function 
(i.e. shortening of T, Figure 6, left axis) and hearing threshold (Figure 6, right axis). 
No significant difference was detected; as indicated above, age of onset of 
hearing deterioration was most reliably estimated at 0.25-2 kHz, where it was in 
the range of 46 - 49 years. 
The middle and inner ear structures of two hearing impaired family members (III-8 
and II-13) had normal appearances on MRI and CT scanning 
Discussion 
There are many reports on DFNA97J915,2125. The P51S mutation is the only known 
COCH mutation encountered so far7 in the Netherlands and is considered to be a 
founder mutation. A Dutch DFNAg family carrying a G88E mutation is therefore 
quite remarkable. Previous reports on a family carrying this latter mutation 
originate from the US. This family was designated the iSu family26,27 and these 
reports also included histopathology of temporal bones of affected individuals. By 
giving a thorough description of the phenotype associated with the G88E 
mutation of the COCH gene, this report extends the available clinical data on the 
DNFAg phenotype. 
Some remarks can be made on the pattern of inheritance in this family. A clear 
autosomal dominant pattern of inheritance with complete penetrance based on 
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anamnestic and audiometrie data is not present in the pedigree. There is no doubt 
that this finding relates to the fact that the complete phenotype only develops at 
a more advanced age. Most of the participating family members who turned out 
to be mutation carriers, were still too young (maximum age 53 years of age) to 
clearly exhibit clinical features. Assuming that the G88E mutation is pathogenetic, 
it will be interesting to see whether the present non-affected mutation carriers in 
this Dutch family will develop the characteristic DFNAg symptoms. 
The reported mean age of onset of hearing loss in family W99-101 (5th-6th decade) 
was comparable to that reported for the original DFNAg/iSu (G88E) kindred and 
the DFNAg (P51S) families27. The other American DFNAg families (iW, iSt) showed 
an earlier age of onset (2nd-3lh decade)27,28. In general, hearing loss in all DFNAg 
families first affects the high frequencies, later followed by the mid and low 
frequencies, resulting in progressive loss in the low to mid frequencies coupled 
with a high-frequency slope15,25. The annual threshold deterioration was similar in 
all DFNAg families studied so far and this includes the present family. The 
audiometrie characteristics of the present family are fairly consistent with those 
found in the original DFNAg/G88E (iSu) and the previously reported DFNAg/PsiS 
families. 
Symptoms indicating vestibular dysfunction, for example dizziness, balance 
problems and oscillopsia, have been described for the American kindreds ISu and 
iW, but not for iSt2528. Khetarpal et al27 reported that about 50% of affected 
members of family iSu complained of vertigo or dizziness. In a later report, 
Khetarpal specified the symptoms encountered in the American family iW 
carrying the V66G mutation29. Vestibular dysfunction and Ménière-like symptoms 
are frequently seen in DFNAg patients carrying the P51S mutation21. In the present 
family, anamnestically, vestibular symptoms were noted in six clinically affected 
cases as mentioned above. Almost all tested patients with obvious hearing 
impairment showed loss or lack of vestibular function. Vestibular testing in the 
asymptomatic mutation carriers revealed no abnormalities. Furthermore a high 
prevalence of Ménière-like symptoms and of cardiovascular disorders have been 
noted in the past in COCH/P51S mutation carriers21,22,24, however we could not 
establish this association in the present family. 
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Special attention was also given in the present study to a comparison of age-
related features between progressive hearing and vestibular impairment. Hearing 
started to deteriorate in all G88E mutation carriers from age 46-49 years onwards, 
whereas deterioration of vestibular function started from about age 46, i.e. at 
about the same age. Vestibular impairment started earlier, at about age 34 years, 
in the P51S mutation carriers, i.e. at a significantly younger age in those patients 
than the apparent age of onset found for their progression in hearing 
impairment20. So it would seem that the G88E mutation carriers showed 
simultaneous progression of vestibular and hearing impairment, whereas the 
P51S mutation carriers, who showed progression of hearing impairment at about 
the same ages, exhibited earlier progression of vestibular impairment. Although 
there was no significant difference in the age of onset of vestibular impairment 
detected between the G88E and P51S mutation carriers, it was remarkable that a 
significantly smaller proportion of the G88E mutation carriers developed complete 
vestibular areflexia at ages in the range of 40-56 years. It is therefore possible that 
the G88E mutation carriers either showed more limited expression of complete 
vestibular areflexia or developed this feature at an older age (> 56 years) than the 
P51S mutation carriers. If this is true, it might explain why in the original 
American family vestibular impairment among the G88E mutation carriers may 
have been a less prominent finding than in the Dutch P51S mutation carriers. 
Recently Grabski et al29 reported that different COCH mutations vary in the 
amount and pattern of cochlin deposition in the extracellular matrix. One of the 
mutations that resulted in lack of deposition is the G88E mutation, whereas the 
P51S mutation led to extracellular depositions indistinguishable from wild-type 
cochlin. One could speculate that these diminished or absent depositions in this in 
vitro study cause the less severe development of vestibular symptoms. Since G88E-
associated hearing loss shows a similar pattern as that associated with the P51S 
mutation might indicate that the difference in effect of the mutations does not 
occur in the cochlea. 
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Abstract 
Objectives: analysis of phenotype-genotype correlation. 
Study design: family study. 
Methods: auditory and vestibulo-ocular functions were examined in a Dutch family 
with autosomal dominantly inherited sensorineural hearing impairment, caused by 
a 208OT mutation in the COCH gene, located in chromosome I4qi2-13 (DFNAg). 
Linear regression analysis of individual longitudinal hearing threshold data (n=ii) 
on age was performed. 
Results: fifteen of the sixteen genetically affected persons could be evaluated. They 
all developed hearing and vestibular impairment symptoms - and in many cases 
also cardiovascular disease - in the fourth to fifth decade. At the low frequencies 
(0.25-2 kHz) hearing impairment started at the age of about 40 years and showed 
an average annual progression of approximately 3 dB, finally resulting in profound 
hearing losses. In two exceptional cases, annual progression attained levels of up to 
24 dB. At the high frequencies (4-8 kHz), the average threshold deteriorated from 
about 50 dB at the age of 35 years to about 120 dB at the age of 75 years (which 
amounts to 1.8 dB annual threshold increase). All affected individuals tested 
showed normal ocular motor functions. The patients older than 46 years generally 
showed absence of the vestibulo-ocular reflex, but their cervico-ocular reflex was 
enhanced compared with normal subjects, whereas those aged 40-46 years showed 
either severe vestibular hyporeflexia or unilateral caloric areflexia. 
Conclusion: these findings suggest a gradual development of cochleovestibular 
impairment caused by the new mutation found. 
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Introduction 
Inherited sensorineural hearing impairment can be classified into two forms: 
syndromic and nonsyndromic. The latter form accounts for about 75%1'2 of all 
cases of congenital hearing impairment and is highly heterogeneous; nearly each 
family maps to a unique chromosomal locus. Prelingual nonsyndromic hereditary 
hearing impairment is diagnosed in approximately 1 in 700 newborns,3 of which 
75% is autosomal recessive, 20% to 25% autosomal dominant and up to 5% X-
linked or mitochondrial2. 
Thorough genotypical and phenotypical analysis can provide the necessary 
definition and delineation of types of monogenic hearing impairment4. More than 
40 human chromosomal loci associated with nonsyndromic hearing impairment 
have been reported in recent years, including more than 15 autosomal dominant 
(DFNA) loci5. More than eight different genes have been identified since 1997, 
including late-onset progressive types with high-frequency involvement. In some 
studies moderate or subclinical hearing impairment was detected in individuals 
heterozygous for autosomal recessive gene defects6,7,8. It is possible that 
heterozygous recessive gene defects or DNA variants in dominant deafness genes 
are risk factors for presbyacusis. 
A large multigenerational nonconsanguineous Dutch kindred is presented, 
showing progressive hearing and vestibular impairment with a relatively late 
onset, ultimately leading to profound deafness and vestibular areflexia. 
Materials and methods 
We examined auditory and vestibulo-ocular functions in 16 affected members of a 
Dutch family of about 200 members (family W98-011, Figure 1). In addition, six 
deceased individuals seemed to be affected. Thus a total of 22 affected individuals 
were identified. The pattern of inheritance was autosomal dominant with 
apparently full penetrance. 
Possible exogenic, nonhereditary causes of hearing and vestibular impairment were 
excluded. Family history data were obtained and the pedigree was drawn. Prior 
written consent was obtained to retrieve previous audiograms and relevant medical 
information. All 119 persons participating in this study underwent otoscopy. Special 
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attention was paid to vestibular impairment symptoms, as well as possible 
syndromic features. Seven persons with vestibular areflexia were also examined by 
a neurologist. 
Figure l Pedigree of family W98-011 Solid symbols mark affected individuals, amongst whom are several 
deceased individuals (l-l, II-2,11-6,11-8, II-10 and lll-ig) 
Blood samples for genetic linkage analysis were collected from 16 presumably 
affected individuals and 103 presumably unaffected individuals, in which 
chromosomal markers for the 15 known loci for nonsyndromic autosomal 
dominant hearing impairment were screened first, guided by the pattern of 
inheritance in the pedigree. Linkage to the DFNA9 locus was found and mutation 
analysis was performed9. 
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Audiograms were obtained from all individuals, according to International 
Standards Organization (ISO) standards1011, including air-conduction and bone-
conduction levels. The method of ISO 7029" was followed to calculate for each 
patient individually the 95th percentile (P95) threshold values for presbyacusis at 
each frequency in relation to the patient's age and sex. Because of lack of other 
known causes, thresholds above the P95 value in the better ear were initially 
considered as inherited sensorineural hearing impairment. The final selection 
comprised the mutation carriers only. Previous audiograms were retrieved from 
elsewhere, including affirmative audiograms from three deceased (presumably 
affected) individuals. 
Linear regression analysis was performed in those cases where a sufficient 
number of serial audiograms (covering at least three years) was available. It was 
tested whether there was significant progression (that is, where the regression 
coefficient [in this report called the annual threshold deterioration, ATD, and 
expressed in decibels per year] was significant). The Y intercept was called the 
offset (threshold) and, in case of this being a negative value, an onset age was 
calculated (X intercept). Where appropriate, regression lines were compared 
using the F test (one-way ANOVA options included in the Prism computer 
program, PC version 2.0, GraphPad, San Diego, CA) to detect any significant 
differences. The Prism program tests the slopes first and subsequently the 
intercepts, but it abandons testing as soon as a significant difference is detected; 
pooled values are calculated where possible. The level of significance used was 
0.05. 
Gaze positions were tested to investigate whether there was any gaze-evoked 
nystagmus. Saccades, smooth pursuit and horizontal optokinetic nystagmus 
responses were elicited and analyzed as reported earlier13. Vestibular tests 
(velocity-step tests and caloric tests) were conducted with the patient in the dark 
with the eyes open. It was evaluated whether there was any spontaneous 
nystagmus. Velocity-step tests were performed with a rotatory chair (Toennies 
GmbH, Freiburg im Breisgau, Germany). The postrotatory nystagmus response 
was analysed with a computer method. Only the time constant is specified as a 
key response parameter in the cases with severe hyporeflexia (P5-P95, 11-26 s). The 
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cervico-ocular reflex was elicited in the dark by applying sinusoidal stimulation to 
the body with the head fixed in space14. 
Results 
Affected persons reported an age of onset for hearing impairment symptoms 
ranging from 36 to 63 years. Hearing impairment was characterized by variable -
in most cases rapid - progression to profound sensorineural impairment (Figure 
2). Affected individuals showed no evidence for other factors predisposing toward 
hearing impairment, except for case IV- 37, where ear surgery had taken place 
Figure 2 Individual audiograms (R, right ear; L, left ear) of 15 affected family members, ordered by the age at 
which the most recent audiogram was obtained (see key to symbols next to each graph). Air-conduction 
threshold in decibels hearing level (dB HL). HIS, hearing impairment symptoms (age, y); VA, vestibular 
areflexia (age, y). 
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previously. In most individuals, vestibular symptoms and hearing impairment 
symptoms started simultaneously. 
The former symptoms consisted of head-movement-dependent oscillopsia and 
imbalance when walking in the dark; patients also reported having difficulties 
when riding a bicycle, especially when attempting to look over their shoulders. 
With their eyes closed, they generally exhibited a broad-based gait. Several 
affected individuals had a history of hypertension (cases III-23, III-24, III-26, III-37, 
IV-46, IV-48 and IV-50), stroke (cases III-18, III-19, III-24 and 111-26), or ischaemic 
heart disease (cases III-23, 111-35 and III-37). Hence 10 out of 15 individuals 
exhibited cardiovascular disease. One individual (case III-24) had recently 
experienced an episode of glossopharyngeal neuralgia. One individual (case III-2) 
exhibited mild symmetric distal polyneuropathy. One individual (caselV-46) had a 
mild cervical myelopathy. Apart from these incidental findings, no consistent 
neurological deficits other than vestibular impairment were found. 
Linkage analysis mapped the gene defect underlying cochleovestibular 
impairment in this family to an 11.0-centiMorgan (cM) region overlapping the 
DFNA9 interval15 on chromosome I4qi2-13. Sequence analysis revealed a 208C->T 
mutation (exon 4) in the COCH gene, resulting in a P51S substitution in the 
predicted protein in all affected individuals of the family; this mutation was not 
found in unaffected family members or in 200 control individuals9. 
All audiograms obtained from the genetically affected family members included 
in this study are presented in Figure 2. Case l\/-37 was excluded because of 
previous ear surgery. All identified carriers of the mutation demonstrated 
sensorineural hearing impairment. At a relatively young age (generation IV; note 
that in Figure 2 cases are ordered by the age at which the most recent audiogram 
was obtained) considerable sensorineural hearing impairment at the highest 
frequencies was already present; audiograms showed downsloping hearing 
impairment in most cases. In addition, sensorineural hearing impairment at the 
lower frequencies had developed at a more advanced age. The patients in 
generation III showed moderate to severe hearing impairment with (eventually) 
an almost flat threshold or residual hearing (that is, functional hearing only at the 
low frequencies). In three of the six probably affected, deceased individuals 
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audiograms could be retrieved; they all exhibited severe losses typical of the 
general audiometrical picture in this family. Audiometrically, remarkable 
variability and asymmetry was seen in the progression of hearing impairment 
with increasing age (Figure 2). 
Regression analyses of longitudinal threshold-on-age data were performed only 
for those age intervals where (approximately) linear homogeneous progression 
occurred. Relevant parameter values are presented in the Table. The estimates 
obtained for the longitudinal annual threshold deterioration (ATD) at the 
frequencies 0.25 to 2 kHz varied from 2 to 4 dB in most instances. In two 
exceptional cases (III-26 and IV-46) ATDs of up to 24 dB were found. ATDs for the 
frequencies 4 to 8 kHz were smaller in all cases in which those increases could be 
evaluated. Estimates for onset age could be obtained only for the low frequencies 
in most cases; estimates were in the range of approximately 35 to 50 years, except 
in case III-23, in which the extrapolated onset age was about 18 years. Case IV-46 
exhibited an apparent onset age of between 25 and 40 years at all frequencies. In 
case 111-35, an onset age of 0 years was extrapolated for the high frequencies, but 
the raw data (not shown) clearly indicated nonlinear, increased progression 
following onset at about 45 years of age. 
In Case III-37 extrapolation produced an apparent onset age of about 20 years for 
hearing impairment at 4 to 8 kHz, but given the amount of scatter in the raw data, 
this estimate seems inaccurate.ln five cases backward extrapolation of the 4 to 8 
kHz regression lines (that is, toward the Y axis) yielded an offset threshold 
(positive intercept) in at least one ear, for one of these frequencies (Table). 
This offset differed significantly from zero in two measurements. These findings 
suggest sensorineural hearing impairment at 4 to 8 kHz being present well before 
the presumed age at onset of hearing impairment in the lower frequencies as well 
as vestibular impairment. More appropriate analysis of these findings may be 
performed after having genotyped the youngest family members. 
All available threshold data are shown in Figure 3, with separate trend lines for 
each of the two sets of low and high frequencies. It should be noted that formal 
regression analysis of the data shown was not permitted, because of the 
replications (that is, the presence of longitudinal individual measurements and 
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separate entries for the two ears in most cases). At 0.25 to 2 kHz, we assumed an 
average trend with onset at 40 years of age and progression by 3 dB/year (see 
mean values in the Table). At the 4 to 8 kHz frequencies, we assumed an average 
threshold trend from 50 dB at the age of 35 years to 120 dB at the age of 75 years 
(that is, average annual progression about 1.8 dB, see Table I). 
Table I Relevant results of the longitudinal analyses (i.e. linear regression analysis for η > 2) of the binaural 
mean threshold in relation to age applicable to cases with suitable observation intervals. 
Cose 
II1-2 
111-18 
III-23 
111-24 
111-26 
111-29 
111-33 
111-35 
111-37 
111-43 
Mean 
IV-46 
age interval (y) 
58-72 
52-80 
55-73 
65-70 
44-47 
53-69 
66-71 
51-69 
46-67 
49-66 
56-69 
42-48 
η 
7 
8 
7 
3 
3 
10 
4 
9 
18 
7 
9 
13 
ATD (dB/yf 
lo 3, hi 0 
L o l 
Lo 2 
Lo 4 
R lo 5, L lo 24 
lo* 3, hi* 2 
Lo 3 
Lo 4 
lo 3, hi 1 
lo 3, hi 2 
lo 3, hi 1 
io 3.0, hi 1.8 
lo 6-16, hi 4-5 
Onset age (yf 
lo 46 
lo 18 
lo 50 
Lio 44 
lo* 41 
lo 51 
lo 45 
lo 34, hi 0 
lo 36, hi 19 
lo 47 
lo 41 
lo 36-41, hi 27-30 
Offset (dB)b 
R 7/58, L 85/129 
R 28/na, L 51/na 
R na, L na 
R na, L na 
R 28/na, L na/23 
R na, L na 
R na/72, L na/89 
(nonlinear) 
R na, L na 
R 117/49, L 20/na 
R na, L na 
a
, pooled regression estimate, b, 4 kHz/8 kHz ; significant difference from zero in bold; lo, low frequenoes 
(0.25-2 kHz; *, 0.25-1 kHz); hi, high frequencies (4-8 kHz; *, 2-8 kHz); R, right ear; L, left ear; na, not applicable 
(1 e. negative value) 
Vestibulo-ocular examination was performed on all affected family members 
(Figure 2), except in cases IV-37 (previous ear surgery) and III-18 (not fit to 
undergo the tests). All cases had normal ocular motor function. In generation III, 
all affected family members (aged over 60 years), except for one individual (case 
III-2) had an absent vestibulo-ocular reflex, but their cervico-ocular reflex was 
enhanced compared with normal subjects, which is typical of labyrinthine-
defective patients14. In case III-35 the same findings had been obtained seven 
years earlier. In Case III-2 severe hyporeflexia of the vestibulo-ocular reflex was 
evident, but with a well-developed cervico-ocular reflex; this individual had 
relatively late onset of hearing impairment symptoms. Similar vestibular findings 
were obtained in generation IV in cases IV-48 and IV-54 (aged 45 and 40 years, 
respectively). These three cases showed a very short vestibulo-ocular reflex time 
constant (1-4 s). In generation IV, only case IV-46 (aged 47 years) showed bilateral 
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vestibular areflexia, whereas cases IV-39 (aged 46 years) and IV-50 (aged 43 years) 
exhibited unilateral caloric areflexia. 
0.25 kHz R&L 0.5 kHz R&L 
50 60 70 
age (y) 
50 60 70 
age (y) 
1 k H z R & L 2 kHz R&L 
50 60 70 
age (y) 
50 60 70 
age (y) 
4 kHz R&L 8 kHz R&L 
age (y) age (y) 
Figure 3 Plots of all the available threshold-on-age data for each frequency with "trend lines" (bold). For 
each ear (0, right; x, left) longitudinal data points are connected by thin lines. The trend line for each of the 
frequencies 0.25, 0,5, l and 2 kHz is based on the mean values (slope and onset age) in the Table. The trend 
line for each of the frequencies 4 and 8 kHz has a mean slope of 1.8 dB/year (Table) and was arbitrarily 
drawn at an offset level of 50 dB at age 35 years. 
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Discussion 
This clinical study of a family (family W98-0119) with the DFNA9/COCH mutation 
revealed distinct characteristics of cochleovestibular impairment. 
Considerable intersubject and interaural variability in the development of hearing 
threshold with advancing age were found (Figure 2 and Table). Most of the 
progression occurred at the low frequencies (3 dB/year, Figure 3). At the high 
frequencies, sensorineural hearing impairment may have been due to 
presbyacusis. In the Table annual increases in threshold levels of about l to 2 dB 
are shown for the high frequencies in cases where this could be evaluated. We 
simulated average presbyacusis by plotting P50 presbyacusis threshold values12 for 
each frequency at several equidistant ages over the age interval of 50 to 70 years. 
We calculated virtual values for annual threshold deterioration (ATD) and related 
these values to median presbyacusis values by linear regression analysis for these 
hypothetical threshold data. The resulting values were between 0.7 dB/year 
(women) and 1.4 dB/year (men) at 4 kHz and between 1.3 and 1.8 dB/year at 8 
kHz. These estimates are in the same range as most of the ATD values estimated 
for the high frequencies in the Table. 
Vestibular areflexia was found from the age of 47 years (case IV-46) onwards, 
whereas at a younger age (40 to 46 years) the affected individuals showed either 
severe hyporeflexia or unilateral caloric areflexia. Those younger subjects are 
likely to develop vestibular areflexia as well. 
The DFNA9 family reported on by Manolis et al.15 displayed onset of low-
frequency hearing impairment at about 16 to 28 years of age, which seems earlier 
than in the family in the present study. Khetarpal et al.16 reported that in this 
kindred onset age was about 20 years of age, whereas in another family it would 
be about 40 years. From previous reports1517 we derived individual annual 
threshold progression values in the range of 3 to 8 dB, predominantly at the low 
frequencies. Some of our cases exhibited more rapid progression (up to about 24 
dB/year), especially at the beginning of the observation period. Given this finding, 
the possibility cannot be excluded that in some of the previously described cases 
such progression was only transient and escaped detection. 
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Three distinct COCH mutations pertaining to three American families with 
nonsyndromic autosomal dominantly inherited hearing impairment, different 
from the mutation in the family of the present study, were described by 
Robertson et al.18 The P51S mutation in the family in the present study was also 
found in three additional Dutch families (families W98-065, W98-066, and W98-
094)9. All families originated from the southern region of the Netherlands. One of 
them has previously been described by Verhagen et al.19 (family W98-0949). A 
Flemish family with the P51S mutation has recently been studied by Fransen et al. 
(personal communication), who also found this mutation in two other previously 
described Dutch families2022. Only one American patient with DFNAg-linked 
sensorineural hearing impairment had proven hypoactive labyrinths at age 49 and 
inactive labyrinths at 53 years (case IV-3, kindred 2)16. 
Cardiovascular disease was a prominent additional finding in the family in the 
present study, as in a family described by Verhagen et al.21 The latter family was 
recently shown to have the present DFNA9/COCH mutation (Fransen et al., 
personal communication). 
Some histopathological descriptions of DFNA9 have been reported. Khetarpal et 
al.16 and Robertson et al.18 discovered an acidophiylic mucopolysaccharide-
containing ground substance in the cochleas, maculas and cristas of DFNAg 
patients, as well as severe degeneration of vestibular and cochlear sensory 
elements and dendrites. These depositions occurred at sites similar to those 
where COCH gene expression is seen in the chicken inner ear18. Such a deposition 
may cause functional impairment in a straightforward manner - in terms of 
"strangulating" nerve endings - as has been hypothesized by Khetarpal et al.16. It 
also seems possible, however, that this deposition does not cause structural or 
functional impairment, but rather is a result from it. Nevertheless, more 
conclusive pathophysiological explanations require further study. 
Conclusions 
The findings presented in this family study suggest a gradual development of 
cochleovestibular impairment caused by a 208C->T mutation in the COCH gene 
located in chromosome I4ql2-13 (DFNAg). The gross characteristics of this trait 
139 
Chapter 3 
are progressive middle-age onset (at the age of approximately 40 years) low-
frequency hearing impairment of about 3 dB/year and high-frequency threshold 
increases from approximately 50 dB hearing level at the age of 35 years to 
approximately 120 dB hearing level at the age of 75 years. At the time of onset of 
low-frequency hearing impairment, development of vestibular areflexia starts as 
well. 
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Abstract 
Objective: To perform linkage analysis and to outline hearing loss characteristics 
in a family exhibiting a non-syndromic, autosomal dominant type of progressive 
sensorineural hearing loss. 
Design: Genetic analysis was performed using microsatellite markers. Audiometrie 
data were collected and analyzed longitudinally. Sigmoidal dose-response curves 
enabled us to perform nonlinear regression analysis per frequency and on 
phoneme recognition scores. Speech recognition scores were compared with 
those of DFNA2, DFNA5, DFNAg and presbyacusis subjects. 
Subjects: Affected family members of a Dutch family (W99-060). 
Results: We revealed linkage of hearing loss to the DFNA20/26 locus (maximum 
lod score 3.1 at θ = 0.04) and reduced the critical region from 12 cM to 9.5 cM. 
Patients younger than 15 years already showed gently downsloping audiograms. 
At the ages of 15-20 and 25-40 years, hearing loss was profound at 8 and 1-4 kHz. 
The 0.25-0.5 kHz thresholds showed more gradual progression by about 1.5-2 
dB/year. From about 40 years onwards hearing was residual. Hearing impairment 
took a more severe course than in a known DFNA20 family. Score recognition in 
DFNA20/26 was better than in DFNAg at any pure tone average (1-4 kHz) 
threshold. Compared with subjects having DFNA2 and DFNA5, speech recognition 
in DFNA20/26 scored better at threshold levels below 85 dB HL, but worse at levels 
above 90 dB. Compared with presbyacusis subjects, those with DFNA20/26 scored 
better in speech recognition at levels below 100 dB and worse at levels above 100 
dB. 
Conclusions: Autosomal dominant hearing loss is linked to the DFNA20/26 locus in 
this Dutch family. The critical region is reduced from 12 to 9.5 cM. Phenotypically, 
patients are more severely affected compared to patients of the original DFNA20 
family. 
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Introduction 
Genetic hearing loss is one of the most frequent forms of sensorineural deficits 
handicapping people of all ages all over the world. Ten percent of the population 
older than 65 years and 50% older than 80 years are affected1. About one child in 
a thousand is born with prelingual hearing loss and in at least half of these cases 
the cause is inherited2,3. According to Morton1 approximately 77% of the non-
syndromic inherited forms of moderate to profound hearing loss in early 
childhood shows an autosomal recessive pattern of inheritance (DFNB), in 
contrast to 22% with an autosomal dominant (DFNA) type. The percentage of X-
linked hearing loss (DFN) is 1%, whereas hearing loss with a mitochondrial 
pattern of inheritance occurs sporadically1,4. It seems that most of the hereditary 
types of postlingual hearing loss are due to either autosomal dominant or 
mitochondrial mutations5. In recent years, mapping of deafness loci has become a 
common research effort. So far, 41 autosomal dominant, 33 autosomal recessive 
and 6 X-linked loci associated with non-syndromic hearing impairment have been 
mapped and 29 different genes have been identified6. 
Recessive forms of hearing loss generally involve all frequencies, are mostly 
congenital or prelingual, and range in severity from severe to profound7. For 
dominantly inherited hearing loss there is more variation and clearly different 
types can be distinguished on the basis of the frequencies involved, severity, age 
of onset and speech recognition scores710. Despite intra- and interfamilial 
variation in hearing loss caused by specific loci/genes, it is possible to 
differentiate between a number of these loci based on their clinical 
characteristics7,9,11,12. Phenotypic and genotypic characterization of families is 
important for insight into intra- and inter-locus variation in hearing loss. 
Herein, we describe a Dutch family (W99-060) with progressive sensorineural 
autosomal dominant hearing impairment linked to the DFNA20/26 locus. 
Statistical analysis was performed on pure tone audiometry data and on speech 
recognition scores. The results were compared to those previously reported for 4 
affected family members of a known DFNA20 family13; speech recognition scores 
were compared with those found in subjects with DFNA28, DFNA59, DFNA98 and 
presbyacusis14. 
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Patients and methods 
In 1999, we began our investigations of hearing loss in a large Dutch family (W99-
060) spanning six generations (Figure l) with the approval of the institutional 
review board. Fourteen family members had a history of progressive hearing 
impairment that first manifested in adolescence. After having obtained written 
and informed consent, we obtained pure-tone and speech audiograms from 22 
individuals using standard procedures and, in some cases, a portable audiometer. 
Previously obtained audiograms were retrieved for 13 individuals. Blood samples 
were collected from 11 presumably affected and 22 unaffected persons for linkage 
analysis. Special attention was paid to the presence of syndromic features possibly 
accompanying hearing loss. 
Linkage analysis 
Genomic DNA was extracted from peripheral blood lymphocytes according to 
established procedures15. Analysis of polymorphic markers involved amplification 
by polymerase chain reaction (PCR). Each reaction contained 100 ng genomic DNA 
and 30 ng of each primer, in 15 μΐ Supertaq buffer (50 mM KCl, 1.5 mM MgCl2, 10 
mMTris-HCl pH 9.0, 0.1% Triton X-100, 0.01% (w/v) gelatin) in the presence of 32P-
dCTP with 0.06 U Supertaq (HT Biotechnology LTD, Cambridge, England). 
Amplification was achieved by 35 cycles of l min 94°C, 2 min 550C and 3 min 720C 
with microsatellite markers. The radiolabeled PCR products were mixed with 15 μΐ 
sample buffer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue) heated to 
950C for 3 minutes and 4 μΐ of this mixture were separated on a 6.6% denaturing 
Polyacrylamide gel. Subsequently, the gel was dried and exposed overnight to 
Kodak X-OMAT film to visualize the separated allelic bands. Two-point lod scores 
were calculated using the MLINK subroutine of the computer program LINKAGE 
(version 5.1)10 on the basis of autosomal dominant inheritance. For the 
calculation, the relative prevalence of the disease allele was assumed to be 0.0001 
and penetrance 95%. A relative prevalence of 0.001 was assumed for phenocopies. 
The cutoff age for unaffected family members was 20 years. 
Audiometrie analysis 
Audiometrie configuration and threshold asymmetry were evaluated according to 
the criteria and classification established by the European Work Group on 
Genetics of Hearing Impairment16. Serial audiometry was available in 8 patients 
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and suitable for longitudinal analysis in 5 of them (VI-4, IV-19, V-6, V-15, V-21). 
Nonlinear longitudinal regression analysis (air-conduction threshold on age) was 
performed using a commercial program (Prism 3.02, GraphPad, San Diego, CA, 
USA). The bone conduction threshold was measured to exclude conductive 
hearing loss. One-way analysis of variance (ANOVA) was used to detect significant 
differences between any (sub)group of patients. Pooling was only performed 
where it was permitted according to the results of such tests. All these data 
enabled us to construct age related typical audiograms (ARTA). Speech 
recognition scores were measured using (phonetically balanced) standard 
consonant-vocal-consonant syllables (Dutch CVC word lists). The phoneme score 
was analyzed in relation to age and pure tone average of the thresholds at l , 2 
and 4 kHz (PTA14 kHz). Nonlinear regression analysis was performed using a 
sigmoid response curve with variable slope. Details can be found in a previous 
report8. 
Analysis of variance and the t test (with Welch's correction if Bartlett's test 
demonstrated significantly unequal variances) were used to compare the results 
with those previously obtained in: (1) a group of patients with presbyacusis14; (2) a 
group of DFNAg patients8; as well as (3) a group of DFNA5 subjects9. 
Vestibulo-ocular examination and imaging techniques 
Seven family members (IV-7, IV-11, l\/-22, V-5, V-6, V-15 and VI-4) underwent 
vestibular and ocular motor tests. These included evaluation of vestibulo-ocular 
responses, using electronystagmography with computer analysis and saccadic, 
smooth pursuit and optokinetic nystagmus responses. Vestibular stimulation 
comprised rotatory and caloric tests. Details and normal values have been 
previously described17. A CT scan of the petrosal bones of case IV-22 was 
performed (Siemens Somatom Plus 4, Siemens, Forchheim, Germany). 
Results 
The hearing loss trait in the family (Figure l) exhibits an autosomal dominant 
pattern of inheritance. The case histories and physical examinations excluded 
syndromic involvement. Most of the patients dated their first symptoms of 
hearing loss to the first 2 decades of life. Given the normal speech and language 
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development and the substantial progression of hearing loss, especially in the 2nd 
decade, the hearing loss is expected to be mainly postlingual in origin. 
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Figure l Pedigree of family W99-060 and genotypic data for 17P25 markers, listed in centromere-to-telomere 
order The most likely haplotypes are shown A black bar indicates the haplotype that is associated with the 
affected status Solid lines indicate an unknown phase The order of the markers D17S1806, D17S784, D17S668 
and D17S928 was according to the Marshheld genetic map (http//research marshfieldclinic org/genetics) and 
the Decode high-resolution recombination map2 0 The additional markers were positioned as given in the most 
recent freeze (April 2003) of the Human Genome Working Draft (http//genome ucsc edu) and the Celera 
database •, man, o, woman, • / · , affected persons, /, deceased, //, separated, ' , affected by history 
Linkage analysis results 
Because of the apparent similarity of the present type of hearing loss to DFNA5, 
this locus was tested first with polymorphic markers (e.g. D7S673, D7S2444 and 
D7S2493). The locus was excluded by lod scores lower than -2 (data not shown). 
Subsequently, a genome scan was initiated and after exclusion of about one third 
of the genome, linkage was detected with marker D17S928 (l7q25) with a 
maximum two-point lod score of 3.1 at θ= 0.04. This marker flanks the DFNA20 
interval at the telomeric side18. Additional markers derived from this region were 
tested and two-point lod scores were calculated (Table 1). 
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Table ι Two-point lod scores between the hearing loss and polymorphic markers of the DFNA20/26 region 
Theta / Marker 
D17S1806 
D17S1830 
D17S784 
D17S761 
D17S668 
D17S928 
D17S623 
0.00 
-12.03 
-4.08 
-9-34 
-1.61 
2.20 
1.89 
0.79 
0.01 
-6.06 
0.54 
-3.62 
0.38 
2.06 
2.87 
2.07 
0.05 
-4.65 
1.71 
-1.64 
0.89 
1.89 
3.07 
2.36 
0.1 
-3.86 
1.95 
-0.91 
0.94 
1.65 
2.78 
2.18 
0.2 
-2.04 
1.65 
-O.48 
O.70 
1.12 
I.84 
I.52 
0.3 
-1.04 
0.97 
-0.39 
O.38 
0.54 
0.79 
0.74 
0.4 
-O.42 
0.29 
-0.25 
0.09 
0.04 
-0.03 
0.00 
Ζ™, (Θ) 
3.10 (0.04) 
Abbreviations Θ, recombination fraction, Zm„, maximum logarithm of odds score 
The most likely haplotypes were constructed to determine the borders of the 
critical region (Figure 1). This revealed that individual IV-2 shares only the allele 
for marker D17S668 as seen with the affected haplotype. A genotyping error was 
excluded by analyzing DNA from two independent samples. Since both parents 
had died we were unable to determine whether or not allele 2 is derived from the 
affected mother. Therefore, we decided to determine the critical region primarily 
on the basis of the remaining part of the pedigree. On the centromeric side, the 
critical region is flanked by D17S784 as can be deduced from a recombination 
event seen in the affected individual V-s. Individual V-10 (33 years old at 
examination) also displays a recombination event suggesting that marker 
D17S784 is the proximal flanking marker. However, for this individual non-
penetrance cannot be excluded. The given location of the marker D17S1830 
relative to D17S784 is based on physical maps (see Figure 1 and 6) and might 
therefore be less reliable than marker orders based on genetic maps or radiation 
hybrid maps. In case markers D17S1830 are located distally from D17S784 the 
former marker would be the proximal flanking marker. There is no recombination 
seen for the most telomeric marker D17S623 and thus the linkage interval for this 
family is in between D17S784 and I7qter. Marker D17S623 is the only marker 
shown for which the position in the physical map is not compatible with that in 
the Marshfield genetic map in which it is at the same position as D17S1830 and 
D17S784 (http://research.marshfieldclinic.org/genetics). Recombination events 
seen in the individuals V-5 and V-io indicate that D17S623 is located at the 
telomeric side of D17S784. The definition of the critical region is not dependent 
on the position of D17S623. 
Regarding the allele of marker D17S668 in individual IV-2 as being derived from 
the haplotype that carries the mutation, the critical region based on the given 
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marker order would be delimited to the interval between D17S761 and D17S928. 
However, because of the extent of genetic heterogeneity and environmental 
causes of hearing loss, the results for individual IV-2 must be regarded with 
caution. Unfortunately patient IV-i refused to participate in this study. Assuming 
that one gene is involved in the hearing loss in the four families known to be 
linked to I7q2551819, our data reduce the critical region from 12 cM18, between 
D17S1806 and D17S668, to 9-5 cM between D17S784 and D17S668. In the recently 
published high resolution recombination map of Decode20 this distance measures 
only 6.1 cM. 
Audiometrie analysis 
The available audiograms of 10 affected cases are shown in Figure 2 (page 154). 
The patients showed gently downsloping audiograms already at age < 15 years. 
By the ages of 15-20 and 25-40 years, hearing loss had become severe to profound 
at 8 and 1-4 kHz respectively. The thresholds at O.25-0.5 kHz showed more gradual 
progression at an average increase of about 1.5-2 dB/year. There was residual 
hearing, i.e. mainly at the lower frequencies, at ages from about 40 years 
onwards. Figure 3 shows the age-related typical audiograms (ARTA) of the present 
and, for the sake of comparison, of a known DFNA20 family. 
dB W99-Q60, dB D^NA20 
τ Γ 
.25 .5 ι 2 4 8 kHz 
Frequency 
8 kHz 
Figure 3 Age Related Typical Audiograms (ARTA) of family W99-060 and of a known Amencan DFNA20 
family13 Italics indicate age in years 
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Figure 2 Serial audiograms of 10 family members (Α-J) shown for the right (R) and left (L) ear, 
separately (air conduction threshold in dB HL). Note that the panels are ordered (top left to bottom 
right) by age (y = year) at the last visit. Some of the serial audiograms have been omitted for clarity 
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The plots in Figure 4 combine the longitudinal analyses in the suitable cases with 
the (cross-sectional) data in the other cases. 
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Figure 4 Plots combining individual, longitudinal data (with connection lines) and separate, cross-sectional 
data for binaural mean air conduction threshold and phoneme recognition score (open circles) against age 
(bottom panel). Black triangles and squares indicate cross-sectional and longitudinal data from the American 
family described by Elfenbein et al.1 3 
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Cross-sectional data reported by Elfenbein et al.13 are included for the purpose of 
comparison. The bottom panel shows the phoneme recognition score in relation 
to age. The threshold data showed much higher progression at the high 
frequencies than at the lower frequencies. The maximum rate of progression 
culminated within the age range of 10 to 35 year and varied in individual cases 
between about 3 and 8 dB/year. Onset ages were in the range of 5 to 25 years, 
showing an apparent decrease at increasing frequencies in some cases. At age 15 
to 35 years, 50% of the final degree of deterioration had developed, and by age 30 
to 50 years 90% of the final degree of deterioration had developed. 
Appreciable deterioration of speech recognition (score < 90%) began between 
ages 15 and 40 years and showed large intersubject variations (Figure 4, bottom 
panel). At 20-45 years of age, recognition scores deteriorated maximally (range 5 
to 20 %/year). With few exceptions, speech recognition became problematic 
(maximum phoneme score < 50%) from an age of about 25-45 years onwards. 
Between the ages of 30 and 60 years, speech recognition was almost completely 
lost, except in 1 patient. In relation to the corresponding threshold level (i.e., PTAj. 
4 kH2), the phoneme recognition score was relatively good compared to that 
previously obtained at our clinic in patients with presbyacusis14, DFNA28, DFNA59 
and DFNAg8 patients. The slope at which the phoneme recognition score decayed 
with increasing PTA level appeared to be steeper than in the aforementioned 
different groups of patients8,9,14 (Figure 5). The recognition score in DFNA20/26 
was better than in DFNA9 at any PTA. Compared with DFNA2 and DFNA5 subjects, 
DFNA20/26 subjects scored better in speech recognition at PTAs lower than 85 dB 
of hearing loss, but worse at PTAs higher than 90 dB. Compared with presbyacusis 
subjects, those with DFNA20/26 scored better in speech recognition at PTAs lower 
than 100 dB and worse at PTAs higher than 100 dB. 
Vestibulo-ocular examination and imaging results 
While caloric testing revealed no abnormalities, patient IV-7 exhibited vestibular 
hyporeflexia and asymmetrical responses to rotatory tests. Severe vestibular 
hyporeflexia and an enhanced cervico-ocular reflex were noted in family member 
IV-22. Vestibular testing in six other participants (IV-ll, IV-22, V-5, V-6, V-IS and VI-
4) revealed no abnormalities. The middle and inner ear structures of family 
member IV-22 had a normal appearance on CT scans. 
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Figure 5 Plot showing relationship between phoneme recognition score (% Correct) and binaural mean PTA14 
k H z (dB HL) schematically by lines drawn for DFNA2, DFNA5, DFNAg and the Dutch DFNA20/26 family 
Presbyacusis (presby) is represented by a dotted line 
Discussion 
The Dutch family in the present study shows postlingual non-syndromic 
progressive sensorineural hearing loss with probably no or very limited vestibular 
involvement. This is the fourth DFNA-family found to have hearing loss linked to 
chromosome I7q25. The critical region, originally described by Morell et al.18, is 
located between the markers D17S1806 and D17S668, and occupies an interval of 
about 12 cM (Figure 6). Yang and Smith19 presented two unrelated American 
families with progressive autosomal dominant hearing loss with linkage to a 
region overlapping the DFNA20 interval6. The locus for these two families was 
designated DFNA266. Flanking markers for the DFNA26 locus have not been 
reported so far. Extensive clinical comparison with these DFNA26 families is 
prohibited by the present lack of reported audiometrie data. 
The originally reported type of hearing impairment associated with DFNA20 
showed progressive sensorineural hearing impairment with a relatively late onset 
(age 20) that predominantly affected the high frequencies. The pattern of hearing 
loss was suggested to resemble presbyacusis with an onset that is 30 years earlier 
than normal18. Recently, audiometrie data were reported for 4 affected family 
members by Elfenbein et al.13, who described downsloping sensorineural hearing 
loss, first evident at 6 kHz and later followed by 8 kHz. This pattern could be 
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demonstrated in some cases in their early teens but was clearly evident only by 
age 24 to 29 years. By the end of the third and fifth decades, clear differences 
were found at some frequencies between affected and unaffected persons. With 
increasing age, hearing loss increased at all frequencies, ultimately leading to a 
"corner audiogram" configuration. The hearing loss of the presented Dutch 
DFNA20/26 family shows some similarities with the American family reported by 
Elfenbein et al. However, the audiometrie data also revealed apparent differences. 
We demonstrated that hearing loss was profound by the ages of 15-20 and 25-40 
years at 8 and 1-4 kHz, respectively. Loss at the lower frequencies, i.e. 0.25-0.5 kHz, 
showed more gradual progression with an average increase of ~l.5-2 dB/year. 
Affected individuals have only residual hearing from an age of about 40 years 
onwards. Thus, hearing impairment in the Dutch DFNA20/26 family has a more 
severe appearance than that in the American family (Figure 3). Higher threshold 
levels were attained at an earlier age at any given frequency. Obviously, 
comparing purely longitudinal data of both families would be more appropriate, 
however, Figure 3 may give some indication of the difference in severity. 
The DFNA20/26 patients in the present family showed better maximum speech 
recognition scores in relation to the level of pure tone hearing impairment at 
levels below 80-90 dB HL than was found in DFNA2, DFNA5, DFNA9 and 
presbyacusis patients. However, owing to a steeper slope of the trend line 
pertaining to DFNA20/26, these patients showed lower scores at levels above 90 
dB than the DFNA2 and DFNA5 patients and scores similar to presbyacusis at 
about 100 dB (Figure 5). Elfenbein et al.13 mentioned the proband's poor speech 
recognition scores without details and included data on acoustic emissions, but 
no detailed data on speech recognition scores were given13. We did not evaluate 
otoacoustic emissions. 
A survey of the critical region for candidate genes for DFNA20/26 suggested the 
P4HB gene, encoding the beta subunit of prolyl 4-hydroxylase, as the most 
promising candidate gene. The P4HB protein catalyses the formation of 4-
hydroxyproline in collagens and thereby is important for the structure and 
function of collagen. In addition, the protein functions as protein disulphide 
isomerase and as a cellular thyroid hormone binding protein. However, a disease-
causing mutation in this gene could not be demonstrated in the DFNA2018 family 
and in the present family. 
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The difference in phenotype between the previously described American DFNA20 
family1 8, based on data of only four family members13, and the present family does 
not exclude the involvement of the same causative gene. Different types of 
mutations might lead to different phenotypes. However, it can also be 
hypothesized that different genes are causing different traits linked to the 
DFNA20/26 interval. An example is the recent localization of a gene for Usher 
syndrome type iG (USHiG) to I7q24-q252 1 overlapping with the DFNA20 interval 
as it was described by Morell et al.18. Since the critical region for USHiG is flanked 
by D17S1830 at the telomeric side, this locus does not overlap with the critical 
region determined for the Dutch family (Figure 1, Figure 6). 
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Figure 6 Representation of the critical regions of family W99-060 of the present study, a known DFNA20 
family1 and the USHlC locus2 1 Order and distances in centimorgans of the underlined markers are 
according to the Marshfield genetic map (available at http //research marshfieldclinic org/genetics) (left) 
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Therefore, we conclude that the distal part of chromosome I7q harbours at least 
two causative genes for hearing loss. The mouse mutation jackson-shaker (y's) 
associated with deafness and vestibular impairment is located in the region of 
mouse chromosome 11 homologous to human chromosome I7q2522. Given the 
vestibular impairment it seems more likely that the mutated gene in the y's mouse 
is the orthologue of the USHiG gene than that of the gene for nonsyndromic 
hearing loss in the present family. Already three genes have been found to be 
involved in both Usher syndrome and in non-syndromic hearing loss7 1 2 1 6 2 3 2 9. 
Therefore, the identification of the disease-causing mutations is needed to 
elucidate whether DFNA20 and DFNA26 are caused by mutations in the same 
gene. This will also show whether the USHiG gene is involved. 
The present research was successful in mapping the causative gene for hearing 
loss in a Dutch family to the DFNA20/26 interval and in refining its critical region. 
The present report is the second to provide detailed tone and speech audiometrie 
data for this locus. The publication of additional data available from other 
DFNA20/26 families is needed to improve phenotypic comparison. Clinical 
features of the two available families show some audiometrie similarity. However, 
members of the Dutch family appear to be more severely affected already at an 
earlier age. As yet, no gene or disease-causing mutations have been identified for 
DFNA20/26. It has been previously suggested that DFNA20 might represent a 
suitable model of presbyacusis13.The present data however, do not demonstrate 
any striking similarity between the phenotype of DFNA20/26 and presbyacusis. 
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Abstract 
Deafness is genetically heterogeneous. Approximately half of the autosomal 
recessive forms of deafness are caused by mutations in CJB2, the gene coding for 
connexin 26. This protein is believed to play an essential role in the transport of K+ 
ions in the endolymph of the inner ear after sound stimulation. Mutation analysis 
of the connexin 26 gene (CJB2) is being performed fairly widely in the western 
world. This offers a good starting point for the further investigation of autosomal 
recessive and sporadic forms of hearing impairment. 
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Introduction 
Hearing impairment is a sensory disability that affects millions of people all over the 
world. Though not life-threatening, it can become a major burden in social and 
professional life. In the industrialized world, deafness of infective and/or 
environmental origin has become less frequent, with a consequent rise in the 
proportion of hereditary hearing impairment. Deafness occurs in 1:1000 neonates1 
and the cause is hereditary in about half. This type of hearing impairment is 
sometimes referred to as prelingual, as it affects the child before the age of speech 
development. A distinction can be made between syndromic deafness, in which the 
deafness is accompanied by other specific abnormalities, and non-syndromic 
deafness (about 75%), in which there are no additional abnormalities. 
Approximately three-quarters of the non-syndromic forms are caused by a recessive 
disorder14. Table 1 gives an overview of some epidemiological features. 
Table 1 Epidemiological features of prelingual hearing loss 
Incidence 
Percentage of genetically caused cases of 
hearing loss 
Syndromic vs non-syndromic causes 
Autosomal dominant 
Autosomal recessive 
X-linked 
Mitochondrial 
Prelingual hearing loss 
1/1000 
50% 
25 vs 75 % 
20% 
74% 
5% 
1 % 
Between 1997 and today, many non-syndromic hereditary forms of deafness have 
been localized on the human genome by genetic linkage techniques. Depending on 
the pattern of inheritance of the deafness, these loci are designated DFNA 
(autosomal dominant), DFNB (autosomal recessive) or DFN (X-linked). They are 
numbered in chronological order of discovery. For the majority of these loci the 
underlying disease-causing genes have not been identified so far. On the Hereditary 
Hearing Loss Homepage5 all these currently known forms of hereditary deafness are 
summarized. Tables 2-5, derived from this homepage, illustrate the achievements in 
this field of research. 
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Table 2 Loci and genes associated with autosomal dominant, non-syndromic hearing impairment, with the 
year of publication ( · , unpublished observations) 
Locus 
DFNAl 
DFNA2 
DFNA3 
DFNA4 
DFNA5 
DFNA6 
DFNA7 
DFNA8/12 
DFNA9 
DFNAlO 
DFNAll 
DFNA12 
DFNA13 
DFNA14 
DFNA15 
DFNA16 
DFNAl? 
DFNA18 
DFNA19 
DFNA20 
DFNA21 
DFNA22 
DFNA23 
DFNA24 
DFNA25 
DFNA26 
DFNA27 
DFNA28 
DFNA29 
DFNA30 
DFNA3I 
DFNA32 
DFNA33 
DFNA34 
DFNA35 
DFNA36 
DFNA37 
DFNA38 
DFNA39 
DFNA40 
Localisation 
5q31 
1P34 
13ql2 
19ql3 
7P15 
4P16.3 
iq21-23 
llq22-24 
14ql2-13 
6q22-23 
l lq l2.3-21 
l l q 22-24 
6p21 
4pl6 
5q31 
2q24 
22q 
3q22 
10 
17q25 
6ql3 
14q21-22 
4q 
12q21-24 
17q25 
4ql2 
8q22 
15q26 
l l p i S 
lq44 
9ql3-21 
lp21 
4P16.3 
4q21.3 
Reference 
Leon et al. 
Coucke et al. 
Chaibeto/. 
Chen et al. 
Van Camp et al. 
Lesperance et al. 
Fagerheim et al. 
Kirschhofer et al 
Manolis et al. 
Ò'Neill et al. 
Tamagawa et al. 
Verhoeven et al 
Brown et al. 
Van Camperò/. 
Vahava et al. 
Fukushima et al. 
Lalwani et al. 
Boensch et al. 
Green et al. 
Morell et al. 
Melchionda et al. 
Salam et al. 
Hafner et al. 
Greene et al. 
Yang et al. 
Fridell et al. 
Anderson et 0/. 
reserved 
Mangino et al. 
withdrawn 
Li et al. 
reserved 
Kurima et al. 
reserved 
Kurima et al. 
Talebizadeh et al. 
Young et al 
Xiao et al. 
reserved 
Year 
1992 
1994 
1994 
1995 
1995 
1996 
1996 
1996 
1996 
1996 
1996 
1997 
1997 
1999 
1998 
1999 
1999 
1998 
1998 
2000 
2001 
2000 
1999 
1999 
2000 
1999 
1999 
1999 
2000 
2000 
2000 
2000 
2001 
2001 
Associated Cene 
HDIAl 
GM (CX31) 
KCNQ4 
GJB2 (CX26) 
GJB6 (CX30) 
DFNA5 
WFSl 
TECTA 
COCH 
EYA4 
MYO7A 
TECTA 
COL11A2 
WfSl 
POU4F3 
MYH9 
MYO6 
WFSl 
DSPP 
Reference 
Lynch et al. 
Xiaeto/. 
Kubisch et al. 
Denoyelle et al 
Grifa et al. 
Van Laer et al. 
Bespalova et al.* 
Verhoeven et al. 
Robertson et al. 
Wayne et al. 
ùu et al. 
Verhoeven et al. 
McGuirt et al 
Bespalova et al.' 
Vahava et al. 
Lalwani et al. 
Melchionda et al. 
reserved 
withdrawn 
reserved 
reserved 
Young et ai* 
Xiao et 0/. 
reserved 
Year 
1997 
1998 
1999 
1998 
1999 
1998 
2001 
1998 
1998 
2001 
1997 
1998 
1999 
2001 
1998 
2000 
2001 
2001 
2001 
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Table 3 LOG and genes associated with autosomal recessive, non-syndromic heanng impairment, with the 
year of publication 
Z.OCUS 
DFNBl 
DFNB2 
DFNB3 
DFNB4 
DFNB5 
DFNB6 
DFNB7 
DFNB8 
DFNB9 
DFNBlO 
D F N B l l 
DFNB12 
DFNB13 
DFNB14 
DFNB15 
DFNB16 
DFNB17 
DFNB18 
DFNB19 
DFNB20 
DFNB21 
DFNB22 
DFNB23 
DFNB24 
DFNB25 
DFNB26 
DFNB27 
DFNB28 
DFNB29 
DFNB30 
/.oco/isation 
1 3 q l 2 
l l q l 3 5 
1 7 Ρ 1 1 2 
7q31 
1 4 q l 2 
3P14-P21 
9 q l 3 - q 2 1 
21q22 
2P22-23 
2 l q 2 2 3 
9 q l 3 - q 2 1 
10q2l-q22 
7q34-36 
7q31 
3 q 2 l - q 2 5 * 
19P13* 
15q21-q22 
7q31 
l l p l 4 - 1 5 1 
l 8 p l l 
l l q 2 5 - q t e r 
l l q 
l O p l l 2-q21 
l l q 2 3 
4P15 3-ql2 
4 q 3 1 
2q23-q31 
2 2 q l 3 
2 l q 2 2 
l o p 
Reference 
Guilford et ai 
Guilford et al 
Fnedman et ai 
Baldwin et ai 
Veske ef al 
Chaib ef al 
Bonne-Tamir et al 
Scott ef al 
Chaib ef al 
Mustapha et al 
Mustapha et al 
Chen ef al 
Campbell et al 
Gremwald ef al 
Jain e f a i 
Green et al 
M o y m h a n et al 
Mustapha e t c ì 
Riazuddin et ai 
Pulleyn ef al 
Walsh ef al 
Wilcox et al 
Year 
1994 
1994 
1995 
1995 
1996 
1996 
1996 
1997 
1996 
1998 
1998 
1997 
1997 
1998 
1998 
1998 
1999 
1999 
2000 
2000 
2000 
2001 
Associated Gene 
GJB2 (Cx26) 
MY07A 
MYO15 
SLC26A4 
TMPRSS3 
OTOF 
TMPRSS3 
CDH23 
TECTA 
CLDN14 
Reference 
Kelsell et al 
Liu et al 
W e i l e f o / 
Wang ef al 
Li ef al 
Fukushima et al 
Fukushima et al 
Jam et al 
Scott et al 
Yasunaga et of 
Scott ef al 
Bork et al 
Mustapha et al 
reserved 
reserved 
reserved 
reserved 
Wilcox ef al 
reserved 
Vear 
1997 
1997 
1997 
1998 
1998 
1995 
1995 
1995 
2001 
1999 
2001 
2001 
1999 
2001 
* , the two loci revealed similar LOD scores 
Table 4 Loci and genes associated with X-hnked, non-syndromic heanng impairment, with the year of 
publication 
Locus 
D F N l * 
DFN2 
DFN3 
DFN4 
DFN5 
DFN6 
DFN7 
DFN8 
Localisation 
Xq22 
Xq22 
X q 2 l l 
X p 2 1 2 
Xp22 
Reference 
Tranebjaerg et al 
Tyson ef al 
De Kok ef al 
Lalwani étal 
Year 
1995 
1996 
1995 
1994 
Associated Gene 
DDP 
POU3F4 
Reference 
Jin et al 
De Kok et al 
withdrawn 
del Castillo et al 
withdrawn 
reserved 
Year 
1996 
1995 
1996 
* , later recognised as syndromic 
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Table 5 Mitochondrial mutations associated with ηοπ-syndromic hearing impairment, with the year of 
publication 
Gene 
12S rRNA 
tRNASer 
(UCN) 
Mutation 
1555A-»G 
1445A-»G 
7472insC 
7510T-»C 
751lT^C 
Reference 
Prezant et al. 
Usami et al. 
Estivili et al. 
•Reidefo/., "Fischel-
Ghodsian et al. 
•Sevior et al. 
•Tiranti et al. 
•Jakscheto/. 
•Schuelke et al. 
Verhoeven et al. 
Hutchin et al. 
Friedman et al. 
Sue et al. 
Year 
1993 
1997 
1998 
1994 
1995 
1998 
1995 
1998 
1998 
1999 
1999 
1999 
1999 
·, additional symptoms were present in some patients 
Certain research groups, having found preliminary evidence of a new locus, have 
claimed ('reserved') loci in advance. 'Withdrawn' indicates those which turned out 
not to be correct. Most of these genetic types of hearing impairment are quite rare, 
with the exception of DFNBl. This paper addresses DFNBl, which is caused by 
mutations in the connexin 26 gene. 
Hearing impairment 
Although the connexin 26 gene GJB2, is also involved in an autosomal dominant 
form of deafness (DFNA3), most mutations in this gene cause recessive hereditary 
bilateral deafness/hearing impairment, soolled DFNBl. This form of sensorineural 
non-syndromic hearing loss is prelingual and its severity varies from mild to 
profound, depending to some extent on the type of mutation6,7. Hearing loss in the 
high-tone range has recently been described as a characteristic feature, but all 
frequencies are affected8. In two thirds of cases, the hearing loss is non-progressive 
and there usually no vestibular and/or labyrinthine abnormalities. 
Genetics 
DFNBl was the first locus incriminated in autosomal recessive deafness; in 1997, 
GJB2 was found to be responsible9. GJB2 is a small gene situated on chromosome 
I 3 q i i ; it has a length of about 5.5 kilobases. There are two exons, of which only one 
contains the coding sequence. The mRNA is 2.4 kilobases long and translates into a 
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protein with 226 aminoacids. This protein belongs to the connexin family, which 
currently has more than a dozen members10. 
The protein 
Connexins are membrane proteins with four transmembrane domains. Six chains of 
these proteins form a complex (a hexamer), called connexon. Two hexamers in the 
membranes of adjacent cells form a cell-to-cell channel, a so-called gap junction, 
which allows the transport of small molecules and ions between cells. A hexamer 
can contain various types of connexin, and various types of hexamer can form cell-
to-cell channels. The channel constituents determine which molecules or ions can 
pass through11. 
Figure 1 Schematic representation of a gap junction. Six connexins form a connexon. Two connexons of 
neighbouring cells form pores which allow intercellular transport of small molecules. (Adapted from Furshpan 
and Potter, 19S919) 
The cell 
Recently, the hypothesis was put forward that CX26 protein is essential for 
maintaining the high K+ concentration in the endolymph of the inner ear. Sound 
stimulation of the ossicular chain causes vibrations in the endolymph. K+ ions 
enter the hair cells under the influence of these vibrations and the vibration signal 
is ultimately converted into a neural signal. The system is regenerated by the 
release of K+ from the hair cells into the supporting cells. The K+ ions are then 
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passed from cell to cell via gap junctions and are eventually released into the 
endoiymph. Except for sensorineural cells, the connexin 26 protein is present in 
gap junctions connecting all cell types in the cochlea, including the spiral limbus, 
the supporting cells, the spiral ligament and the basal and intermediate cells of 
the stria vascularis. It is therefore very likely that connexin 26 is involved in K+' 
recycling in the cochlea11. 
Epidemiology 
Mutations in CX26 are the most common cause of autosomal recessive deafness 
throughout the world. This gene is believed relevant to half of all cases of hereditary 
deafness. CX26 shows diverse mutations, but one mutation occurs very frequently in 
Europe: the 35delG mutation. Average carrier frequency in Europe is 1:51 
(north/middle Europe 1:79, south Europe l:35)u (Table 6). In the Mediterranean 
countries the carrier frequency exceeds even that of the ΔΡ5θ8 mutation in the CFTR 
gene which causes cystic fibrosis. Carrier frequencies in North America and Australia 
are comparable to those in north/middle Europe. In oriental populations and the 
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Ashkenazi Jews, other mutations in the same gene play a more important role 
(234delC13 and lyödelT14, respectively). The high frequency of connexin-26-related 
hearing impairment in certain populations may be the result of the tradition of 
marriages between hearing-impaired persons15. The 35delG mutation gives rise to a 
severely shortened, non-functional protein16. More than sixty other, far less 
frequent, mutations have been described in CX2617. Uncertainty about the 
pathogenicity of some of the mutations complicates interpretation of mutation 
analysis18. 
Table 6 Carner frequency of mutation 35delG in the GJB2 gene in 17 European countries. Adapted from 
Gasparim et al, 200012 
Country 
Northern and Central Europe 
Norway 
Denmark 
Estonia 
United Kingdom 
Germany 
Belgium 
Holland 
France (Bnttany) 
France 
Czech Republic 
Slovenia 
Bulgaria 
Total" 
Southern Europe 
Portugal 
Spain 
Italy 
Italy (Sardinia) 
Malta 
Greece 
Turkey 
Total 
Total average of Europe 
Carner frequency 
1/47.5 
1/190 
1/22.5 
0/119 
1/50 
1/190 
1/445 
1/96 
1/200 
I/487 
I/I82 
I/IS? 
1/29 3 
1/45 
1/40 
1/32 
1/29.5 
1/36 
1/33 
1/37 5 
1/Ï5.2 
I /5 I . I 
Denoyelle et al.7 found mutations in the CX26 gene in 49% of the families from 
France, Great Britain and New Zealand who had severe to profound prelingual 
hearing loss. CX26 mutations were present in 51% of the group with, versus 31% in 
the group without, a clear familial history of hearing impairment; 86% of the CX26 
mutations were 35delG mutations. Mueller et α/.19 studied a group of 284 English 
patients with early childhood hearing impairment or deafness, with and without 
hereditary causes. They found CX26 mutations in 27.8% of the familial cases and in 
7.9% of the sporadic cases; 70% of the CX26 mutations were 35delG mutations. This 
difference can be explained by the fact that families with different ethnic 
backgrounds were included in the study. The prevalence of non-familial, sporadic 
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hearing impairment based on CX26 mutations in an English-Belgian population of 
68 children was io%20. 
Diagnosis 
An increasing number of medical centres can perform mutation analysis to 
determine involvement of the CX26 gene in congenital hearing impairment. This 
method has been available for several years at the department of medical genetics 
in Nijmegen. We retrospectively analysed the outcome of ninety-one CX26 mutation 
analysis requests covering a fixed period of time. Nineteen unrelated cases were 
shown to have two mutations in the gene. Twelve of them turned out to be 
homozygous, whereas four others were heterozygous for the 35delG mutation. 
Overall, the 35delG mutation was involved in 84% of these cases, thirteen cases 
originated from multi-affected families, whereas three others were sporadic cases. 
Information on the remaining three families could not be retrieved. Table 7 gives an 
overview of the CX26 mutations found in Nijmegen. 
Mutation analysis applies not only to children with a clear family history, but also to 
children whose parents have normal hearing (sporadic cases). Moreover, if a 
mutation in CX26 is present, genetic counselling can be offered to provide 
information on the aetiology answers and on the likelihood of recurrence in future 
offspring. When a mutation analysis is positive there will usually be no need for 
further investigations such as imaging and ophthalmological tests, because other 
causes of congenital deafness no longer have to be excluded. In these cases, 
attention can immediately be focused on optimizing the child's hearing. 
Histopathological examination of the cochlea in a patient with confirmed CX26 
mutation has revealed an intact acoustic nerve21. This means that these patients are 
suitable candidates for cochlear implantation, provided that their hearing loss is 
sufficiently profound. Early diagnosis leads to early treatment, which gives the best 
results with cochlear implantation. 
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Table 7 Overview of the CX26 mutations found in Nijmegen 
Patient 
1 
2 
3 
4 
5 
6*(f) 
7*(m) 
8*(d) 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
First mutation* 
35delC 
35delG 
35delG 
35delG 
35delG 
71G>A 
7lG>A 
7lG>A 
35delG 
35delG 
35delG 
35delG 
35delG 
35delG 
35delG 
35delG 
10lT>C 
35delG 
35delG 
109G>A 
35delG 
Implication for protein structure 
Shortened 
Shortened 
Shortened 
Shortened 
Shortened 
W24X 
W24X 
W24X 
Shortened 
Shortened 
Shortened 
Shortened 
Shortened 
Shortened 
Shortened 
Shortened 
M34T 
Shortened 
Shortened 
V37I 
Shortened 
2'"' mutation-* 
35delG 
109G>A 
35delG 
313dell4 
35delG 
407insA 
427C>T 
407insA 
35delG 
35delG 
35delG 
35delG 
35delG 
35delG 
449delT 
35delG 
427C>T 
IVSl+lG>A 
35delG 
109G>A, 
35delG 
Implication for protein structure 
shortened 
V37I 
shortened 
shortened 
shortened 
shortened 
R143W 
shortened 
shortened 
shortened 
shortened 
shortened 
shortened 
shortened 
shortened 
shortened 
R143W 
unknown 
shortened 
V37I 
shortened 
, belong to the same family; (f), father; (m), mother; (d), daughter 
Conclusion 
Unlike many other genes CX26 is small, so that screening for mutations is fast and 
relatively simple. Besides, the overall high involvement of CX26 mutations in 
autosomal recessive non-syndromic forms of deafness, and even in sporadic cases, 
makes mutation analysis distinctly worthwhile. CX26 mutation analysis has therefore 
secured a place as a useful tool in clinical practice. So far, many different mutations 
in the CX26 gene causing DFNBi have been identified17. The uncertainty about the 
pathogenicity of the mutation demands close collaboration with geneticists who are 
familiar with deafness18. Nevertheless, CX26 mutation analysis provides a good 
starting-point in the molecular diagnosis of patients with non-syndromic congenital 
deafness. 
The text is based on an article published in Nederlands Tijdschrift Voor 
Geneeskunde 
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Summary and discussion 
Summary 
Genetic hearing impairment became a topic of research in Nijmegen ORL 
department in the early seventies, about three decades ago. The application of 
gene linkage studies for genetic hearing impairment started in the late eighties, 
focusing mainly on genetic syndromes. In the early nineties these techniques 
started to be used for non-syndromic types of genetic hearing impairment. A co-
operation has been established between the Nijmegen University ORL department 
and the otogenetic laboratory of Boys Town, Omaha, Nebraska, USA (Prof. dr. W.J. 
Kimberling and Prof. S. Kumar) for BOR and Usher syndrome. With the Antwerp 
Department of Human Genetics the cooperation mainly regarded genotyping of 
DFNA families and otosclerosis. The establishment of the Nijmegen otogenetic 
laboratory (dr. H. Kremer) in collaboration with the Nijmegen Department of 
Human Genetics (Prof. dr. H. Brunner, dr. F. Cremers), has provided new and 
forceful opportunities for research on the genetics of hearing impairment. 
This PhD thesis project took advantage of the previous efforts in the field of 
genetic hearing impairment. The BOR families had part of their mutations 
established early on in Boys Town. The DFNA9 and DFNA20/26 linkage studies 
were performed successfully at the Nijmegen Research laboratory and so this 
laboratory succeeded to identify the genes and their mutations involved in DFNA9 
and DFNA20/26. The co-operation with the Department of Human Genetics (dr L 
Hoefsloot) was successful in providing important diagnostic mutation analysis 
data for DFNBi (6/02). Outcomes of these research projects have been brought 
together in chapters 2, 3, 4 and 5. 
This thesis includes pheno- and genotypic descriptions of several types of 
hereditary hearing loss. Successively scientific reports on autosomal dominant 
syndromic (BOR syndrome, Chapter 2), autosomal dominant non-syndromic 
(DFNAg and DFNA20/26, Chapters 3-4) and autosomal recessive non-syndromic 
(DFNBl, Chapters) forms of hereditary hearing loss are presented in four separate 
chapters. Chapter 1 presents a general introduction to the field of genetic hearing 
impairment. 
Chapter 2 discusses BOR syndrome and provides a review on this clinical entity in 
Chapter 2.1. The first report (Chapter 2.2) is a clinical report on a father and his 
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son from a small BOR family focusing on the presentation of a long-term 
audiometrie follow-up related to its radiological appearance. This provided us 
with the first notion of the presence of concomitant progressive fluctuating 
hearing loss and an enlarged endolymphatic duct and sac (LEDS) in the youngest 
of the studied patients. This encouraged us to include five other Dutch BOR 
families in a magnetic resonance imaging (MRI) study (Chapter 2.3). These 
findings, together with long-term audiometrie data and mutation analysis results, 
were studied and analysed (Chapter 2.4). Although we observed many different 
forms of middle-ear and inner-ear anomalies, none of them could be pinpointed 
as pathognomical for BOR syndrome (Chapter 2.3). We were able to substantiate 
progression and even fluctuation of hearing thresholds in some of the studied 
cases. Patients with LED(S) and/or an age of 25 years or under seemed to be prone 
to be more severely affected in terms of hearing loss thresholds and suffered from 
progressive fluctuating hearing loss (Chapter 2.4). Each family in this study 
showed linkage data compatible with EYAi involvement. So far mutation analysis 
has disclosed three different mutations in three of the six families. The limited 
amount of genetic data and a high degree of big inter- and intra-familial 
variability prohibited finding a clear geno-phenotype correlation. The recently 
published observation that genomic rearrangements of the EYAl gene are 
responsible for a high proportion of formerly undiagnosed BOR patients is of 
great interest. This sheds a new light on the available genetic data of 
undiagnosed BOR families and suggests an adaptation of the present method of 
EYAl mutation analysis. Expanding this diagnostic procedure might provide us 
with more genetic and clinical data on BOR syndrome. Hopefully, this will help to 
understand the issues raised during our work, as well as on the pathogenicity of 
this syndrome in general. 
Chapter 3 reports on DFNA9/COCH and begins with a review on this subject 
(Chapter 3.1). In Chapter 3.2 we describe the genetic and phenotypic analysis of a 
Dutch family carrying a G88E/COCH mutation. Hearing loss was found to be 
progressive, first affecting the high frequencies and, at a later stage, the mid and 
low frequencies. The age of onset was between the 5th and 6th decade and 
hearing loss thresholds deteriorated at approximately 3.6-4.6 dB/year. Almost all 
patients with obvious hearing impairment showed lack of vestibular function. We 
did not detect any substantial phenotypic differences between the original and 
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the present Dutch family. Chapter 3.3 describes a large Dutch family affected by 
cochleovestibular impairment due to the P51S/COCH mutation. This mutation is a 
founder mutation in Belgium and the Netherlands and has frequently been 
encountered amonst patients visiting the Nijmegen ORL department. Analysis 
showed predominant high frequency hearing impairment with an onset in the 
fourth to fifth decade of life, progressing by 3dB/year. Vestibular impairment up 
to and including areflexia developed concomitantly. Since then various other 
P51S/COCH family studies comprised audiometrical, genetic and vestibular test 
analyses and revealed a recognisable phenotype. DFNA9 is histopathologically 
characterised by extracellular glycosaminoglycan mucopolysaccharide depositions 
in the cochlea. This observation was first made in the temporal bone of a 
deceased patient affected by a G88/COCH mutation. Recent observations have 
shown that the mutated protein cochlin is normally processed and secreted in 
inner ear cells. The major effect probably occurs beyond the point of excretion in 
the extracellular matrix of the inner ear, and might be the result of interference 
with protein-protein interactions or mechanical problems due to cochlin 
aggregation. At present a post-mortem temporal bone study is being performed 
in the P51S/COCH family. It will be interesting to compare these results to the 
above-mentioned findings. 
In Chapter 4, we present a Dutch family with an autosomal dominant type of 
hearing loss linked to the DFNA20/26 locus at chromosome I7q25. We reduced 
the critical region from 12 cM to 9.5 cM. Audiometrie longitudinal data, including 
speech recognition scores, and vestibular data were collected and analysed. At 
age < 15 years hearing loss thresholds were gently downsloping and hearing loss 
became profound at the ages of 15-20 years (8 kHz) and 25-40 years (1-4 kHz). The 
0.25-0.5 kHz thresholds progressed more gradually at ~l.5-2 dB/year. From ~40 
years onwards hearing was only residual. Although speech recognition begun to 
be problematic between 25 and 45 years of age, maximum phoneme recognition 
scores were higher than those found in DFNA2, DFNA5 or DFNAg. Compared to 
the original North-American DFNA20 family, the present DFNA20/26 family is 
more severely affected. The DFNA20/26 locus harbours the gamma 1 actin gene 
(ACTGl). Recently, colleagues of the Nijmegen Otogenetic Laboratory identified a 
Thr278lle mutation in this gene, which suggests its involvement in DFNA20/26. 
The consequences of such a mutation on the protein itself, on protein-protein 
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interactions and on cochlear stereocilia function can be considered new goals for 
future research. 
Chapter 5 deals with DFNBl/C7S2. Mutations in this gene, encoding the protein 
connexin 26, play a major role in autosomal recessive and sporadic cases of 
hearing loss. GJB2 mutation analysis has become a successful diagnostic tool, 
which can be easily implemented in a diagnostic DNA laboratory. This chapter 
reviews this subject and summarises the first results of this diagnostic procedure 
in Nijmegen. Nineteen unrelated cases were shown to have two mutations in the 
gene. Twelve of them turned out to be homozygous, whereas four others were 
heterozygous for the 35delG mutation. Overall, the 35delG mutation was involved in 
84% of these cases. These findings are in line with results from our neighbouring 
countries. Additional studies should be conducted to investigate whether the type 
of mutation is correlated to the severity and the type of hearing impairment. 
Discussion 
In summary, clinical and genetic data on one syndromic and three non-syndromic 
types of hereditary hearing are outlined and discussed in this thesis. The 
complexity of the auditory system and the high number of identified loci prove 
that many other genes are involved, many of which have not yet been identified. 
Since the first description of a locus involved in hereditary hearing loss in 1992, 
the number of loci for this impairment seems to grow exponentially. Due to the 
laborious nature of identifying disease-causing genes and the fact that the human 
genomic sequence and its annotation are still incomplete, the discovery of 
deafness genes progresses at a slower rate. Performing studies leading to 
accurate standardised clinical descriptions, e.g. the analysis of audiometrie and 
vestibular data, is essential for the proper distinction of different phenotypes. 
Although such a distinction may seem trivial, the smallest difference or the 
slightest resemblance in clinical characteristics may be directive for candidate 
gene selection. Furthermore, the function of genes involved in hearing will be 
better understood, if all effects of a mutated gene are thoroughly known. Taken 
together this will hopefully lead to developments of new molecular diagnostic 
tools, perhaps even contribute to new therapeutic options and, last but not least, 
will optimise patient care in general ENT practise as well as in genetic counselling. 
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Samenvatting 
Ongeveer dertig jaar geleden, in het begin van de jaren zeventig van de vorige 
eeuw, werd erfelijke slechthorendheid een wetenschappelijk aandachtspunt van 
de Nijmeegse KNO afdeling. Eind jaren tachtig startten de eerste 
genkoppelingsstudies naar erfelijke slechthorendheid, die vooral gericht waren 
op syndromale afwijkingen gepaard gaande met slechthorendheid. Dezelfde 
techniek werd gebruikt voor erfelijke niet-syndromale vormen van 
slechthorendheid in het begin van de jaren negentig. Een samenwerkingsverband 
voor onderzoek naar het BOR- en het Usher-syndroom werd opgericht met 
deelname van de Nijmeegse KNO afdeling en het otogenetische laboratorium van 
Boys Town in Omaha (Nebraska, USA) onder leiding van Prof. dr. W.J. Kimberling 
en Prof. S. Kumar. De gezamelijke inspanningen van de afdeling Humane Genetica 
uit Antwerpen (dr. G. Van Camp) en de Nijmeegse KNO afdeling zijn meer gericht 
op genotypering van autosomaal dominante vormen van slechthorendheid en 
otosclerose. Het steeds intensievere contact met de afdeling Humane Genetica 
van het UMC St Radboud (Prof. dr. H. Brunner, dr. F. Cremers) heeft geleid tot de 
oprichting van het Nijmeegs otogenetisch laboratorium (dr. H. Kremer). Dit 
laboratorium is een zeer bruikbare toevoeging en biedt nieuwe én krachtigere 
mogelijkheden voor onderzoek naar erfelijke slechthorendheid. 
Dit promotie-onderzoek heeft veel profijt gehad van eerder verrichte 
onderzoeksinspanningen op het gebied van erfelijke slechthorendheid. Zo werd in 
een eerder stadium de mutatie-analyse in de verschillende families met het BOR 
syndroom uitgevoerd. Het koppelingsonderzoek in de DFNAg en DFNA20/26 
families werd met succes afgerond in het Nijmeegse otogenetisch laboratorium 
en heeft geleid tot de identificatie van de ziekte veroorzakende mutaties in de 
desbetreffende genen. De Nijmeegse afdeling DNA diagnostiek (dr. L Hoefsloot) 
heeft de gegevens met betrekking tot de uitslagen van DFNBi/connexine 26 
(CJB2) mutatie-analyse ter beschikking gesteld. Het resultaat van al deze 
onderzoeksprojecten komen in de hoofdstukken 2, 3, 4 en 5 aan de orde. 
In dit proefschrift worden diverse vormen van erfelijke slechthorendheid feno- en 
genotypisch beschreven. In vier afzonderlijke hoofdstukken worden 
achtereenvolgens enkele wetenschappelijke aspecten en resultaten besproken 
met betrekking tot een syndromale (BOR syndroom, Hoofdstuk 2), autosomaal 
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dominante (DFNAg and DFNA20/26, Hoofdstuk 3 & 4) en een autosomaal 
recessieve (DFNBl, Hoofdstuk 5) vorm van erfelijke slechthorendheid. Hoofdstuk l 
is een algemene inleiding over deze aandoening. 
Hoofdstuk 2 is gewijd aan het BOR syndroom en bevat een overzichtsartikel over 
deze aandoening (Hoofdstuk 2.1). Hoofdstuk 2.2 is een klinische beschrijving van 
een vader en zijn zoon met het BOR syndroom, met speciale aandacht voor de 
audiometrische follow-up in relatie tot het beeldvormend onderzoek. Hierbij 
vertoonde de jongste patiënt de opvallende combinatie van progressieve 
fluctuerende slechthorendheid met een verwijding van de ductus en sacculus 
endolymphaticus (LEDS). Dit is aanleiding geweest om vijf andere families met het 
BOR syndroom radiologisch te onderzoeken (MRI) (Hoofdstuk 2.3). De resultaten 
van dit onderzoek zijn samen met gedetailleerde audiometrische en genetische 
gegevens geanalyseerd. Hoewel er op MRI diverse afwijkingen van zowel het 
midden- als het binnenoor zichtbaar waren, kon geen van deze afwijkingen 
beschouwd worden als typisch voor het BOR syndroom (Hoofdstuk 2.3). Het was 
mogelijk om in sommige van de bestudeerde patiënten achteruitgang en/of 
fluctuatie van het gehoor aan te tonen. BOR patiënten, bij wie een verwijding van 
de ductus en sacculus endolymphaticus (LED(S)) aantoonbaar is en die 25 jaar of 
jonger zijn, lijken gepredisponeerd te zijn om slechter te horen én vertonen 
progressief fluctuerende slechthorendheid (Hoofdstuk 2.4). Hoewel iedere 
participerende familie koppeling vertoonde met het EYAl locus, konden er maar 
drie mutaties in drie van de zes families aangetoond worden. Door de beperkte 
beschikbaarheid van genetische gegevens en de onderlinge klinische verschillen 
binnen en tussen de families was het niet mogelijk een betrouwbare fenotype-
genotype correlatie te bepalen. Een recente wetenschappelijke publicatie heeft 
aangetoond dat herschikking binnen het EYAl gen verantwoordelijk zijn voor het 
grote gedeelte van de BOR patiënten, bij wie voorheen geen mutatie aangetoond 
kon worden. Dit werpt een nieuw licht op de beschikbare genetische data van 
dergelijke BOR families en vereist in feite een aanpassing van de huidige methode 
van EYAl mutatie-analyse. Aanpassing van deze methode zal mogelijkerwijs 
leiden tot het beschikbaar komen van meer genetische en klinische data over 
deze erfelijke aandoening. Wellicht draagt dit bij aan de beantwoording van de 
door ons geopperde vragen en zal het leiden tot meer inzicht in de Pathogenese 
van deze aandoening. 
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Hoofdstuk 3 behandelt DFNA9/COCH en begint met een overzichtsartikel over dit 
onderwerp (Hoofdstuk 3.1). In Hoofdstuk 3.2 wordt een Nederlandse familie 
beschreven die de G88E/COCH mutatie herbergt met de hierbij behorende 
genetische en klinische analyse. Het gehoorverlies heeft een progressief karakter, 
wat in eerste instantie de hoge en in een later stadium de midden en lage 
frequenties aantast. Het gehoorverlies begint tussen de 5e en 6e decade en 
verslechtert jaarlijks met ongeveer 3.6-4.6 dB. Bij vrijwel alle patiënten met een 
duidelijke beperking van het gehoor werd een verminderde evenwichtsfunctie 
geconstateerd. Een aantal mutatie-dragers waren nog te jong voor volledige 
expressie en vertoonden daarom geen klinische afwijkingen. Er waren nauwelijks 
klinische verschillen met de oorspronkelijke beschrijving van deze mutatie 
aantoonbaar. Hoofdstuk 3.3 beschrijft een grote Nederlandse familie met 
patiënten bij wie zowel het gehoor als het evenwicht aangetast is op basis van de 
P51S/COCH mutatie. Deze mutatie is een founder-mutatie in Nederland en België 
en wordt regelmatig aangetroffen bij patiënten van de Nijmeegse KNO-kliniek. 
Audiometrische analyse laat zien dat het gehoorverlies tussen het 40e en het 50e 
levensjaar begint en zich grotendeels beperkt tot de hoge frequenties. Terwijl het 
gehoor jaarlijks met ongeveer 3 dB verslechtert, vermindert tegelijkertijd de 
functie van het evenwichtsorgaan. Dit leidt zelfs tot totale uitval van dit orgaan. 
Sinds deze beschrijving zijn verscheidene andere families met de P51S/COCH 
mutatie audiometrisch, genetisch en vestibulair onderzocht geanalyseerd, 
hetgeen geleid heeft tot de omschrijving van een karakteristiek fenotype. DFNAg 
wordt histopathologisch gekenmerkt door extracellulaire glycosamineglycaan 
(mucopolysaccharide) deposities in de cochlea. Deze observatie werd voor het 
eerst gedaan in het os temporale van een overleden patiënt met de G88/COCH 
mutatie. Recent is bekend geworden dat het gemuteerde cochline eiwit zonder 
problemen wordt verwerkt en uitgescheiden door cellen van de cochlea. Het 
uiteindelijke effect van dergelijke deposities ontstaat waarschijnlijk pas na de 
secretie van cochline in de extracellulaire matrix. Wellicht dat mutaties leiden tot 
gestoorde eiwit-eiwit interacties óf dat aggregatie van dit product uiteindelijk 
zuiver mechanische problemen veroorzaakt. Op dit moment wordt er gewerkt aan 
een post-mortem histopathologisch onderzoek van het os petrosum van één van 
de P51S patiënten. Een vergelijking van de bevindingen met die van aanverwante 
binnenoorstudies zal wetenschappelijk interessant zijn. 
189 
Chapter 6 
In Hoofdstuk 4 wordt een Nederlandse familie besproken met een autosomaal 
dominant overervende slechthorendheid die gekoppeld is aan het DFNA20/26 
locus op chromosoom I7q25. De kritische regio werd gereduceerd van 12 cM tot 
9-5 cM. Toon- en spraak-audiometrische gegevens, evenals vestibulaire gegevens 
zijn verzameld en geanalyseerd. Tot de leeftijd van 15 jaar werd een licht aflopend 
hoogfrequent gehoorverlies gezien, dat bij 8 kHz ernstig verslechterde tussen het 
15e en het 20e jaar. Tussen het 25e en het 40e levensjaar verslechterde de 
kwaliteit van het gehoor bij 1-4 kHz. De lage tonen (0.25-0.5 kHz) verslechterden 
jaarlijks wat gematigder met een snelheid van ±1.5-2 dB. Vanaf het 40e levensjaar 
was het gehoor nauwelijks nog functioneel. Hoewel spraakherkenning 
problematisch begon te worden tussen het 25e en het 45e levensjaar, was de 
maximaal haalbare spraakherkenningscore beter dan bij DFNA2, DFNA5 en 
DFNA9. De huidige DFNA20/26 familie vertoont een ernstiger ziektebeeld dan de 
oorspronkelijk Noord-Amerikaanse familie. Het DFNA20/26 locus bevat het 
gamma-i actine gen (ACTCi). Vrij recent hebben collega's van het Nijmeegs 
Otogenetisch Laboratorium een Thr278lle mutatie gevonden in dit gen, wat 
betrokkenheid bij DFNA20/26 suggereert. De gevolgen van een gemuteerd ACTGi 
gen op het eiwit zelf, op eiwit-eiwit interacties onderling, evenals op de functie 
van cochleaire haarcellen zijn interessante vraagstukken voor toekomstig 
onderzoek. 
Hoofdstuk 5 is gewijd aan DFNBl/C7ß2. GJB2 codeert het connexine 26 eiwit. GJB2 
mutaties spelen een belangrijke rol in autosomaal recessieve en sporadische 
vormen van slechthorendheid. Mutatie-analyse van het GJB2 gen is relatief 
eenvoudig te verwezenlijken binnen een DNA diagnostische setting en is 
gebleken een succesvolle diagnostische procedure te zijn. Dit artikel geeft een 
overzicht over dit onderwerp en toont de eerste resultaten van deze 
diagnostische procedure in Nijmegen. De uitslag van eenennegentig mutatie-
analyses bij personen met een autosomaal recessieve of sporadische vorm van 
erfelijke slechthorendheid zijn retrospectief geanalyseerd. Negentien niet-
verwante personen vertoonden een mutatie op beide allelen. Twaalf hiervan 
hadden een homozygote 35delG mutatie, vier anderen een heterozygote 35delG 
mutatie. De 35delG-mutatie is betrokken bij 84% van de gevallen, waarin een 
mutatie aangetoond kon worden. Deze bevindingen zijn in overeenstemming met 
die van de ons omringende landen. Verder onderzoek naar de correlatie tussen de 
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soort mutatie en de ernst van het gehoorverlies zouden interessant kunnen zijn 
voor toekomstig onderzoek. 
Discussie 
Samengevat wordt er in dit proefschrift aandacht besteed aan de klinische en 
genetische aspecten van één syndromale en drie niet-syndromale vormen van 
erfelijke slechthorendheid. De complexiteit van het auditieve systeem en de grote 
hoeveelheid geïdentificeerde doofheidsloci bewijzen dat er nog veel meer 
onontdekte genen betrokken zijn bij deze aandoening. Vanaf de eerste 
beschrijving van een locus betrokken bij erfelijke slechthorendheid in 1992 lijkt 
het aantal loei vrijwel exponentieel te zijn gegroeid. Door de grotere 
bewerkelijkheid van het identificeren van de betrokken genen en het feit dat de 
humane genoomsequentie nog steeds incompleet is, verloopt de identificatie van 
slechthorendheid veroorzakende genen in een vooralsnog lager tempo. Het 
verrichten van klinische studies die leiden tot een nauwkeurig gestandaardiseerde 
klinische beschrijving met behulp van bijvoorbeeld audiometrie en vestibulaire 
gegevens, is essentieel om verschillende fenotypes te onderscheiden. Een 
dergelijk onderscheid mag dan misschien bijzaak lijken, maar zelfs de kleinste 
klinische verschillen of overeenkomsten kunnen van invloed zijn op de selectie 
van een kandidaat-gen. Daarnaast zal de kennis met betrekking tot de functie van 
genen in het binnenoor alleen verbeteren als alle klinische effecten van een 
genmutatie tot in details bekend zijn. Uiteindelijk zal dergelijk onderzoek hopelijk 
leiden tot de ontwikkeling van nieuwe moleculaire diagnostische procedures en 
misschien zelfs bijdragen aan de ontwikkeling van therapeutische mogelijkheden. 
Zeker niet op de laatste plaats zal een optimale kennis op het gebied van erfelijke 
slechthorendheid ten goede komen aan de patiëntenzorg in de algemene KNO 
praktijk, in het bijzonder bij genetische counseling. 
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Stellingen 
Behorend bij het proefschrift 
Genetic hearing loss 
Some clinical and genetic aspects of 
the BOR syndrome, DFNAg, DFNA20/26 and DFNBi 
Martijn Kemperman 
Nijmegen, 14 april 2004 
1. Bij patiënten met het branchio-oto-renaal syndroom zijn 
frequent anatomische afwijkingen van het midden- en/of 
binnenoor aantoonbaar (dit proefschrift) 
2. Het gehoorsverlies van jonge patiënten met het branchio-oto-
renaal syndroom die ook een vergrote saccus en/of ductus 
endolymphaticus hebben, is vaak ernstig (dit proefschrift) 
3. Een progressief fluctuerend gehoorsverlies bij patiënten met 
het branchio-oto-renaal syndroom die ook een vergrote saccus 
en/of ductus endolymphaticus hebben, is meer dan een 
toevallige bevinding (dit proefschrift) 
4. Aminozuursubstituties P51S en \/88E in het cochline eiwit 
(DFNAg) geven nagenoeg hetzelfde klinische beeld (dit 
proefschrift) 
5. De Nederlandse DFNA20/26 familie vertoont een ernstiger 
fenotype dan de oorspronkelijke Amerikaanse familie (dit 
proefschrift) 
6. Mutatieanalyse van het CJB2 gen is een zinvolle start bij het 
onderzoek naar de predeze oorzaak van waarschijnlijk 
autosomaal recessief overervende en sporadisch 
voorkomende slechthorendheid (dit proefschrift) 
7. Joris Driepinter, het prototype van de Nederlandse 
melkdrinker, is een mutant (Elsevier, november 2002;45:97-98) 
8. Optimalisering van de inbreng van ouderen in hun 
huisartsenzorg vereist een zekere cultuuromslag van zowel 
ouderen als huisartsen. (Involving older patients in 
general/family practice. Wetzels et al IMPROVE collaboration 
2004) 
9. In tegenstelling tot wat geldt voor een hoortoestel, wordt het 
dragen van de huidige, haast identieke headsets van mobiele 
telefoons niet als esthetisch problematisch ervaren 
10. Het steevast reageren met "Wat zeg je?!", na het horen van 
het onderwerp van mijn proefschriftstudie, is niet bijster 
origineel 
11. Hoewel een computer het predikaat "personal" heeft, dient 
deze te allen tijde gewantrouwd te worden (1 harddisk & 2 
moederborden) 

